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Abstract 
Neil David HAMILTON – Influences of first-line oral monotherapy on 
outcomes in Pulmonary Arterial Hypertension in association with 
Connective Tissue Disease 
Keywords: pulmonary arterial hypertension, connective tissue disease, bosentan, 
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Background 
Pulmonary arterial hypertension (PAH) is a rare progressive disease with no 
known cure.  Of various aetiologies, PAH in association with connective tissue 
disease (PAH-CTD) is the most rapidly progressive and difficult to treat.  
Management of PAH has evolved significantly in the past ten years since the 
introduction of oral therapies.  Evidence for the efficacy of these agents outside 
randomised controlled trials is limited, but guidelines exist. 
Aim 
To measure the impact of first-line monotherapy with bosentan or sildenafil and 
the introduction of prescribing guidelines on outcomes in PAH-CTD. 
Methods 
Following a retrospective analysis of consecutive, incident, treatment-naive 
PAH-CTD cases identified by the ASPIRE registry, influences on outcome 
measures have been compared.  First-line monotherapy episodes for 247 
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patients was analysed against four distinct endpoints: change in exercise 
capacity, WHO functional class, time on monotherapy and all-cause mortality. 
Results 
Treatment with bosentan or sildenafil resulted in clinical stability at 2 years for 
nearly 1/4 patients.  No difference was identified between the groups in terms of 
either exercise capacity or WHO functional class.  Sildenafil patients were found 
to remain on monotherapy longer than those prescribed bosentan.  Patients 
prescribed sildenafil have improved survival over those treated with bosentan.  
Unexpected baseline differences in between groups may confound the results 
as the haemodynamics of the bosentan patients were more severe. 
Conclusions 
A significant number of patients with PAH-CTD remain clinically stable on 
monotherapy at 2 years.  Both agents seem equally effective in this aggressive 
form of PAH.  A novel endpoint “TOM” may be of value in future research 
assessing response to treatment. 
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Chapter 1 – Introduction 
1.1 Preface 
 
Pulmonary Hypertension (PH) is a broad term encompassing a group of rare 
conditions.  Some of these are progressive with no known cure.  Current 
specific pharmacological options are few in number.  PH is characterised by a 
raised mean pulmonary arterial pressure (Ppa) at rest of at least 25 mmHg as 
measured at right heart catheterisation (Badesch et al., 2009).  Whilst the 
presenting symptoms may be similar in different forms of PH, there are 
important differences in the disease trajectory and response to treatment in the 
various aetiologies of PH.  As a result, detailed, systematic phenotyping of 
patients by expert clinicians is needed to ensure that patients are managed in 
the most appropriate way for the specific nature of their condition.   
 
Pulmonary Arterial Hypertension (PAH) is a chronic, progressive disorder of the 
pulmonary vasculature characterised by a vasculopathy affecting the pulmonary 
arterioles resulting in an increased pulmonary vascular resistance (PVR).  
Crucially, for patients to receive a specific diagnosis of PAH they must 
demonstrate these haemodynamic changes in the absence of raised Pulmonary 
Capillary Wedge Pressure (PCWP).  A raised PCWP in conjunction with 
increased Ppa would suggest that the PH was as a consequence of left heart 
disease.  PAH if untreated leads to right heart failure and premature death.  
Despite increasing awareness of the condition, improvement in diagnostic 
imaging techniques and treatment options, the disease continues to have a 
significant impact on life expectancy.  Survival outcomes without successful 
treatment are worse than some forms of cancer (Avouac et al., 2008, D’Alonzo 
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GE, 1991).  Of all the aetiologies of PAH recognised by the current classification 
(Table 1) (Simonneau et al., 2009), it is acknowledged that PAH-CTD is the 
most devastating form of this rare disease.   
   
For certain difficult cases, current management of all sub-classes of PAH relies 
on the clinician’s expertise in prescribing for patients not specifically covered by 
randomised controlled trials (RCTs) or guidelines.  The shortcomings of current 
guidelines can be attributed to two main factors: firstly recruiting a suitably 
representative patient cohort into studies and the absence of robust trial data 
identifying the most appropriate way to approach the treatment of PAH e.g. 
combination therapy from diagnosis or “treat to target” with escalation of therapy 
if arbitrary goals are not met.  As a direct consequence of these shortcomings, 
further systematic interrogation of the experience and outcomes of patient 
management to date is warranted to gain insights into the use of the complex 
and expensive treatments currently prescribed.   
 
The Introduction (Chapter 1) provides background and context for the specific 
questions challenged in this study.  It begins in Section 1.1.1 with an overview 
of PH, the classification of different forms of the condition and their 
epidemiology.  Following this, a summary of the clinical presentation and 
aetiologies of the condition are covered (Section 1.1.2).   
  
An overview of CTD is described in Section 1.2, with some detail outlining the 
association with PAH.  Next, the rationale behind the choice of focusing on the 
particular form of PH under review here (PAH-CTD) is set out.  The chapter 
continues with a summary of how care for PH is organised and delivered in the 
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UK (Section 1.3).  Pharmacological therapies for PH are expensive.  In the UK, 
rational prescribing of these is the responsibility of clinical experts in specialist 
centres.  This process, together with the national commissioning policy (NCP) 
(the prescribing guidance) and the funding mechanisms underpinning it will be 
described in Section 1.4.  Various models of care exist worldwide, but in the 
National Health Service (NHS) of the UK and in Ireland, a network of nationally 
designated specialist centres delivers high quality medical care and treatment.  
A brief synopsis of this model with its impact on patient care is the subject of 
Section 1.5. 
 
Section 1.6 describes how the NHS is monitored and what processes are in 
place to ensure a high quality service is sustainable and deliverable.  In Section 
1.7, the various guidelines used worldwide are described, contrasting these with 
the policy used in the NHS.  The introductory chapter progresses through 
Section 1.8 with a summary of how this project was evolved, how it is unique 
and how it will seek to address some of the gaps in the already published 
works.  Sections 1.9 and 1.10 conclude the introduction via summaries and an 
outline of how the rest of the thesis maps out.  Some of the areas covered by 
the introduction will be discussed in greater depth in the course of the Literature 
Review (Chapter 2). 
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1.1.1 PAH – Epidemiology and classification 
 
Published registry data from several countries has estimated the prevalence 
and incidence of PAH.  The French registry describes the lowest estimate of 
incidence as 5.9 cases/million adult population with a prevalence of 15.0 
cases/million (Humbert et al., 2006).  This varies considerably from the data 
observed in the Scottish centre, where an incidence of 7.1 cases/million adult 
population and prevalence of 52 cases/million is described (Peacock et al., 
2007).  Some of this difference may be accounted for in the relatively low 
numbers enrolled into the French registry.  The most recent estimation of 
prevalence in the UK is provided by the report of the National Audit of 
Pulmonary Hypertension (NAPH) 2012 (HSCIC, 2013).  This Audit showed a 
prevalence of 40.8 cases/million in England, with fractionally higher figures for 
Scotland and Wales.   
 
Despite increasing awareness of PAH, the NHS system of specialist centres in 
the UK results in patients potentially living considerable distances from their 
nearest centre.  Although NAPH data for the UK historically shows that 
populations with a diagnosis of PAH are clustered around the specialist centres, 
recent audit data shows that the prevalence in Wales where there is no 
specialist PH centre is higher than average suggesting that there is improved 
access to PH services.  This burden of travel could, however, result in lack of 
referral or unwillingness by the patient to travel due to inconvenience.  All UK 
PH specialist centres have large “catchment” areas.  The UK patient 
organisation, the Pulmonary Hypertension Association (PHA) has conducted 
research into patient perception of the specialist centre model.  These are 
discussed further in Section 1.1.5.   
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The latest classification of PH (see Table 1 below) is the Dana Point 
Classification, 2008.  This has now been reviewed after a five-year interval at 
the World Symposium for Pulmonary Hypertension held in Nice, March 2013.  
Following the symposium, the classification has been subtly revised based on 
emerging data and experience.  The revised classification had not yet been 
published at the time of writing. 
 
Interestingly although differences in response to therapies is described in 
different forms of PAH (Galiè, 2005, Galiè, 2008, Rubin LJ, 2002, Zuckerman et 
al., 2011) this is not reflected clearly in the guidance (Badesch et al., 2009, 
Members et al., 2009, Authors/Task Force et al., 2009), which talks in terms of 
similar management strategies across PAH.   
 
Clinical trials of pharmacological therapies for PAH have excluded patients at 
extremes of age and data for treating older patients is limited.  This is not an 
issue confined to PH but presents another challenge to managing patients 
using the principles of evidence-based medicine.  Hence there is an absence of 
randomised controlled trial (RCT) data on the benefits of this older-age group.  
If such patients are seen and diagnosed, although their treatment would be 
recommended by licences and guidelines, it may not be evidence-based.   
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Table 1 – Updated Clinical Classification of Pulmonary Hypertension 
(Dana Point, 2008).  Taken from (Simonneau et al., 2009) 
1  Pulmonary arterial hypertension (PAH) 
1.1  Idiopathic PAH 
1.2  Heritable 
1.2.1  BMPR2 
1.2.2  ALK1, endoglin (with or without hereditary hemorrhagic 
 telangiectasia) 
1.2.3  Unknown 
1.3  Drug- and toxin-induced 
1.4  Associated with 
1.4.1  Connective tissue diseases 
1.4.2  HIV infection 
1.4.3  Portal hypertension 
1.4.4  Congenital heart diseases 
1.4.5  Schistosomiasis 
1.4.6  Chronic hemolytic anemia 
1.5  Persistent pulmonary hypertension of the newborn 
 
1  Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary  
 hemangiomatosis (PCH) 
 
2  Pulmonary hypertension owing to left heart disease 
2.1  Systolic dysfunction 
2.2  Diastolic dysfunction 
2.3  Valvular disease 
 
3  Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1  Chronic obstructive pulmonary disease 
3.2  Interstitial lung disease 
3.3  Other pulmonary diseases with mixed restrictive and obstructive 
 pattern 
3.4  Sleep-disordered breathing 
3.5  Alveolar hypoventilation disorders 
3.6  Chronic exposure to high altitude 
3.7  Developmental abnormalities 
 
4  Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
5  Pulmonary hypertension with unclear multifactorial mechanisms 
5.1  Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2  Systemic disorders: sarcoidosis, pulmonary Langerhans cell 
 histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3  Metabolic disorders: glycogen storage disease, Gaucher disease, 
 thyroid disorders 
5.4  Others: tumoral obstruction, fibrosing mediastinitis, chronic renal  
 failure on dialysis 
Notes:  Main modifications to the previous Venice classification are in bold.   
ALK1 = activin receptor-like kinase type 1; BMPR2 = bone morphogenetic 
protein receptor type 2; HIV = human immunodeficiency virus.   
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Using prevalence estimates shown in the various published data described 
above, it is appropriate to describe PAH as a rare (or “orphan”) disease as 
classified by an expert group of the Rare Diseases Task Force for the European 
Commission (RDTF).  In their report (RDTF, 2005) to the High Level Group on 
Health Services and Medical Care of the European Union, “rare or orphan” was 
defined, as being any disease with a prevalence of less than 1 in 2000 (or 
500/million).  The European Medicines Agency (EMA) therefore describes PAH 
as an orphan disease.  The Food and Drugs Administration (FDA) defines 
orphan status as a condition where less than 200,000 cases will be treated in 
the United States of America (USA) per year.  Incentives are offered by the FDA 
and EMA for the development of drugs to treat orphan disease so that patients 
with rare diseases are not disadvantaged by the financial cost of developing 
new therapies.   
 
In terms of medication licensing and authorisation, orphan status has profound 
implications.  In the US, the FDA extends the period of patent protection to 20 
years from the standard 15 years.  In addition, a period of market exclusivity 
would apply for the first seven years of the patent.  The situation is slightly 
different in the UK and Europe, subject to the European Medicines Agency 
(EMA) regulation.  Here, a longer period of market exclusivity applies (10 
years), but there is no change to the overall duration of the patent. 
 
Group 1 PAH has been subject of much reclassification and is the major source 
of interest from a pharmaceutical care perspective.  All of the available targeted 
treatments are used for PAH patients, with growing evidence for 
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pharmacological intervention in patients with non-operable CTEPH (Cinarka 
and Ozsu, 2013). 
 
In the main, treatment for Groups 2, 3 and 5 lies outside the specific remit of the 
PAH expert centres.  However, where PH appears out of proportion to 
respiratory or cardiac disease or the PH remains unexplained referral is 
recommended to ensure that patients do not have PAH or CTEPH.  It is 
recommended by PH centres that local physicians should have a low threshold 
for referral.  As such it is not uncommon following an initial work up that patients 
from these groups will be discharged from the specialist centre for more 
appropriate management by their cardiologist, respiratory physician or 
rheumatologist.  Management of PH associated with these aetiologies (for 
example Group 2: PH with left heart disease) revolves around optimisation of 
pharmaceutical management of heart failure, that is, diuretics and fluid balance. 
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1.1.2 PAH – Aetiologies and clinical presentation 
PH is defined as a resting mean pulmonary arterial pressure (Ppa) >25 mm Hg 
(Badesch et al., 2009).  If left untreated, PH leads to right heart failure and 
premature death.  Vasoconstriction, smooth muscle proliferation and thrombosis 
are the main vascular changes observed in PAH and hence are thought to be 
the main contributory factors of the raised PVR (Galiè N et al., 2009).  Also 
implicated is pulmonary endothelial dysfunction characterised by 
overexpression of vasoconstrictors (Mathai et al., 2007).  Appropriate 
management and treatment depends entirely on the aetiology.  Hence 
accurately diagnosing the specific type of PH is all-important. 
 
For all PH patients breathlessness is the most common symptom.  Exertional 
dyspnoea is the most frequent presenting symptom, present in approximately 
60% of patients and is eventually present in virtually all patients as the disease 
progresses (Humbert et al., 2006).  However they may also present with fatigue, 
weakness, chest pain and syncope with various degrees of disease severity 
(Rich et al., 1987).  As symptoms are vague and non-specific, patients often 
have a considerable delay until referral to a PH specialist (Armstrong et al., 
2012).  It is usual for referrals to the PH service to come from respiratory 
physicians, cardiologists or rheumatologists.  Given the importance (Hachulla 
and Denton, 2010, Galiè N et al., 2009) of both early referral to a specialist and 
accurate diagnosis, it is disappointing that there is little to show that raised 
disease awareness is resulting in shorter symptom to treatment times.   
 
US registry data from 1996 showed patients were waiting up to 3 years from 
onset of first symptoms to diagnosis (Abenhaim et al., 1996).  It is likely that 
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these data are outdated as they were gathered before the era of current 
management strategies and specialist centres.  It would also be reasonable to 
expect this to improve markedly over time.  Sadly however, a recent survey by 
the UK patients’ association, the PHA, showed the average wait in this country 
is still 2.5 years (Armstrong, 2011).  On a more positive note the number of 
patients being diagnosed with PAH and CTEPH has increased over the last 
decade.  The delay in diagnosis from symptom onset is likely to be multifactorial 
but will also reflect a delay in affected patients seeking help for their symptoms. 
 
Patients are often referred on the basis of an abnormal trans-thoracic 
echocardiogram performed to investigate breathlessness.  Although this 
method is helpful in detecting or excluding significant PH, its intrinsic and 
operational limitations make early PH diagnosis and screening challenging 
(Brecker et al., 1994, Vachiery et al., 1998).   
 
Upon presentation at a specialist pulmonary vascular disease unit, patients will 
undergo a rigorous series of investigations to confirm (or exclude) the diagnosis 
of PH and its precise aetiology.  Of those referred with suspected PH, Sheffield 
and other specialist Pulmonary Vascular Disease Units (PVDU) are primarily 
concerned with identifying potentially treatable forms of PH i.e. PAH and 
CTEPH.  The PH specialist is likely to conduct further cardiothoracic imaging 
with a combination of: ventilation/perfusion scanning (Q scan), high-resolution 
CT thorax (HRCT), CT Pulmonary Angiogram (CTPA) and cardiac Magnetic 
Resonance Imaging (MRI) with pulmonary angiogram.  Pulmonary Function 
Tests (PFTs) are used to differentiate those with obstructive lung disease.  
TLCO (or DLCO) reflects the lung’s ability to diffuse carbon monoxide.  This is 
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often reduced relative to the patients predicted value, particularly in PAH-CTD.  
The patient’s predicted TLCO takes account of current haemoglobin, age, sex 
and constants.   
 
Patients’ exercise capacity will also be most commonly measured using the six-
minute walk test distance (6MWD) and in certain circumstances patients will 
undergo cardiopulmonary exercise testing.  To formally confirm the diagnosis of 
PAH it is necessary to perform RHC to confirm a Ppa 25 mmHg with a PCWP 
15mmHg.  Parameters indicating a poor prognosis include mean Right Atrial 
Pressure (Pra) >10mmHg, cardiac index (CI) <2.1 and mixed venous oxygen 
saturation (mVO2) <63% (Authors/Task Force et al., 2009).   
 
In addition to the diagnostic criteria to be applied, patients are measured 
functionally by exercise testing, usually in the form of a walk test.  At diagnosis 
and follow up, an assessment by the physician assigns the patient to one of 
four World Health Organisation (WHO) functional classes (FC).  These have 
superseded the previously used New York Heart Association (NYHA) classes 
by using definitions specific to PH.  The contrasting definitions are as follows: 
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Table 2 – Definitions for NYHA and WHO FC 
  
Functional class correlates well to prognosis (McLaughlin et al., 2004) and is an 
important consideration when prescribing medical treatments (Galiè N et al., 
2009, McLaughlin et al., 2009b). 
 
The expertise of the specialist clinician is vital in determining the aetiology of PH 
and accurately categorising the patient into the Dana Point system (Simonneau 
et al., 2009).   Although not exclusively, the patients warrant ongoing 
management by PH specialists if they fall into Group 1 PAH.  Patients from 
other groups will be seen, assessed and either discharged or treated as 
appropriate to the nature of their PH. 
 
The currently prescribed treatment options are summarised below.  
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Table 3 - Treatment options for PAH 
Class of medicine Therapeutic 
agents 
Prescribed dosages Mechanism of action Common side effects 
Calcium Channel blockers Diltiazem Up to 900mg daily (usual target 
720mg daily) 
Relaxation of smooth muscle 
surrounding central coronary 
vessels 
Hypotension, bradycardia, 
peripheral oedema, 
dizziness 
 Nifedipine Up to 240-mg daily (usual target 
120mg daily 
Relaxation of smooth muscle 
surrounding central coronary 
vessels 
Hypotension, bradycardia, 
peripheral oedema 
Phosphodiesterase-5 
Inhibitors 
Sildenafil 20-100mg tds (licensed 20mg 
three times daily) 
Prevents breakdown of c-GMP to 
elicit vasodilatation.  Selective to 
pulmonary bed, penis and kidney 
due to proliferation of receptor 
type 
Headache, nasal 
congestion, reflux, 
hypotension, flushing 
 Tadalafil 20-40mg once daily Prevents breakdown of c-GMP to 
elicit vasodilatation.  Selective to 
pulmonary bed, penis and kidney 
due to proliferation of receptor 
type 
Headache, nasal 
congestion, reflux, 
hypotension, myalgia 
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Endothelin Receptor 
Antagonists 
Bosentan 62.5mg-250mg twice daily Dual endothelin A & B receptor 
antagonist.  Reduces smooth 
muscle proliferation, anti-fibrotic, 
reduces vasoconstriction 
Peripheral oedema, liver 
function test abnormality, 
nasal congestion 
 Ambrisentan 5-10mg once daily Selective endothelin A receptor 
antagonist.  Reduces smooth 
muscle proliferation, anti-fibrotic, 
reduces vasoconstriction 
Peripheral oedema, liver 
function test abnormality, 
nasal congestion 
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Prostanoids Epoprostenol 
(Intravenous) 
Dosed to symptomatic benefit.  
Usual range 20-40ng/kg/min 
Induces vasodilatation, also 
cytoprotective and 
antiproliferative 
Flushing, GI disturbance, 
headache, hypotension, 
jaw pain, foot pain, anxiety 
 Iloprost 
(Intravenous) 
Dosed to symptomatic benefit.  
Usual range 4-8ng/kg/min 
Induces vasodilatation, also 
cytoprotective and 
antiproliferative 
 
 Iloprost 
(Nebulised) 
5micrograms 6-9 times daily Induces vasodilatation, also 
cytoprotective and 
antiproliferative (nebuliser induces 
rapid absorption, local action) 
 
[Type text] [Type text] [Type text] 16 
From this point forward, this work focuses almost entirely on cases in Group 1 
PAH.  It is the exclusion of left heart involvement that is the salient point and 
critical for understanding the distinction between PH and PAH.  These patients 
present the clinical pharmacist with the most interest in terms of medical 
treatments.  This is true of both patient management and potential for research.  
The clinical interest is illustrated by the fact that the disease trajectory of the 
other forms is less likely to be altered by intervention with these specific 
targeted pulmonary vascular therapies.  Secondly, from a research perspective 
an evaluation of all available treatments for all aetiologies of PH would be 
unfeasible in a single study as they are so clinically and pathologically diverse.  
Hence, the remit of this study has been honed to a specific aetiology and 
specific treatment modality.   
 
Thus, influence on outcomes in pulmonary arterial hypertension in association 
with connective tissue disease (PAH-CTD) with the oral agents, bosentan and 
sildenafil is the specific subject studied here.  This decision was based upon the 
researcher’s personal interest together with clinical need, relevance and access 
to suitable cases.  The Sheffield centre cares for one of the largest groups of 
PAH-CTD at any of the PAH centres in Europe and North America. 
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1.2 CTD – an overview 
Collagen Vascular Diseases are more routinely known as CTDs.  The CTDs are 
a range of related disorders, which include systemic sclerosis (SSc), systemic 
lupus erythematosus (SLE), mixed connective tissue disease (MCTD), 
rheumatoid arthritis (RA), dermatomyositis/polymyositis and primary Sjögren’s 
syndrome.  There are common clinical and serological features with some 
patients having multiple overlapping CTDs (Rao and Bowman, 2013).   
 
The CTDs are autoimmune diseases characterised by immune-mediated organ 
dysfunction (Fischer and du Bois, 2012).  These may have either genetic or 
environmental causes.  Serologic testing is important in the evaluation of 
patients with autoimmune CTDs (Mutasim and Adams, 2000).  Accurate 
assessment of the CTD through this serological testing and clinical findings is 
an important part of classifying a patient’s specific PAH-CTD.  Arthritis and 
inflammation are typical presenting symptoms of CTD but the specific 
presentation varies from disease to disease.  CTD is not purely a 
musculoskeletal condition; it is a multi-system with potential effects on not least 
the heart.  Cardiac abnormalities (diagnosed or undiagnosed) are a feature 
particularly in SSc with a high frequency of diastolic dysfunction (Denton et al., 
2011).   
 
PAH aside, the most common pulmonary complication of CTD is interstitial lung 
disease (ILD), indeed some patients have both ILD and PAH.  The ILDs are a 
range of parenchymal lung disorders.  These can be idiopathic but are 
frequently associated with CTDs (Fischer and du Bois, 2012).  Presenting 
symptoms include shortness of breath, cough and weight loss.  Imaging tests 
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are used to diagnose the form of ILD.  Appropriate treatment depends on the 
specific type of ILD but may involve antibiotics, corticosteroids, oxygen 
supplementation or immunosuppression.  Efficacy data showing benefits of 
immunosuppression in PAH-CTD is limited to very small retrospective studies 
(n=<12)(Jais et al., 2008, Miyamichi-Yamamoto et al., 2011). 
 
In advanced cases, lung transplant may be the best option although 
oesophageal problems of precludes transplant in systemic sclerosis due to an 
increased risk of lung rejection.  Further discussion on this complication is not 
made here, but it is important to note that contrary to previous work (Mukerjee 
D, 2003), more recent UK data (Condliffe, 2009) found a statistically significant 
improvement in survival between those patients with “isolated” (lack of lung 
involvement) PAH-CTD compared to those with respiratory disease-associated 
PAH.   
 
Whilst management of the PAH component does not differ between CTDs, 
accurate phenotyping is important and data does show that the outcome of 
patients with PAH related to SLE is significantly better than that seen in SSc 
(Condliffe, 2009).  A close working relationship between pulmonary vascular, 
respiratory and rheumatology specialists is a vital part of a patient’s holistic 
care. 
 
1.2.1 PAH-CTD – Epidemiology and classification 
PAH-CTD represents group 1.4.1 in the Dana Point classification (Simonneau 
et al., 2009).   Approximately 1/3 of patients with CTD develop PAH as a 
complication (Grunig, 2012).  This form of the disease has a similar incidence to 
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idiopathic PAH (IPAH) in our centre (Hurdman et al., 2011).  In the absence of 
pulmonary fibrosis, PAH-CTD is clinically indistinguishable from IPAH (Varga, 
2002).  Despite this, the mortality in this group is high (Coghlan and Handler, 
2006).   
 
PAH is a devastating complication of a number of connective tissue diseases 
(Le Pavec et al., 2010, Galiè N et al., 2005).  The CTD most commonly 
associated with PAH is systemic sclerosis (PAH-SSc).  This is estimated from 
registry data to be prevalent in approximately 7.8-12% of PAH cases (Mukerjee 
D, 2003, Hachulla E, 2005).  Coghlan and Handler (2006) identified SLE (9%) 
and MCTD (7%) as the other important aetiologies associated with PAH.  
Outside these three main types, all remaining CTDs combined to constitute 
12% of all PAH-CTD.  In practice, management of these less common forms will 
follow the principles employed to treat the more prevalent forms of PAH-CTD.  
On the basis of prevalence figures, it is reasonable to devote the majority of this 
introduction to PAH-SSc as this constitutes 73% of the connective tissue 
diseases associated with PAH in the UK (Condliffe, 2009)  but data concerning 
less prevalent conditions will also be reviewed. 
 
The most striking observation we can make regarding PAH-CTD is that it 
appears to be more rapidly progressing than IPAH.  Koh et al (1996) reviewed 
their experience with a small cohort (n=17) and found a 1-year survival of only 
45%.  It is important to remember that this 1996 reference predates the use of 
targeted therapies for PH, and also the patients in this cohort had more severe 
disease than patient cohorts now diagnosed.  This study is often used in the 
literature as an estimation of the untreated survival.  To put this into context, in 
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the absence of PAH, one-year survival of patients with SSc is over 90% (Kawut, 
2003, Koh, 1996).  Ten years after the work published by Koh and colleagues, 
PAH-SSc continues to carry a particularly poor prognosis with a 1 and 3-year 
survival at 78% and 47% respectively, although the UK audit (Condliffe, 2009) 
suggests that 1-year survival may be better than this.  The causes and risk 
factors for death (including PAH) in SSc have been well documented (Tyndall et 
al., 2010).  Coghlan (2006) reported that their patients with other forms of PAH-
CTD appear to do just as badly as the PAH-SSc, with the exception of PAH in 
association of Sjogren’s syndrome.  Data presented by Condliffe et al (2009) 
shows survival is improved in PAH-SLE vs. PAH-SSc. 
 
Further insight into the survival of the PAH-CTD population comes from the 
Registry to EValuate Early And Long term PAH management in the United 
States (US) (REVEAL).  This is a prospective registry of over 3000 PH patients 
from 54 US centres studied over the period 2006-2009.  In comparing the PAH-
CTD group with the IPAH group, the study team noted signs of poor prognosis, 
for example lower 6MWD, reduced transfer factor and presence of pericardial 
effusion.  However the traditional measurements from echocardiography and 
right-heart catheterisation did not accurately reflect disease severity.  The 
authors suggest a unique pathophysiology is evident for PAH-CTD (Chung et 
al., 2010).  The study would suggest that despite milder haemodynamics there 
are other factors present in PAH-CTD resulting in more rapid disease 
progression and more limited survival. 
 
A similar poor survival figure in patients with PAH-SSc of 55% was identified in 
work published by Kawut et al (2003).  This validates Koh’s earlier findings but 
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also raises the question regarding the usefulness of treatments for PAH-CTD.  If 
the 1-year survival only improves by 10% in a sample of which half were 
prescribed potent prostanoid therapy, then complex treatments have not added 
many life years.  There needs to be a significant gain in survival to compensate 
for the burden that prostanoids place on patients’ quality of life in terms of 
medicine reconstitution, maintenance of central lines, aseptic technique, risk of 
infection and body image problems.   
 
A UK cohort study published in 2006 of patients treated at the Royal Free in 
London before ERAs were available, showed a 1-year survival of 69% (Coghlan 
and Handler, 2006).  Some of these patients would also have received 
prostanoids but all three articles indicate a rapidly progressive, hard-to-treat 
condition in need of better treatment options.   
 
In the current treatment era, it is quoted that patients with PAH-SSc in WHO 
FCII only demonstrate a 3-year survival of 70-75% (Hachulla et al., 2010, 
Condliffe, 2009).  A study in a small French cohort (n=77) found less than 20% 
of PAH-SSc patients to be in FCII at diagnosis.  On this basis, >80% of PAH-
SSc patients have a 3-year life expectancy of 20-70% from diagnosis (Condliffe, 
2009, Hachulla et al., 2010). 
 
The following Table presents data from the REVEAL registry.  The most recent 
work describing survival across all aetiologies from the US registry.  This 
illustrates clearly the variation between types of PAH and the relative survival 
estimation for each up to seven years.  The recent review of survival data by 
Desai (2011) collates the findings of all the current registries. 
[Type text] [Type text] [Type text] 22 
Table 4 – Survival Estimates of PAH Sub-groups at Years 1, 3, 5, and 7 
Years From Diagnosis 
PAH 
Subgroup 
No. 1 3 5 7 
IPAH 1,201 88.4 ± 1.9 73.7 ± 2.0 64.3 ± 2.1 56.5 ± 2.2 
APAH-CHD 251 88.3 ± 4.5 81.4 ± 4.8 74.4 ± 4.7 67.3 ± 4.8 
APAH-CTD 742 79.5 ± 2.6 57.1 ± 2.6 43.7 ± 2.4 35.5 ± 2.5 
APAH-
PoPH 
157 74.9 ± 5.8 51.6 ± 5.5 39.4 ± 4.9 29.3 ± 5.3 
APAH-DT 123 92.7 ± 5.1 83.7 ± 5.7 73.5 ± 6.2 63.0 ± 6.6 
APAH-HIV 48 93.3 ± 6.2 75.1 ± 8.8 63.8 ± 9.5 63.8 ± 9.5 
APAH-
othera 
33 100.0 82.6 ± 8.8 64.4 ± 11.3 47.0 ± 12.8 
FPAH 66 92.9 ± 6.6 72.2 ± 8.2 60.1 ± 8.1 50.5 ± 8.5 
Data are presented as estimate ± SE, %.  APAH = pulmonary arterial hypertension 
associated with other conditions; CHD = congenital heart disease; CTD = connective 
tissue disease; DT = drugs and toxins; FPAH = familial pulmonary arterial 
hypertension; IPAH = idiopathic pulmonary arterial hypertension; PoPH = 
portopulmonary hypertension. 
Taken from (Benza et al., 2012). 
 
Systematic detailed phenotyping of patients in UK centres now allows a fine 
degree of aetiology differentiation.  For this reason, and because PAH-CTD is 
particularly aggressive, some PAH centres have developed tools for screening 
CTD patients for early referral to a UK specialist centre for assessment and 
perhaps diagnosis (see Appendix 3) (Elliot and Kiely, 2004). 
 
The use of screening protocols is well documented (McGoon et al., 2004) and 
was validated by Humbert’s group (2011).  They retrospectively reviewed two 
European incident cohorts from the same management era (2002/3) that were 
diagnosed with PAH-SSc.  After 8 years, Humbert’s group looked back at 
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survival data for each cohort and found that patients identified earlier were 
found to have milder disease and went on to do better with treatment.  The 
suggestion here is that patients diagnosed earlier in their disease trajectory may 
benefit from earlier treatment.  The implication is that those patients waiting 
longer for diagnosis may be diagnosed and treated too late to achieve maximal 
benefit and reinforced the need for early screening. 
  
1.2.2 PAH-CTD – Pathophysiology and clinical presentation 
All forms of pulmonary hypertension have some common features regardless of 
their aetiology, that is: medial hypertrophy of muscular and elastic arteries; 
dilation and intimal atheromas of elastic pulmonary arteries; and right ventricular 
hypertrophy (Pietra et al., 2004).  In addition to these, PAH is characterised by 
constrictive and complex arterial lesions involving the pulmonary arteries.  
Pathological differences between PAH-CTD and IPAH are evident by the lack of 
plexiform lesions noted in PAH-CTD (Pietra et al., 2004).   
 
The exact pathophysiological mechanisms in the development of this 
vasculopathy remain unclear (Chung L, 2009).  That said, there are data to 
show that patients with PAH-CTD have a worse prognosis than the IPAH 
patients.  If the pulmonary vasculopathy appears to be largely similar, there 
must be other features of the disease that differentiate the groups.  PAH-CTD 
patients will experience additional symptoms to IPAH patients, that is to say 
they also experience problems due to the CTD.  As age is a very strong 
predictor of survival and patients with SSc are older than IPAH this may be a 
powerful factor influencing survival. 
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PAH-SSc is the most likely CTD seen in association with PAH because the 
principal abnormality is of skin and internal organ thickening.  The spectrum of 
the disorder ranges from limited cutaneous disease, formerly known as CREST 
syndrome (calcinosis, raynauds, oesophageal dysfunction, scleridactyly, 
telangiectasia) to diffuse cutaneous disease with a higher prevalence of renal 
involvement and pulmonary fibrosis (Rao and Bowman, 2013).  Patients with 
the limited cutaneous form are more likely to develop PAH-CTD (Galiè N et al., 
2005).  Hence accurate diagnosis is essential as with other forms to avoid 
potentially deleterious treatment with PAH therapies. 
 
Interestingly, the clinical features of the PAH aspect of PAH-CTD include the 
whole spectrum of pulmonary vascular pathology.  Effects of CTDs on the 
myocardium may result in a left-sided presentation of PH (Kahan and Allanore, 
2006).  Other manifestation includes pulmonary veno-occlusive disease and 
pulmonary capillary hemangiomatosis (Galiè N et al., 2005).  In a 2003 study, 
148 patients with PAH-SSc were evaluated (Mukerjee D, 2003).  From this 
cohort, the strongest predictor of mortality was a high mean Ppa.  The authors 
concluded from this that treatment should be implemented earlier to delay or 
prevent right ventricular decompensation.   
 
1.3 Service Organisation and delivery 
 
Having described the need for timely, systematic phenotyping of these complex 
patients, it is now important to understand how this takes place within the NHS.  
Whilst patients with rheumatological conditions including CTDs may be seen 
locally, numbers of patients with PAH are far smaller.  This coupled with fewer 
specialist healthcare professionals means that a different model is necessary. 
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Care for patients with PH is delivered via a network of specialist centres.  These 
centres are where multi-professional expertise is concentrated.  Across the UK 
in the NHS, only the specialist centres are able to prescribe targeted therapies 
(either directly or via shared care arrangements).  The centres must prescribe 
treatments in accordance with the National Commissioning Policy (NCP).  The 
clinical details of any patient registered with any of the UK PH centres is 
captured via the NAPH (HSCIC, 2013).  The quality of care provided by the 
centres is measured regularly against national standards. 
 
1.4 The National Commissioning Policy 
 
The NCP for PH was the first National Commissioning Policy in any clinical area 
of the NHS.  The NCP in its current (2011) form has evolved since the first NCP 
introduced in 2008.  This in turn was an evolution of the first 2 supra-regional 
commissioning policies developed in the North West of England and the 
NORCOM policy (Sheffield and Derbyshire).  Both of these were developed 
between the Sheffield centre and commissioners.  The NORCOMa policy was 
the agreement set up between the Sheffield centre, its referring centres and the 
hosting Primary Care Trusts in 2004.  The NCP remains to date the only binding 
national clinical policy in the NHS. 
 
The NCP draws data in terms of drug efficacy and safety from the ESC/ERS 
guidelines (Galiè N et al., 2009) but tailors the recommendations and treatment 
criteria to better fit with the mechanisms of funding currently employed within 
the NHS.  This delicate balance has been achieved through regular and 
constructive dialogue and engagement between clinicians and commissioners.  
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The close working relationship between clinicians and commissioners has 
ensured that all parties are aware of each other’s issues, concerns and 
agendas. 
 
Working collaboratively to ensure best practice in accordance with available 
evidence yet within available resources has largely been possible.  The best 
example of output from the clinician/commissioner relationship in PH has been 
the development of the NCP.  The guideline applies to all involved in the care of 
PH patients.  It was produced to rationalise prescribing and clarify funding 
arrangements for all key stakeholders.   
a.  NORCOM – a local collaborative commissioning group made up of the 
following PCTs: Sheffield, Doncaster, Rotherham, Barnsley and part of 
Derbyshire County PCTs. 
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The guideline was created through a similar process to the one described by 
NICE (NICE, 2013).   
 
The NICE technology appraisal process is grouped into the main headings: 
1. Guideline topic is referred.   
2. Stakeholders register interest.   
3. Scope prepared. 
4. Guideline development group established. 
5. Draft guideline produced. 
6. Consultation on the draft guideline. 
7. Final guideline produced.  Guidance issued.   
Unlike NICE, where a defined level of cost cannot be exceeded for treatments 
to be approved, the NCP in PH had no such ceiling.  It did not seek to exclude 
agents purely on the basis of cost.  However, it was clear that there would be an 
annual budget nationally for these treatments.  The NCP set out to ratify current 
best practice.  The guideline was created to reflect available evidence and best 
practice.  Although it was the first such document in the NHS, its success as a 
concept can be assessed by the minimal alterations made at the first review in 
2011.  Adherence to the policy by clinicians is recorded through data inputted to 
the National Audit of Pulmonary Hypertension (NAPH) (HSCIC, 2013).  Ongoing 
work by NHS England will inform the next review of the NCP due in autumn 
2013.  It is likely that this review may not only review the guidance in light of 
recent developments but also make progress into assessing national 
expenditure on PH treatments and the impact of the NCP on expenditure. 
 
All patients prescribed targeted therapies since the introduction of the NCP are 
eligible for a prescription without prior funding approval from NHS England via 
their local team, provided they meet the criteria as defined within the document.  
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If patients do not meet the criteria, alternative funding must be sought prior to 
initiation.  This is processed via an Individual Funding Request (IFR) to NHS 
England.  The clinician wanting to initiate treatment outside the NCP must 
complete a standard IFR template with clinical information detailing the patient’s 
condition and crucially their grounds for exceptionality.  These are the 
characteristics of the case marking it exceptional and hence how it can be 
deemed worthy of funding outside the policy.  Wherever possible IFRs should 
be accompanied by published evidence detailing the previous use of the 
proposed treatment in the specific scenario requested.   
 
Since April 2013, IFR conditions have tightened, making the possibility of 
funding outside the policy less likely.  There are two main changes, which are 
important to note.  Firstly, in addition to the pre-existing need to demonstrate 
exceptionality the number of IFRs submitted to the panel must not exceed five 
from any commissioning board region.  Once the number of IFRs from one 
region exceeds five, it is expected that a service development be proposed as 
an amendment to the current policy as the requests are no longer deemed 
exceptional or individual.  The second major change since April is that the same 
panel reviews all IFRs to improve consistency of decision and allow closer 
monitoring of the submissions. 
   
In return for funding either via the prior approval or IFR route, commissioners 
require that all patients’ clinical details be recorded in the NAPH (HSCIC, 2013).  
This is an in-depth registry, which will in time yield useful data across the UK 
PAH population in terms of phenotyping, baseline characteristics and response 
to therapy.   
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Following the original publication in 2008, the NCP revision in 2011 took 
account of three significant factors.  The first of these factors was the 
introduction of a new Endothelin Receptor Antagonist (ERA) (ambrisentan) and 
with it the request from clinicians to have freedom within class to choose the 
most appropriate agent.  Secondly, a drive by clinicians backed by international 
guidelines to use combination treatment more frequently.  This second factor 
had the greatest impact on the new NCP, because although the ERS/ESC 
guidelines recommend combination treatment, supportive evidence in the form 
of RCTs or other high quality data is distinctly lacking.  Indeed a recent paper, 
Fox (2011) suggested that combination data has no more beneficial effect than 
monotherapy with the exception of a modest increase in exercise capacity.   
 
The use of combination therapy in the absence of RCT data is controversial but 
increasingly common in clinical practice.  Current data at the SPVDU shows 
that combinations of two or three agents are prescribed to 40% of treated 
patients although triple therapy occurs in only 1% of patients.  Despite being 
recommended by guidelines, more data is necessary before a definitive 
conclusion can be reached as to whether combination use is justified.  In other 
disease areas, combining agents with contrasting or synergistic mechanisms is 
commonplace, for example, systemic hypertension.  However, in these areas 
there are not the same challenges of cost or RCT recruitment.  As a 
compromise for the current NCP, it was agreed that if combination prescribing 
was to become more commonplace within an unchanged prescribing budget, 
the cheapest monotherapy, a Phosphodiesterase type 5 Inhibitor (PDE5i) must 
be used as the first-line monotherapy.   
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The recommendations published in the NCP are based around data from the 
licensing studies.  Unusually for national guidelines, the PH NCP also allows for 
unlicensed and off-license prescribing in defined circumstances.  Although 
unusual this seems acceptable, indeed unavoidable given the narrow range of 
licensed agents and indications in the armamentarium.  It is unlikely that two 
regularly prescribed parenteral prostanoids (iloprost and treprostinil) will ever be 
approved by the MHRA and hence will remain unlicensed.  This is further 
justification for specialist assessment, diagnosis/classification and treatment if 
necessary. 
 
The validity of the NCP recommendations is open to challenge.  Very small 
subgroups (n=40) have been examined as part of sub-group analysis (Galiè, 
2005, Rubin LJ, 2002) performed by the steering groups behind the RCT, often 
post-hoc and the results of these have been used to justify prescribing 
recommendations.  However, had a phase III study been carried out purely 
recruiting from a specific aetiology of PH, it would be very unlikely that the 
numbers of patients would have powered the study to demonstrate a 
statistically significant result given the effect sizes noted.  As a consequence of 
the lack of RCT data, the construction of the guidance pragmatically took expert 
opinion together with the published work to give a rational framework for 
prescription of treatments in the NHS.  In situations such as this where there is 
a paucity of data but a need for guidance, an essential part of the ongoing 
revision is the ability to review the experience and outcomes through the NAPH 
and studies such as this one to improve future versions. 
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2013 has seen the introduction of the first national tender for supply of 
homecare services for PH medications and the switch from proprietary 
(Viagra®) to generic sildenafil.  Both will have a major impact on future practice, 
prescribing expenditure and even access to specialist care.  The advent of a 
generic preparation (albeit off-license) could have a dramatic impact on the 
specialist centre system if GPs or local clinicians act outside recommendations 
and prescribe treatment rather than refer to a regional centre.  The next 
generation of the NCP is expected to be published before the start of the 
financial year, 2014 and will reflect these fundamental changes to practice. 
1.5 Structure for care delivery 
 
As already eluded to, since 2001 (Evans et al., 2002) a network of centres of 
excellence has provided NHS care to PAH patients.  In England there are six 
adult centres and one paediatric centre.  The location of these seven centres is 
subject to scrutiny, as they are not ideally spread geographically.  However their 
location has evolved over time as a consequence of the expertise of the teams 
situated in each.  The six adult centres (in addition to Great Ormond Street, 
London – which cares for all paediatric cases) are found at: 
1. Freeman Hospital, Newcastle 
2. Royal Hallamshire Hospital, Sheffield 
3. Papworth Hospital, Nr Cambridge 
4. Royal Free Hospital, London 
5. Hammersmith Hospital, London 
6. Royal Brompton Hospital, London 
 
Patients in Scotland are all managed at the national centre in Glasgow.  
Patients from Wales, Northern Ireland, Channel Islands and the Isle of Man are 
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referred to the nearest PH centre.  The funding for their activity and medication 
is released by the local funding body as appropriate but are managed in one of 
the specialist units in the same way as English patients. 
 
This network of specialist care is unique in Western healthcare terms.  
Contrasting models are preferred in the major European nations.  In France, 
patients are referred nationwide to the centre at the Hospital Antoine Béclère, 
Clamart, Paris for diagnostic assessment.  Following this initial admission, only 
those local to the centre are followed up.  Patients travelling long distances to 
Paris would be managed nearer home for their ongoing care.  Across Germany 
there are large centres treating PH patients.  The centres in Giessen, Hannover 
and Berlin are amongst those most renowned internationally. 
 
In addition to the international societies, the European Respiratory Society 
(ERS) and the European Society of Cardiology (ESC), healthcare professionals 
involved in PH care meet and share best practice through affiliate organisations 
such as the PHA and PHA Europe.  UK-based Allied Healthcare Professionals 
(AHPs) also collaborate clinically and academically through the PH 
Professionals group.  Specialist nursing forums exist in other Western European 
countries where the profile of specialist pharmacists is not as high as in the UK, 
where most PH centres now have access to senior clinical pharmacy support. 
 
In order to investigate the patient’s experience of specialist centres, the PHA 
(patient organisation) has undertaken two patient surveys in the UK.  These 
both looked at the patient experience of all with a diagnosis of PH.  The PHA 
surveyed its membership of approximately 1200 patients invited to take part in 
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the IMPAHCT survey (Armstrong, 2011).  The most recent collected data from 
514 self-selecting patients (representing a response rate of over 80% of those 
agreeing to take part), the results of which were disseminated at the meeting of 
the American Thoracic Society in Denver 2011.  Amongst the findings, people 
managed in specialist centres are more satisfied with the support they receive 
than those managed in other hospitals.  Data from the survey found that 93% of 
patients found the care in specialist centres “good” or “excellent” vs. 73% who 
were managed by other hospitals.  In addition, 1 in 5 surveyed described 
specialist centres as “essential”.  This was important data in justifying the 
specialist centre concept.   
 
Clearly this model of care has several significant theoretical advantages: 
concentration of expertise and experience, consistency of care through easier 
communication between all members of the multi-professional teams and not 
least pooling of patients for recruitment to research purposes.  However, from a 
patient perspective the difference seems to revolve around: finally getting 
answers; accurate diagnosis; initiation and subsequent monitoring of treatment; 
and tailored care.  Of those surveyed, the average time to diagnosis was 2 
years and 2 months with nearly half (47%) seeing 4 doctors prior to diagnosis.  
Once diagnosed and treated by specialist centres, 94% of patients stated that 
their quality of life had improved.   
 
An important function of the expert centres that is easily overlooked is to 
appropriately discharge those patients found either not having PH or those 
identified as being PH in association with left diastolic dysfunction.  These 
patients may appear to have symptoms similar to those exhibited by PAH 
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patients, but this group will not benefit from targeted therapies, indeed these 
may make their symptoms worse.  As a consequence these patients should be 
referred back to local cardiologists or pulmonologists for management. 
 
From 1st April 2013, PH commissioning has been taken on by NHS England.  In 
a similar model to other specialised services, PH has a designated Clinical 
Reference Group (CRG).  This group has representation from clinicians, 
commissioners, allied healthcare professionals and importantly the patient 
voice.  The CRG’s principal responsibility is to advise the national team at NHS 
England on all key decisions to ensure high quality care to PAH patients in the 
NHS in England. 
 
In addition, national clinicians group, the PH Professionals group and an 
established patient organisation all collaborate closely to deliver a high quality, 
sustainable model of care.  The adult services in the NHS are not funded 
centrally as with the paediatric PAH patients.  This makes the links between 
clinicians and commissioners more vital so that high quality care is resourced 
appropriately.  This is becoming ever more important during the difficult financial 
environment of the modern day NHS. 
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1.6 Monitoring of service quality 
 
The nationally designated specialist centres are required to meet the 
Department of Health’s standards of care (DH, 2003).  Rigorous assessment by 
inspectors from the Department of Health (DH) ensures that the standards are 
being met occur at a three-yearly visit to each centre.  The centre provides 
evidence for each of the twenty-four key standards to the assessors. 
 
A positive assessment guarantees the ongoing practice of the centre with areas 
for improvement also highlighted.  This validation confirms to referring clinicians 
and commissioners that patients are receiving the specialist level of care 
expected.  This is of particular importance because in the UK the prescription of 
targeted pulmonary vascular therapy is confined to the centres.  It is worth 
bearing in mind that the medicines in question are of high cost and require 
ongoing monitoring in terms of safety and efficacy. 
 
1.7 Guidelines and protocols for management of PAH 
 
The principal guideline across Europe is that produced by a collaboration 
between the ESC and ERS which is endorsed by the International Society of 
Heart and Lung Transplantation (ISHLT) (Galiè N et al., 2009).  Similar 
guidelines have been published in the USA (McLaughlin et al., 2009b).  Whilst 
there is universal agreement and adoption of much of the content, these 
international guidelines for treatment are subtly different from those used in the 
UK.  UK clinicians employ the general principles of the document in terms of 
diagnosis and classification of patients, but since 2008 UK has implemented its 
own prescribing guidance.   
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The need for prescribing guidance is in no small part due to the expansion of 
options coupled with the high cost associated to each.  In 2001, the first agent 
was licensed for PAH, intravenous epoprostenol, was introduced in 2001 (SPC, 
2012c), after a number of years of unlicensed usage worldwide.  Oral 
treatments were approved shortly after this and it is this group that has 
transformed the way the condition is managed.  NICE undertook a review of the 
treatments in 2008, and decided not to publish a full technology appraisal.  This 
was because NHS specialised commissioners had now put in place agreed 
arrangements for the supply of targeted therapies for all patients affected at the 
most severe stages of the condition – referring to the NCP (NICE, 2009).  
Evidence also suggests that only one of the treatment options was likely to 
meet the NICE cost per Quality-adjusted Life Year (QALY) threshold of £30,000 
per annum.   
 
By looking at treatment and outcomes data collected by the NAPH for cohorts in 
large centres such as Sheffield, the NHS has the opportunity to test various 
hypotheses regarding treatment effect.  Not only “are the treatments more or 
less effective in particular aetiologies?” but also “did this treatment-led guidance 
benefit the Sheffield Pulmonary Vascular Disease Unit (SPVDU) population?”.  
Patients in the NHS are managed potentially differently to similar patients in 
Europe (Sitbon, 2010, Hoeper et al., 2005), where “goal-orientated” and 
“treating to target” approaches are utilised and reimbursed accordingly. 
 
“Goal-orientated” therapy and “treating to target” are similar strategies borne out 
of a planned aim of improving (or maintaining) patients’ exercise capacity (as 
measured by 6MWD) to at least 380m.  This distance has been shown by 
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Sitbon (2002) to be linked to long-term survival.  Their group found a 
significantly improved prognosis for those able to walk further than this distance 
after three months on intravenous epoprostenol.  “Goal-orientated” therapy and 
“treating to target” both employ the use of combination treatment if this distance 
is not achieved.  It is important to note that the Sitbon study used intravenous 
prostanoids.  Data published by Hoeper (Hoeper et al., 2005) puts the concept 
into context for this thesis and approved clinical practice.  This work validated 
the approach of treating to target having commenced patients on first line oral 
therapy with escalation of doses, oral combination and eventually additional 
nebulized iloprost as necessary to help patients meet the 380m target distance. 
It is unclear at this moment whether the European approach is superior to the 
recommendation of the NCP, particularly for PAH-CTD.  Published data for 
“treating to target” did include PAH-CTD patients, but these represented a small 
proportion of the group that was studied (6.5%).   
1.8 Rationale for the study 
 
Evidence based medicine (EBM) was originally defined as “the conscientious, 
explicit, and judicious use of current best evidence in making decisions about 
the care of individual patients.”  The practice of EBM means integrating 
individual clinical expertise with the best available external clinical evidence 
from systematic research (Sackett et al., 1996).  The revised and improved 
definition of EBM is “a systematic approach to clinical problem solving which 
allows the integration of the best available research evidence with clinical 
expertise and patient values” (Sackett DL, 2000).  True evidence based practice 
(EBP) involves more than just using research literature to determine or support 
a diagnosis or therapy.  EBP “is an approach to health care and medical 
practice in which you (the clinician) are able to evaluate the strength of that 
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evidence and use it in the best clinical practice for the patient sitting in your 
office.” (Mayer, 2004) 
 
“Making a conscientious effort to base clinical decisions on research that is 
most likely to be free from bias, and using interventions most likely to improve 
how long or well patients live" (Ebell, 2011).  EBP and Evidence-Based 
Healthcare (EBHC) are now commonly regarded as the cornerstone of clinical 
decision-making.  They are not without criticism, however, with opinions 
regarding the restriction of clinical freedom being voiced in opposition.  The 
other concern with EBM regards its use by healthcare managers to cut 
expenditure.  However, voicing these criticisms demonstrates a limited 
understanding of the concept.  Whilst clinical decision-making is increasingly 
reinforced with clinical evidence, the skill of the clinician today is demonstrated 
by the ability to blend clinical evidence with personal expertise and also to 
respect the beliefs and expectation of the patient.  This concept of overlapping 
is known as the EBM Triad (See figure 1 below). 
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Figure 1 – The EBM Triad, taken from (Cochrane, 2013) 
Thus, clinical decision making is now based on information derived from 
research to a greater degree than ever before (Gray, 2001).  PAH is no 
exception and as previously mentioned, the NCP is one of the best examples in 
the NHS today of clinical guidance outside of NICE HTAs.  The first piece of 
prescribing guidance produced outside NICE or a Royal College in any clinical 
field, it demonstrated how commissioners and clinicians could forge agreement 
over treating patients in all specialist centres according to current “best 
practice”. 
 
It is my contention, however, that whilst the policy gained agreement from all 
parties, not all of the content should be regarded as best practice or indeed 
evidence based.   Although licensed, treatments in PAH are used for patients 
and populations differing significantly from those in clinical trials.  As a result, 
whether or not the terms EBP and EBHC can be appropriately applied directly 
in this instance depends somewhat on semantics.  The award of a product 
licence should not automatically infer “best practice”?  Experience beyond the 
trial populations is desirable in order to instill one particular treatment as the 
“drug of choice” in a specific aetiology of disease as the RCT provided limited 
proof of treatment effect in a small population.  However, despite the lack of 
additional experience or research, one agent (bosentan) was approved as first 
line for PAH-CTD with only sub-group analysis of the phase three data from the 
licensing study.  The same level of evidence was available the alternative 
(sildenafil) at that time.  Neither had been explored in trials within specific 
aetiologies, as was the case in PAH associated with congenital heart disease 
(PAH-CHD) through the BREATHE-5 study (Galiè et al., 2006). 
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Although perhaps not perfect, the development of a NCP in PAH was doubtless 
a step in the right direction in terms of standardising and rationalising expensive 
prescriptions.  Enough of a step indeed for the National Institute for Clinical 
Excellence (NICE) to withdraw its own attempts at a technology appraisal in 
2009 (NICE, 2009).  The rationale for NICE’s postponement was given as being 
the successful introduction of the NCP only a year earlier.  In tandem with the 
NCP and conditional of its “prior approval” approach to funding availability, 
research and study into treated populations in centres is ongoing in the form of 
the national audit of pulmonary hypertension database (NAPH).  Before outputs 
from the NAPH are available and have been validated, we must continue to use 
the current evidence and also develop practice research to assist in answering 
some of the clinical questions that the currently available published work cannot 
(Roberts R, 2010). 
 
Much has been made of the literature in recent times of the importance of PH 
registry data to give a better understanding of the condition (Badesch et al., 
2010, Humbert et al., 2006).  In the era of evidence-based practice, in addition 
to registries giving a better understanding of baseline data and patient 
phenotypes, there is a need to justify prescribing policies with robust clinical 
studies.  Unfortunately, there are still only a few prospective randomised pivotal 
licensing studies and small-number open label studies showing the safety and 
efficacy of treatments.  This leaves a number of gaps in the evidence base.  In 
this situation clinical experience and case-series evaluation play a more 
important role in understanding how best to manage patients effectively.  The 
inevitable consequence is a higher-than-usual level of unlicensed and off-
license prescribing.  Extrapolating the data generated by sub-group analysis 
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(Galiè, 2005, Rubin LJ, 2002) of the major prospective randomised controlled 
trials (RCTs) is also necessitated.  Post-hoc analysis is not amongst the highest 
quality of evidence.  Unfortunately, it is, to date, the best available evidence.  
This is because unlike an essential hypertension trial for example, recruitment 
of patients with rare diseases such as PAH-CTD is difficult.   
 
In this situation, where there is little data from RCTs, observational studies can 
form a useful and valid part of the evidence base.  These will not be prospective 
and randomised, but will investigate a different, and larger, population from that 
studied in phase 3 trials.  All RCTs to date in PAH have recruited prevalent 
patients.  Prevalent in this context is defined as being those patients usually 
known to the centre prior to recruitment into the trial.  These are patients who 
have been diagnosed already.  There are advantages and disadvantages to 
recruitment of a purely prevalent population.  Prevalent cases give us important 
insight with regard to efficacy, safety and tolerability.  However, recruitment is 
by definition taken from cleaner, selected groups with less polypharmacy and 
fewer co-morbidities than general “real life” populations.  This retrospective 
study includes primarily incident cases.  Incident cases are those newly 
identified by the centre during the period of interest, or those presenting to the 
centre for a diagnosis and requiring treatment.  The most striking benefit of 
reviewing the progress of incident cases is that these will more accurately 
reflect treatment initiation in everyday clinical practice.   
 
Incident cases are likely to have a worse outcome than prevalent cases and 
there are several reasons why;  firstly there is a recognised high-risk phase 
after diagnosis, notably affecting the acutely unwell referrals.  It is logical to 
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assume that prevalent cases stabilised on treatment will have a better outlook.  
In addition, inclusion criteria for studies investigating prevalent cases usually 
require patients to have been stable with no recent medication changes in the 
preceding few weeks.  There are also common upper restrictions on age and a 
minimum required exercise capacity.  All of these criteria are more achievable in 
stable cases that, by default will have a better prognosis.  They are impossible 
to apply in everyday practice (incident cases) where anyone with a diagnosis 
should be appropriately treated.   
 
This study will complement the findings of formal trials of treatments for PAH by 
contributing a real-life element to the evidence base for the expensive 
treatments given for this devastating disease.  Other members of the Sheffield 
group have carried out previous work looking specifically at the PAH-CTD 
population across the United Kingdom (Condliffe, 2009).  My research forms an 
important part of this ongoing multi-professional research programme and adds 
to it from a pharmacy, treatment-related perspective. 
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1.9 Chapter summary 
 
PH is a rare, progressive and life-limiting condition.  Of the many forms of the 
disease, PAH-CTD is the associated with worst prognosis.  There is only limited 
evidence to suggest that current treatment options are successful in treating this 
type of PAH.  On a positive note, the PH service in the UK is amongst the most 
evolved and organised anywhere in the world.  Recent years have seen the 
development of clinical pharmacy services in a number of centres.  As a result, 
there is now a multi-professional approach to patient care in all UK centres. 
 
Consequential to the cost and range of treatment options available in the NHS, 
the UK has developed its own prescribing guidance, which differs in some 
respects from internationally agreed guidelines.  The guidance, by necessity, 
had to take a pragmatic approach in areas where there were gaps in the 
evidence base.  There is a need to support clinicians’ decisions by enhancing 
the evidence base for this condition in order to inform future reviews of the 
guidance.  Interrogation of the patient databases at one of the specialist 
treatment centres offers the opportunity to study treatment and outcomes in a 
large cohort of patients over a period of years.  Drawing on experience of 
working in a specialist centre has facilitated access to population numbers 
necessary for this type of research.  Such analysis has the potential to inform 
clinical practice.  The national audit data will, in due course provide answers to 
the questions being asked, but in the meantime justification is necessary over 
and above the current evidence base for the use of specialist, expensive 
treatment regimens for rare diseases.   
Therefore, in summary, two key points justify a retrospective review of the 
treatment of PAH-CTD: 
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1. Pulmonary Arterial Hypertension (PAH) in association with connective 
tissue disease is an aggressive form of the disease (Condliffe, 2009) and 
often the most difficult to treat (Avouac et al., 2008). 
2. Oral treatments (bosentan and sildenafil) have been used to treat PAH 
for around ten years, but evidence is limited beyond licensing studies 
and sub-group analysis. 
1.10 Brief Outline of this thesis 
 
In Chapter 2, a literature review examines the published works pertinent to the 
project.  It presents the data to show that pharmacological intervention is less 
effective than in other types of PAH.  It describes the outcome measures used 
in published PAH studies and whether they are suitable to be applied to 
PAH-CTD. 
   
In Chapter 3, the aims and objectives are described.  Chapter 4 covers methods 
and methodology.  This chapter begins with the choice of study design.  
Following a breakdown of the methodology it discusses in depth why and how 
retrospective data will be collected and crucially how it will be analysed.  The 
pilot project conducted a retrospective analysis of the use of a second ERA 
(ambrisentan).  How this pilot has influenced and improved the design of the 
main study is documented.  Following on from the preliminary work is a detailed 
account of the methods employed in this study to test the hypothesis. 
 
Chapter 5 presents the results from the various streams of data analysis 
undertaken in determining the effects on outcomes of the different treatments 
and the introduction of the NCP.  Chapter 6 discussed the implications of the 
findings.  It compares, contrasts and relates the findings here to other previous 
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published works.  It explores implications for future commissioning policy and 
other currently used guidelines and further research.  Chapter 7 presents the 
conclusions from the research and suggests future work together with the 
unanswered questions.  It summarises the implications on future practice of the 
results described in Chapter 6.   
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Chapter 2 – An overview of the literature 
2.1 Introduction 
Chapter 1 provided the background to this rare disease.  It described PAH and 
its sub-classification, together with an overview of the CTDs.  It described both 
the way that these patients are managed in the UK and how treatment in the 
UK is undertaken in accordance with the NCP.  However, it is my contention 
that due the paucity and quality of available data, some of the treatment 
recommendations that the policy stipulates can be challenged.  The evidence 
base is closely examined in the coming chapter. 
   
This literature review addresses some fundamental points in understanding the 
treatment of PAH-CTD: 
 What is the evidence base for any of the targeted therapies (focusing 
particular attention on oral agents) for this particular form of the disease?   
 Is the use of first line bosentan (in accordance with the 2008 National 
Commissioning Policy) justified given the available evidence?   
 Are the endpoints used in the studies an appropriate way of assessing 
treatment effect for this particular aetiology?   
A review of the literature answering each of these points in turn will demonstrate 
the importance of this project in terms of the gap in the evidence base.   
2.2 Search methodology 
In order to reliably capture all of the salient, peer-reviewed literature on this 
narrow area it was necessary to conduct an “exhaustive review with selective 
citation”.  This term was first introduced by Cooper (Cooper, 1988) as a means 
by which an exhaustive review could be made manageable.  An exhaustive 
review would have merit, but finding every piece of available research would be 
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both time and labour intensive.  This is a specialised clinical area and the 
diversity of clinical and translational health research is generating a rapidly 
growing breadth of literature regarding PAH.  Some of the more general 
information is relevant to this work.  That said, careful selection of the data is 
necessary to gain an understanding which evidence is pertinent specifically to 
patients with PAH-CTD.   
 
The National Library for Health (NLH) search interface was the primary search 
tool.  Two databases, Medline and Embase were interrogated.  MEDLINE 
(Medical Literature Analysis and Retrieval System online, or MEDLARS online) 
is a database of life sciences and biomedical information.  The National Library 
of Medicine compiles it in the USA.  Embase (Excerpta Medica database) is the 
most comprehensive international biomedical database.  It collates journal 
articles with a lean to medication, treatments and toxicology.  Whilst some 
overlap between the results produced by each database was expected, it was 
essential to search both in order to confidently capture all relevant articles.   
Both search strategies are included in the thesis as Appendix 1.  Searches for 
the terms pulmonary hypertension, connective tissue disease, bosentan and 
sildenafil were undertaken.  The search strategy undertaken is very similar to 
that employed in other recently published reviews.   
 
Both the EMBASE and MEDLINE searches used these terms as free text 
words.  The search terms were verified in the MeSH thesaurus prior to the 
Medline search and against Emtree for the Embase search in order to optimise 
the returns.  It was expected that some articles might mention CTD or SSc 
within the body of the text but not necessarily in the title of the article or as a 
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keyword.  Use of free text searching got around this issue.  Note subtle 
differences between the strategies employed from the respective search 
engines.  These strategies were conducted in line with the UK Medicines 
Information training package for online literature reviewing in order to optimise 
returns. 
 
It was also anticipated that being such a broad search strategy, the results 
would include some general PAH articles that might have relevance to the 
discussion.  Where appropriate these have been used.  Additional references of 
interest were identified in the bibliographies of identified papers.   
 
In order to ensure that newer material was not missed, alerts were set up within 
the NLH search tool.  These alerts took the form of a weekly email.  Every week 
the engine re-ran both queries and if any additional results were identified, the 
email would notify me as and when a new article or piece of work that met my 
search criteria was detected.  This avoided the need for repeatedly running the 
searches personally.  It also gave confidence that at the time of writing up, all 
relevant published literature had been included in the review.  In addition to the 
online bibliographic database trawl, some hand searches within the SPVDU 
were conducted.  These were especially helpful in discovering texts that were 
not listed in the search engines.  Examples identified of the so-called “grey-
literature” to be potentially relevant to this research were excerpts from training 
manuals, abstracts/manuscripts not yet published, conference notes and 
handouts. 
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The searches were limited to articles available in English.  The rationale for this 
was two fold; firstly there was no ready means of translation and secondly, with 
the exception of some Japanese work, all of the licensing studies, long term 
extension works, guidelines and meta-analyses have all been either written in 
English or translated as necessary.  This seemed also the case with survival 
analysis papers.  On this basis, the decision was taken decided that articles 
written in other languages would add little of value to the search.   
 
The search was also limited to human studies.  This study focuses on the 
treatment effects of licensed treatments in patients referred to our centre.  On 
this basis, the decision was made that the findings and conclusions of in vitro 
and proof of concept studies would be of little relevance.  As this chapter goes 
on to discuss later, there are valid discussions regarding the difference between 
clinical trial populations and the incident cases routinely treated in clinic.  To 
include animal models, in vitro work or phase one studies would be of less 
relevance still to current practice. 
 
Searches were not limited by date.  As a result of this, Medline searched back 
to 1965, Embase 1947.  Of the references discussed here, the earliest dates 
back to 1987.  Although the development of treatment strategies has evolved 
relatively quickly in recent years, some important work was published some 
time ago and is still of value today.   
 
This strategy resulted in 93 results through Embase and 114 through Medline, 
with a degree of expected overlap seen on reviewing the results of each.  A 
total of 179 unique results were then carefully analysed for the quality of the 
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data, validity of the conclusions and applicability to this study.  When filtering 
the results, although I used critical analysis skills, I did not employ a specific 
tool.  Of particular interest when reviewing the articles was the study design, 
sample size, use of incident cases and endpoints used.  I was also interested in 
the statistical analysis employed to analyse the data.  This would be helpful in 
justifying the most appropriate test to use for data to be collected in this study.  
For the review of the clinical data, the search was limited to RCT and sub-group 
analysis.  A full breakdown of the search results and filtering process is found in 
appendix 2.  The filtered results of the literature search are summarized in the 
able below.  This table details each study, based on a structure used in 
Cochrane reviews. 
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Table 5 - Summary of the evidence 
Study Methods Participants Intervention Outcomes 
Breathe 1 Multicentre randomised 
placebo-controlled, parallel, 
double-blind trial.  
Randomisation was 
conducted according to a 
computer-generated random 
number. Allocation 
concealment was adequate.  
Dropouts and withdrawals 
were described.  Intention-to-
treat was performed. 
Study duration is 16 weeks. 
Total n = 213 (69 in placebo 
group; 144 in bosentan 
group). 
Women (54 in placebo group; 
114 in bosentan group).   
Age (47.2 ± 16.2 in placebo 
group; 48.7 ± 15.8 in 
bosentan group) 
Idiopathic PAH (48 in placebo 
group; 102 in bosentan 
group).   
PAH secondary to collagen 
vascular disease (21 in 
placebo group; 42 in 
bosentan group) 
WHO functional class III (65 in 
placebo group; 130 in 
bosentan group) 
Intervention group: 62.5 mg 
bosentan twice daily for the 
first 4 weeks followed by the 
target dose (125 mg or 250 
mg twice daily) for 12 weeks 
Control group: placebo. 
Primary outcomes: Change 
from baseline in 6MWD. 
Secondary outcomes: Borg 
dyspnoea index; WHO 
functional class 
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WHO functional class IV (4 in 
placebo group; 14 in 
bosentan group) 
6MWD in placebo group was 
344 ± 76m and 330±74m in 
bosentan group 
Breathe 2 Multicentre randomised 
placebo-controlled, parallel, 
double-blind trial.  
Randomisation was 
conducted according to a 
computer-generated random 
number.  Allocation 
concealment 
was adequate.  Dropouts and 
withdrawals were described 
(Each group had one 
premature discontinuation 
due to an adverse event.  One 
patient in intervention group 
discontinued due to clinical 
Total n = 33 (11 in placebo 
group; 22 in intervention 
group). 
Total 28 completed (10 in 
placebo group; 18 in 
intervention group). 
Women (6 in placebo group; 
17 in intervention group). 
Age (47 ± 19 in placebo 
group; 45 ± 17 in intervention 
group). 
Idiopathic PAH (10 in placebo 
group, 17 in intervention 
group). 
PAH secondary to 
33 patients with PAH started 
prostacyclin treatment (2 
ng/kg/min starting dose, up 
to 
14±2ng/kg/min at week 16) 
and were randomised for 16 
weeks in a 2:1 ratio to 
bosentan (62.5 mg twice daily 
for 4 weeks then 125 mg 
twice daily) or placebo 
Primary outcomes: Change 
from baseline to week 16 in 
TPR. 
Secondary outcomes: Change in 
CI, PVR,mPAP, and mean right 
atrial pressure (mRAP) 
, 6MWD, NYHA functional class 
and dyspnoea-fatigue rating 
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worsening and 2 patients in 
intervention group died.)  
Intention-to-treat was 
performed.  Study duration is 
16 weeks 
scleroderma (1 in placebo 
group; 4 in intervention 
group). 
PAH secondary to systemic 
lupus erythematosus (0 in 
placebo group; 1 in 
intervention 
group). 
NYHA functional class III (8 in 
placebo group; 17 in 
intervention group). 
NYHA functional class IV (3 in 
placebo group, 5 in 
intervention group 
Channick 2001 Multicentre randomised 
parallel trial comparing 
bosentan with placebo for 12 
weeks. 
Randomisation was computer 
generated with a block size of 
three. Allocation concealment 
Total n = 32 (30 completed 
protocol; 21 in bosentan 
group; 11 in placebo group) 
Women (11 in placebo group, 
17 in bosentan group). 
Age (47.4 ± 14.0 in placebo 
group; 52.2 ± 12.2 in  
Intervention group: 62.5 mg 
bosentan twice daily for the 
first 4 weeks followed by the 
target dose (125 mg twice 
daily). Control group: placebo 
Primary outcomes: 6MWD. 
Secondary outcomes: 
Cardiopulmonary 
haemodynamics (CI, PVR, 
mPAP, and mRAP) 
, WHO functional class 
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adequate. Dropouts and 
withdrawals were described. 
Intention-to-treat analysis 
was conducted. Study 
duration is 12 weeks 
bosentan group) 
Idiopathic PAH (10 in placebo 
group, 17 in bosentan group). 
PAH secondary to 
scleroderma 
(1 in placebo group, 4 in 
bosentan group) All 
participants were in WHO 
functional class III. 
6MWD was 355 ± 82 m in 
placebo group, and 360 ± 86 
m in bosentan group 
Early Multicentre randomised 
placebo-controlled, parallel, 
double-blind trial. 
Randomisation was  
conducted centrally according 
to centralised integrated 
voice recognition system. 
Allocation concealment 
Total n = 185 (92 in placebo 
group; 93 in intervention 
group). 
Women (71 in placebo group; 
58 in intervention group). 
Age (44.2 ± 16.5 in placebo 
group; 45.2 ± 17.9 in 
intervention group). 
Participants either treated 
with bosentan at an initial 
dose of 62·5 mg twice daily, 
uptitrating 
to 125 mg twice daily after 4 
weeks, or remaining at 62·5 
mg twice daily if bodyweight 
<40 kg, or placebo for a 6-
Primary outcomes: PVR and 
change from baseline in 6MWD. 
Secondary outcomes: time to 
clinical worsening, change from 
baseline to month 6 in 
WHO FC, Borg dyspnoea index, 
mPAP, CI, RAP, and mixed 
venous oxygen saturation 
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adequate. Treating study 
personnel, participants and 
assessors were all blinded 
Dropouts and withdrawals 
were described (In placebo 
group, 12 patients 
discontinued. Of these, 9 due 
to adverse events; 1 
withdrew consent; 2 protocol 
violations. In bosentan group, 
10 patients discontinued. Of 
these, 9 due to adverse 
events; 1 withdrew consent) 
Intention-to-treat was not 
performed. 
Study duration is 6 months. 
Idiopathic PAH (58 in placebo 
group, 54 in bosentan group). 
PAH secondary to connective 
tissue disease (15 in placebo 
group; 18 in bosentan group). 
PAH secondary to HIV (2 in 
placebo group; 5 in bosentan 
group) 
All patients were in WHO 
functional class II. 
6MWD was 431 ± 91m in 
placebo group and 438 ± 86m 
in bosentan group 
month double-blind 
treatment period 
Seraph Single-centre randomised 
head to head double-blind 
trial. 
A stratified central- 
randomization scheme was 
Total n = 26 (14 in sildenafil 
group, 12 in bosentan group). 
Total 25 completed (13 in 
sildenafil group, 12 in 
bosentan group). 
Intervention group: bosentan 
(62.5 mg twice daily for first 
four weeks, then up-titrated 
to 125 mg twice daily). 
Control group: sildenafil (50 
Primary outcome: change in 
right ventricle mass from 
baseline. 
Secondary outcomes:Change 
from baseline in 6MWD,CI,Borg 
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used to assign patients 
to four treatment groups — 
those receiving 
20, 40, or 80 mg of sildenafil 
or placebo three times 
daily — in a 1:1:1:1 ratio. The 
randomization was 
stratified with respect to the 
baseline walking distance 
(<325 m or ≥325 m) and 
cause of pulmonary 
arterial hypertension. 
Allocation concealment was 
adequate. 
Dropouts and withdrawals 
were described (25 patients 
completed the study, one 
patient 
in sildenafil died at week 14.) 
Intention-to-treat analysis 
was conducted. 
Women (11 in sildenafil 
group; 10 in bosentan group). 
Men (3 in placebo group; 2 in 
sitaxsentan group). 
Age (44.4 with range from 28 
to 62 in sildenafil group; 41.1 
with range from 27 to 55 
in bosentan group). 
Idiopathic PAH (12 in 
sildenafil group, 11 in 
bosentan group). 
PAH secondary to 
scleroderma (1 in placebo 
group; 1 in intervention 
group). 
PAH secondary to systemic 
lupus erythematosus (1 in 
placebo group; 0 in 
intervention 
group) 
mg twice daily during the first 
four weeks, then up-titrated 
to 50 mg three times daily) 
dyspnoea index, quality 
of life, and plasma B-type 
natriuretic peptide level from 
baseline 
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Study duration is 16 weeks. 
Super 1 Multicentre randomised 
placebo-controlled, parallel, 
double-blind trial. 
Randomisation 
was conducted centrally 
according to centralised 
integrated voice recognition 
system. 
 
Total n=278 (70 placebo, 69 in 
20mg, 68 in 40mg and 71 in 
80mg groups) 
Men30% in active group, 19% 
in placebo group) 
Age 49+/-17 placebo, 47-
51+/- 15 in sildenafil groups 
Idiopathic PAH (42 in placebo 
group; 173 in sildenafil 
group). PAH secondary to 
collagen vascular disease (8 in 
placebo group; 30 in sildenafil 
group) WHO functional class 
IV (3 in placebo group; 6 in 
sildenafil group) 
6MWD in placebo group was 
344 ± 79m and 345±79m in 
sildenafil group 
 
Patients randomly assigned to 
80 mg of sildenafil tds 
received 40mg of sildenafil 
tds for the first seven days 
before the dose was 
escalated to 80 mg; patients 
randomly assigned to the 
other three treatment groups 
underwent dummy dose 
escalation after 
seven days. 
The primary measure of efficacy 
was the change in 
exercise capacity, as measured 
by the total distance walked in 
six minutes, from baseline to 
week 12. Other measures of 
efficacy were the changes in 
mean pulmonary-artery 
pressure, score on the Borg 
scale of dyspnea (with 0 
representing no dyspnea and 10 
maximal dyspnea), World 
Health Organization (WHO) 
functional classification of 
pulmonary arterial 
hypertension (an adaptation of 
the New 
York Heart Association 
classification), and time 
from randomization to clinical 
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worsening (defined as death, 
transplantation, hospitalization 
for pulmonary arterial 
hypertension, or initiation of 
additional therapies for 
pulmonary arterial 
hypertension, such as 
intravenous epoprostenol or 
oral bosentan). 
Super 2 Two hundred fifty-nine of 277 
randomized and treated 
patients completed a 12-
week, double-blind, placebo-
controlled trial (SUPER-1 
[Sildenafil Use in pulmonary 
Arterial Hypertension) of oral 
sildenafil in treatment-naive 
patients with PAH (96% 
functional class II/III) and 
entered an open-label 
uncontrolled extension study 
Total n=259 (67 placebo, 65 in 
20mg, 63 in 40mg and 64 in 
80mg groups) 
Men 30% in active group, 19% 
in placebo group) 
Age 49+/-17 placebo, 47-
51+/- 15 in sildenafil groups 
Idiopathic PAH (42 in 
placebo group; 173 in 
sildenafil group). PAH 
secondary to collagen 
Patients assigned to 
placebo or sildenafi l 20 or 40 
mg tid in SUPER-1 initially 
received sildenafil 40 mg tid; 
after 6 weeks, they titrated to 
sildenafil 
80 mg tid as tolerated.  
Patients in the sildenafil 80 
mg tid group 
were maintained at this dose 
and underwent a dummy up-
titration. 
Primary efficacy - 6MWD and 
WHO FC. 
If 6MWD or WHO FC data were 
missing at a visit, the worse 
score of nonmissing neighbour 
values was used.  If a patient 
was 
enrolled on the visit day but 
had a missing assessment and 
no subsequent assessment, 
then the data were  classified as 
missing.  The survival status of 
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(SUPER-2) that continued 
until the last patient 
completed 3 years of 
sildenafil treatment.  Patients 
titrated to sildenafil 80 mg tid 
; one dose reduction for 
tolerability was allowed 
during the titration phase. 
vascular disease (8 in placebo 
group; 30 in sildenafil group) 
WHO functional class IV (3 in 
placebo group; 6 in sildenafil 
group) 
6MWD in placebo group was 
344 ± 79m and 345±79m in 
sildenafil group 
 
Patients could down-titrate 
once during the initial 12 
weeks of SUPER-2 for 
intolerable adverse events 
(AEs). 
all patients who discontinued 
(including patients who 
underwent lung or heart-lung 
transplantation) was followed 
on a yearly basis and at study 
end.  Survival rates at 1, 2, and 
3 years were calculated for all 
patients and by subgroups 
using Kaplan- Meier estimates 
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Before digesting the published evidence available for each of the treatments 
investigated during the thesis, an exploration of the endpoints used in PAH is 
necessitated.  This will enable a greater interpretation of the study data. 
 
2.3 Endpoints 
When choosing the endpoints for this study it was desirable to be able to 
assess the treatment effects from different perspectives.  Choosing functional 
endpoints that would map well to previous RCTs would be neat, but there are 
well-described issues with the RCT endpoints when tested in the particular 
aetiology of PAH-CTD (Denton et al., 2011, Avouac et al., 2010).  These issues 
are pertinent to the CTD patients and not the other aetiologies (for example 
IPAH) due to the musculoskeletal co-morbidity, which can have an 
overwhelming impact on patients’ ability to complete the walk tests.  As a 
consequence of both these factors, functional assessment via exercise testing 
and WHO FC will be looked at in this study but not in isolation.  The alternative 
options warrant further consideration in terms of practicality, applicability and 
relevance to this study.   
 
The following table is taken from Denton et al (2011).  It concisely summarises 
the issues around endpoint selection in this group of patients. 
Table 6 – Domains and measurement tools for the assessment of 
pulmonary arterial hypertension in systemic sclerosis 
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Right heart catheterisation (RHC) is the gold standard test for assessment of 
pulmonary haemodynamics.  However, the invasive nature of this test means 
that it does not provide an ideal tool for ongoing assessment of symptoms at 
outpatient clinic visits.  Repeat RHCs in the context of clinical trials after 12 or 
16 weeks have been employed to show the impact on haemodynamics but 
clinical practice does not employ the use of routine repeat RHCs in the UK.  As 
a result of the lack of repeat measurements, we know little regarding the value 
of repeated haemodynamic measurements in incident cases of PAH-CTD.   
 
RHC is the diagnostic test of choice.  It provides a range of readings that 
characterise the PH disease process in terms of pressure and saturation 
measurements.  In the course of the literature, it is clear that RHC is not only a 
diagnostic tool, but the information may be used prognostically.  Haemodynamic 
features of raised Ppa or Pra or reduced CO are all indicators of severe disease 
and more limited survival (D’Alonzo GE, 1991).  More recent data from the 
REVEAL registry also found that raised PVR (>32 wood units) was an 
independent predictor of survival (Benza et al., 2010). 
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There is a need to find a less invasive longitudinal assessment tool that can 
replace the RHC as the gold standard diagnostic test in PAH (Denton et al., 
2011).  In addition to this, we have seen from previous work that, 
haemodynamically; PAH-CTD does not differ greatly from IPAH.  Occasionally, 
patients with PAH-CTD may present with a haemodynamic profile that appears 
less “severe” than IPAH.  In addition to this, haemodynamic change over time 
may not necessarily correlate with progression of disease, as this is likely to be 
multi-factorial, particularly in PAH-CTD.  In routine clinical practice, the repeat 
RHC is only used to gain a better understanding of clinical deterioration, where 
there are a number of co-morbidities or factors that could have an influence.  
They are not utilised to endorse the non-invasive findings seen at follow up, 
either positive or negative.  Hence repeat haemodynamic data was not 
available for use in this study. 
 
2.3.1 Walk tests – 6MWD or ISWT? 
All current treatments prescribed for pulmonary arterial hypertension have been 
licensed on the basis of the effect they exert in terms of improving functional 
capacity.  Indeed, exercise testing forms a central part of the review process of 
patients in clinic settings.  Exercise capacity is measured at baseline (diagnosis) 
and at intervals throughout their attendances at the clinic.  Whilst some patients 
with PAH are unable to perform an exercise test, fortunately these are few in 
number.  The vast majority of patients are able to manage some exercise.  
Patients with PAH are likely to be limited in terms of exercise capacity due to 
the effect of their PAH reducing TLCO and CI.  In general terms, there are well-
described reasons why exercise may not be a good marker in CTD (Denton et 
al., 2011, Schoindre et al., 2009, Kowal-Bielecka et al., 2008).  In addition to the 
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cardio-pulmonary effects, the overlapping CTD will add musculoskeletal 
complications for patients of this particular aetiology.  It is logical that patients 
with myalgia, arthralgia, muscle weakness or fatigue may not be able to walk as 
far in the walk test (McLaughlin et al., 2009a).   
 
Assessment of function and exercise capacity is currently a vital part of the 
consultation.  Patients who may be unable to manage a particularly long 
distance in the walk test may be able to recall tasks in their everyday living 
more easily, for example walking to the shops or pushing trolleys around the 
supermarket.  The clinician and patient view on these activities guides both 
parties toward a global assessment of their wellbeing and the trajectory of their 
illness. 
 
These are important in judging overall improvement, stability or deterioration. 
Unlike complex composite markers such as time to clinical worsening (TTCW – 
see Section 2.2.2), the walk test is a simple, validated and reproducible test 
available in any clinic.  As such, although potentially flawed it has a vital role to 
play. 
 
The most commonly used endpoint to date in pivotal studies has been exercise 
capacity as measured by the 6MWD (Rich, 2012).  The 6MWD is simply a 
measure of the distance covered by the patient in 6 minutes (van Stel et al., 
2001).  The test takes place in a corridor of known length.  Patients are able to 
change the speed at which they walk and even stop for a rest.  At the end, the 
patient should feel that the distance walked represents the maximum they could 
have walked in the time.  In addition to the distance, patients may have other 
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parameters recorded.  These may be pulse, transcutaneous oxygen saturations 
and BORG score (Borg, 1982) for breathlessness.  There is good correlation 
between 6MWD and: NYHA functional class, maximal oxygen uptake, PVR and 
survival in IPAH (Miyamoto et al., 2000).  Patients would undertake the 6-
minute walk test at baseline and follow up with the results compared.  Both the 
FDA and the EMA have accepted the use of 6MWD as an outcome measure.  
There are several good reasons for this, not least it is a simple, cheap, 
reproducible endpoint (Kowal-Bielecka et al., 2008).  It has not, however, been 
specifically evaluated in PAH-CTD.  Indeed a meta-analysis concluded that the 
6MWD showed little by way of treatment effect in the pivotal RCTs in the PAH-
SSc sub groups (Avouac et al., 2008). 
 
When assessing patients with PAH-CTD, there are potential challenges in 
obtaining meaningful oxygen saturations due to skin thickening and peripheral 
vasculature insufficiency.  The BORG breathless score may also be distorted in 
PAH-CTD patients.  As such ultimate breathlessness may not be the limiting 
factor in them achieving a larger distance.  Such patients may be more limited 
by musculoskeletal pain instead.  Avouac (2010) has described the partial 
validation of the 6MWD in PAH-SSc (he doesn’t discuss other CTDs).  In 
contrast, a small study (n=26) was unable to prove the specificity of using the 
6MWD in patients with SSc (Schoindre et al., 2009). 
Further studies are needed to fully validate the test as a result of the co-
morbidities that may be interfering with the results.   
 
Baseline 6MWD correlates with survival in IPAH (Miyamoto et al., 2000).  It has 
been demonstrated as similar to cardiopulmonary exercise testing as an 
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independent predictor or morbidity and mortality (Galiè N et al., 2009, Paolillo et 
al., 2012, Miyamoto et al., 2000, Benza et al., 2010).  Interestingly a more 
recent meta-analyses of 22 randomised controlled trials concluded that change 
in 6MWD does not reflect change in clinical outcomes (Savarese et al., 2012).  
The study showed that changes recorded at first review did not predict a 
reduction in major clinical events.  It has not been proven whether any 
correlation would be seen at longer follow up 
 
In contrast to the 6MWD, the SPVDU has used the ISWT as the measure of 
exercise capacity for PAH patients.  The rationale for this lies in a crucial 
difference between the tests; that the ISWT stresses the patient to a symptom-
limited maximum (Singh et al., 1992).  The patient walks around a 9m course 
defined by two marker cones.  This makes the distance for one complete shuttle 
10m in total.  The speed of walking is determined by audible signals, which 
become increasingly frequent through the test.  This allows the patient 
progressively less time to complete a shuttle.  The patient finishes the test at 
the point that they are unable to keep pace with the beeps.  The walk test 
correlates quite well with the VO2 max (percentage of maximum O2 uptake) 
(Singh et al., 1994) which would act as a suitable guide to aerobic capacity in 
each individual.  However, as patients may be limited for reasons other than 
breathlessness, some of the test results particularly from the PAH-CTD group 
may be misleading.  As with 6MWD, patients at SPVDU undergo pulse, 
transcutaneous oxygen saturations and BORG score for breathlessness in the 
course of an ISWT.  In terms of CTDs, the ISWT has been validated in women 
with RA but these cases did not also have a diagnosis of PAH (MacSween et 
al., 2001).   
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Due to the paucity of data available describing the use of the ISWT in PAH, it is 
hard to make definitive conclusions as to the preferred test.  Clearly the 6MWD 
is the test performed the world over and has been universally accepted by the 
PAH community as the chosen method of measuring exercise capacity.  
However, doubts remain and an alternative in the form of the ISWT may answer 
some of these.  Previous work by Elliot and colleagues from the SPVDU 
demonstrated correlation between ISWT and poor prognosis in a group 
comprising all aetiologies of PAH (Elliot, 2004).  In addition, there seems to be 
less of a learned effect with ISWT, meaning that a practice walk (as undertaken 
in 6MWD) is not necessary (Pepera et al., 2010). 
 
It is not feasible to adopt the same outcome measures here as those chosen by 
previous published studies looking at the effect of medical treatments in PAH.  
In observing treatment effects, a note of importance arises from Wise (Wise and 
Brown, 2005).  The researchers identified a minimum clinically important 
difference (MCID) when undertaking exercise testing.  A conservative estimate 
for the 6MWD was 54-80m.  There were no data for the ISWT.  On the basis 
that most licensing studies describe a difference of 6MWD at 12 or 16 weeks to 
be approximately 40m, none of the currently prescribed PAH treatments deliver 
a MCID. 
 
An alternative exercise measurement to either walk test is Cardio-Pulmonary 
Exercise Testing (CPET).  This has been shown to be more accurate in 
Primary/IPAH than simple walk tests but is also more susceptible to operator 
variability (McLaughlin et al., 2009c).  Use of the CPET has significant resource 
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implications due to the time taken and equipment used.  This test is employed 
in specifically identified cases only rather than routine practice at SPVDU. 
 
2.3.2 Composite Endpoints 
Primary endpoints recording improvements in exercise capacity have recently 
been superseded by composite endpoints such as time to clinical worsening in 
the newest RCTs.  Time To Clinical Worsening (TTCW) has been used with a 
slightly different definition in various studies and hence meaningful comparison 
is difficult (McLaughlin et al., 2009c).  However these have invariably used four 
common themes (see Table 5): 
1. All cause Mortality 
2. Hospitalisation for PAH related causes 
3. Surgical intervention.  For example, transplantation 
4. Evidence of PAH disease progression. 
The most recent attempt to analyse the impact of TTCW on survival used 
registry data from the US REVEAL set (Frost et al., 2013).  The authors took 
four chosen TTCW markers; freedom from worsening functional class (FC), a 
≥15% reduction in 6-minute walk distance (6MWD), all-cause hospitalisation, or 
the introduction of a parenteral prostacyclin analogue therapy.  It was shown 
that patients who experienced clinical worsening had significantly poorer 
subsequent 1-year survival post-worsening than patients who did not worsen. 
 
[Type text] [Type text] [Type text] 69 
Table 7 – Summary of TTCW definitions (adapted from (McLaughlin et al., 2009c)). 
Component\Study BREATHE-1 & 
351  
(Rubin LJ, 2002, 
Channick et al., 
2001) 
EARLY 
 (Galiè N et 
al., 2008) 
STRIDE-1 
(Barst et 
al., 2004) 
STRIDE-2 
(Barst, 
2006)  
ARIES-1 
(Galiè  et al., 
2008) 
ARIES-2 
(Galiè  et 
al., 2008) 
SUPER-1 
(Galiè, 
2005) 
STEP 
(McLaughlin 
et al., 2006) 
PACES 
(Simonneau 
et al., 2008) 
Death ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Hospital Stay ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Lung 
Transplantation 
✓  ✓ ✓ ✓ ✓ ✓ ✓  
Atrial Septostomy ✓  ✓ ✓ ✓ ✓    
Symptomatic 
Progression 
(NYHA/WHO FC) 
✓ ✓  ✓ ✓ ✓    
Lack of 
improvement or 
worsening PAH 
(+/- 6MWD) 
✓ ✓  ✓ ✓ ✓  ✓  
Need for 
additional PAH 
therapy 
✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
P value <0.05 <0.05 NS NS NS <0.05 NS <0.05 <0.005 
CW = clinical worsening; NYHA/WHO FC = New York Heart Association/World Health Organization functional class; PAH = pulmonary arterial 
hypertension. 
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It is interesting to note that four of the nine studies analysed in the paper did not 
reach statistical significance for TTCW.  Whilst it is acknowledged that these 
composite endpoints have certain advantages over traditional functional 
measurements, they are not possible to recreate in the clinic.  As such they tell 
prescribers more about the long-term use of a drug than short-term 
expectations of response.  In summary, whilst this may be the basis for clinical 
endpoints in future RCTs (allowing for some variation on the definitions 
involved), it cannot be employed for a study such as this one.   
 
Two other examples of composite endpoints under review for use are measures 
of response in clinical trials of systemic sclerosis: the Combined Response 
Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary 
Arterial Hypertension related to Systemic Sclerosis (EPOSS) (Khanna et al., 
2009).   Validation data is currently being collected for these tools and if proven 
they may be of relevance to clinical practice and utilised in future RCTs 
evaluating the PAH-CTD group. 
 
2.3.3 Time on Monotherapy 
Establishing appropriate, applicable and relevant endpoints is of paramount 
importance in ensuring that this study’s findings could be useful towards 
informing future practice.  It was very evident that the endpoints used 
traditionally in the RCTs would be of some use but other perspectives should 
also be explored.  The observational nature of the study meant that only data 
already captured could be utilised. 
From the literature search it became increasingly apparent that PAH-CTD 
posed a particular challenge in terms of the lack of robust assessment methods.  
  72 
Not only was this a rapidly progressive aetiology in an area of few (but 
increasing) treatment options, but that the ways to assess treatment benefit 
have been questioned.  Overlapping co-morbidities cast doubt over the best 
“yardstick” to use.  The same co-morbidities were a potential reason for side 
effects and also the need to add or switch treatments, hence ending the 
patient’s monotherapy. 
 
With this in mind, alternative strategies were sought.  It was brought to my 
attention that in the completely unrelated clinical area of psychiatry, a similar 
dilemma faced researchers.  It was noted that discontinuation rates amongst 
psychiatric patients made assessment of effectiveness limited (Lieberman et al., 
2005).  With this in mind, the authors of the CATIE study (Lieberman et al., 
2005) employed a novel endpoint: effectively time on treatment.  The authors 
used time to discontinuation as a surrogate marker for satisfaction with 
treatment.  Using the assumption that discontinuation was a marker of 
dissatisfaction on the part of physician, patient or both, the time on treatment 
represented a favourable clinical outcome measure. 
 
To apply this to PAH-CTD patients seemed to resonate.  There are parallels to 
be drawn in terms of the difficulty in measuring success and discontinuation 
rates.  Application of this endpoint appropriately does make the assumption that 
patients have alternatives available.  Patients with advanced disease on IV 
iloprost have little, if any, options available to them.  Hence, this would not be a 
good marker as they may be on treatment as a result of a lack of obvious 
benefit.  Assessing the two first-line oral treatments with this endpoint seems 
entirely appropriate since there are other options available in the event of 
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treatment failure (due to any cause).  Patients failing first-line treatment may 
have their tablets switched or additional agents added, all within the NCP 
guidelines. 
 
The time on therapy endpoint was used to assess response to an anti-psychotic 
in a similar study to this one.  The rationale for the study by Deslandes et al 
(2009) was very similar to this one.  They noted that RCT data assessed 
treatment over a short period and due to inclusion and exclusion criteria, the 
recruited participants may not be representative of those prescribed in practice.  
Short-term data may not be relevant to different groups in the longer term. 
 
On the basis of these cited articles, this study undertook to measure the “time 
on monotherapy” (TOM) as a combined measure of patient and clinician 
satisfaction.  After all, if a patient was not tolerating or benefiting from oral 
monotherapy, there would no hesitation to add in or switch treatment. 
 
2.3.4 All cause Mortality 
Whilst survival is a valued endpoint, one easily overlooked fact resonated from 
the PHA IMPAHCT survey (Armstrong, 2011).  The findings showed that quality 
of life was the most important treatment goal.  This was deemed more important 
than increased life expectancy.  Hence, whilst survival is more easily measured, 
quality of life matters more to patients.  Various attempts have been made to 
accurately quality of life in PAH.  The most commonly quoted validated tool for 
this is the CAMPHOR questionnaire (McKenna et al., 2006).  The current 
Department of Health (DH) national standards for PAH in the UK require 
centres to perform the test on PAH patients currently under their care.  There 
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was not sufficient data for the cohort recruited regarding CAMPHOR results for 
this test (and scores) to be employed in this study. 
 
Much is written in the literature regarding survival in PAH; whether or not 
prognosis has improved over recent years, whether treatments extend life and 
by how much and what more needs to be done.  The recent paper by Rubenfire 
(2013) suggests that survival in patients with PAH-SSc has not improved “in the 
modern era”.  This label has been applied to the past decade during which oral 
treatments have emerged as the mainstay of first line treatment for PAH.  Using 
registry data from a single centre in the US, the authors demonstrate that 
prognosis is very limited for PAH-SSc compared with IPAH.  Similar articles 
have drawn data from different registries (Launay et al., 2012, Humbert et al., 
2011, Chung et al., 2010, Girgis et al., 2009, Condliffe, 2009) with varying 
estimates. 
 
The 1-year estimates range from 71-86% and 3-year from 47-56%.  The 
intention in this study is to examine the respective survival at yearly intervals for 
the group commenced oral monotherapy.  Although this represents a different 
group to those profiled before, it is reasonable to expect the recruited cohort to 
be representative of the overall PAH-CTD population at SPVDU.  Those not 
represented by the data will be those with either mild or more severe disease.  
There will be those in WHO FCII and only very recently eligible for targeted 
therapy.  Contrasting to this small group are those with severe disease who will 
be excluded by commencing prostanoids or combination therapy de novo.   
 
  75 
2.4 Treatment of PAH-CTD  
This section takes a global look at the available evidence for treatment of PAH-
CTD, the approaches used and what has been learned to date. 
   
The first question to address when dealing with PAH-CTD is establishing what 
are we actually treating.  In the case of idiopathic disease where there is a 
vasculopathy of unknown cause, we attempt to improve breathlessness and 
other symptoms with pulmonary vasodilators.  However, in all the associated 
PAH, and in particular for this project, PAH-CTD, there is the vasculopathy but 
also the underlying causative condition to be addressed. 
   
The possible impact (or lack of) on breathlessness of disease modifying agents 
(DMARDs) in PAH-CTD is not clear from the major licensing studies.  Neither of 
the oral therapy licensing studies (Rubin LJ, 2002, Galiè, 2005) discusses 
permissible concomitant medication in relation to DMARDs.  Whilst diuretics 
and anticoagulation are seen as playing a significant role, DMARDs are not 
discussed.  This is important from both a baseline (study enrolment) and in-
study dose adjustment perspective.  It can be deduced that the study steering 
committees have ruled out any direct link between DMARDs and CTD 
management or PAH control, as there was no exclusion criteria to rule out 
background DMARDs as prohibited concomitant medication.  In Sheffield in 
systemic sclerosis we see the prescription of DMARDs (most commonly 
mycophenolate or cyclophosphamide).  In contrast to systemic sclerosis there is 
growing evidence in SLE that immunosuppression can improve PAH in a cohort 
of patients. 
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Pulsed IV cyclophosphamide is used to treat ILD.  Whether these patients 
exhibiting PH in association with ILD in the setting of CTD have a treatment 
responsive vasculopathy is not known.  They do, however provide specialists 
with a management challenge – to treat or not to treat?  The co-existing lung 
disease is shown to affect the survival (Condliffe, 2009) and is also likely to 
have a negative impact on a patient’s ability to maximise their six minute walk 
test distance (6MWD). 
 
Following what is assumed to be an accurate diagnosis and assessment, the 
decision around which is the most appropriate treatment involves several 
factors.  These can be summarised as: policy/guidance considerations, disease 
factors, co-morbidities, concomitant medication, previous intolerances, 
prescriber choice and (crucially) patient choice.  Involvement of patients in 
shared decision-making is becoming ever more prevalent in clinical practice of 
which several models are described in the literature (Charles et al., 1999).  
These are not discussed in any detail in this review.   
 
Discussions that were published pre-2004 on management and the relative 
efficacies of drug therapy in PAH are now outdated.  Since that time, oral 
treatments have become the most been widely prescribed monotherapies, with 
prostanoids accounting for a smaller proportion (6.5% at time of writing in 
Sheffield).  Condliffe (2009) profiled the UK population, over the period 2001-
2006, as being prescribed: ERAs 68%, PDE5is 15% and prostanoids 17%.  In 
addition, since 2004 it has become more common to prescribe combinations of 
treatments, whereas the earlier papers describe predominantly monotherapy 
outcomes.  This may be due to the steady increase in articles demonstrating 
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benefits on combination therapy, however these have all been small studies.  
Clearly, there would be logical rationale for utilising agents with complementary 
mechanisms to optimise outcomes.  This approach would be routinely 
employed in other clinical areas, such as HIV.  The first major RCT examining 
the effects of first-line combination therapy is due out this year (the AMBITION 
trial using ambrisentan and tadalafil in combination compared to each of the 
agents as monotherapy). 
  
Available literature suggests that the early intervention and maintenance of 
functional class is an essential component of disease management (Hachulla 
and Denton, 2010).  However, some of the supportive data is based on the 
EARLY study – where the primary endpoint (improvement of exercise capacity) 
showed improvement vs. placebo but did not reach statistical significance (Galiè 
N et al., 2008).  The EARLY study was a double-blinded placebo-controlled 
multicentre RCT evaluating Bosentan vs. placebo.  It recruited 168 patients in 
WHO FC II.  One of the inclusion criteria for the study seemed vaguely 
contradictory, given a requirement for a 6MWD distance less than 500m and 
pulmonary vascular resistance (PVR) greater than 320dyn/s/cm2.  The various 
endpoints described in the literature have already been discussed in depth in 
Section 2.3.  The criteria used in the EARLY study would often describe a 
patient to be in WHO FC III rather than II.  The implication is that the 
haemodynamics do not seem to correlate completely to the functional status.  
Clinically, a patient eligible for that study according to the walk test and 
haemodynamics may not be genuinely in FCII or indeed have “early” disease.  
The primary endpoints were change in pulmonary haemodynamics and change 
in exercise capacity. 
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The EARLY study took patients of all aetiologies of PAH, with 18 (19%) and 15 
(16%) of the active and placebos groups were made up of PAH-CTD.  
Unfortunately due to the small numbers, the study was not powered to analyse 
the sub-groups.  However, the overall result was not significant so does not 
provide evidence for use of bosentan in PAH-CTD patients in WHO FC II.   
 
That said, and despite not reaching its primary endpoint, this was a useful study 
in demonstrating that more patients in the untreated group deteriorated by at 
least one functional class.  This was hardly a unique finding, but one that adds 
some weight to the early intervention argument. 
   
2.4.1 Targeted therapies in PAH-CTD  
”Targeted therapies” is a general term applied to the agents employed to 
directly treat PAH.  This group has expanded rapidly over the past 15 years.  
Prior to this, the armamentarium consisted of only IV prostanoids.  In the 
intervening period there has been an expansion into several classes of targeted 
therapies.  These would currently include ERAs, PDE5is and a variety of 
parenteral prostanoids.  In two years from now the range will widen further with 
the introduction of prostaglandin analogues and soluble guanylate-cyclase 
stimulators.  The term “targeted” is applied because the pharmacology of these 
agents is aimed at reducing pulmonary arterial pressures either directly through 
pulmonary vasodilatation or indirectly through anti-proliferative and anti-fibrotic 
mechanisms.  All targeted therapies are universally prescribed across all 
aetiologies.  However for the purposes of the literature review, the evidence in 
PAH-CTD is dealt with in significant depth. 
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The prognostic and survival data leaves us in no doubt that this is the most 
aggressive form of PAH with a significant impact on life expectancy.  The data 
described also indicates that PAH-CTD progresses rapidly.  Screening tools 
have allowed specialist centres to diagnose and commence treatments earlier 
than before, with a positive benefit on average survival (Humbert et al., 2011).  
With several therapies now licensed for the treatment of PAH-CTD, there is an 
assumption that these treatments have been specifically proven to benefit this 
particular population.  However, efficacy data are scarce.  In the following sub-
section, the available evidence for the use of targeted therapies for PAH-CTD is 
summarised. 
   
Hachulla and Coghlan (Hachulla and Coghlan, 2004) even make a theoretical 
case for targeted therapies being deleterious in treating PAH-SSc.  They argue 
that the vasodilator treatment can exacerbate scleroderma-type symptoms such 
as gastric reflux and oesophageal motility.  Anecdotally, we do see these 
problems in our PAH-SSc patients treated with sildenafil, although rarely at the 
licensed dose of 20mg three times daily.  Gastric reflux secondary to sildenafil 
prescriptions reported in Sheffield appear to be predominantly associated with 
supra-licensed doses, e.g. 100mg three times daily.  Sildenafil is recommended 
first line by both the European and UK prescribing guidance.  This theoretical 
risk of dose-related adverse effects is not clinically important enough in practice 
to impact prescribing recommendations as these are based on use of licensed 
doses. 
 
The majority of review articles on the subject of PAH-CTD have been written 
from a medical perspective, with only small sections discussing treatment 
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(Condliffe, 2009, Galiè N et al., 2005).  Patients with this aetiology have been 
included in the licensing studies for the commonly used targeted therapies.  
Despite this, there is little if any robust data demonstrating the efficacy of oral 
targeted therapies specifically in PAH-CTD.  As with all rare diseases, even 
multi-centre randomised controlled studies recruit relatively small numbers of 
patients.  To date, all of the seminal studies have compared the new treatment 
with placebo over 12-16 weeks.  Long-term evidence is largely available only 
from open label extension studies. 
 
In reviewing the literature, in addition to the work describing PAH-CTD 
generally, there is also some work dealing specifically with the most devastating 
form: PAH-SSc.  To date, only continuous epoprostenol treatment has 
demonstrated benefits in improving exercise capacity in PAH-SSc (Badesch, 
2000).  A more recent meta analysis showed that oral treatments are less 
effective in improving exercise capacity in PAH-CTD and particularly PAH-SSc 
(Avouac et al., 2008).  That said, there are significant complexities to the use of 
nebulised and intravenous prostaglandins.  Parenteral medications account for 
only a small percentage of total prescription numbers.  For the majority of 
patients, oral medications form the mainstay of treatment, despite effects on the 
primary outcome of exercise capacity not being definitively shown.  Clearly 
further work is necessary to better understand the way in which treatments can 
alter the disease progression and prognosis in PAH-CTD. 
 
An important point to note is that the vast majority of general PAH review 
articles are now old.  With the exception of data published by Condliffe et al 
(2009) the majority of the papers are pre-2004 (Kawut, 2003, Hachulla and 
  81 
Coghlan, 2004, Varga, 2002).  These older review papers may still be of value 
in characterising the baselines for this patient phenotype as the 
pathophysiology, symptoms and evaluation have not changed.  Between them, 
they review the published data on treatment efficacy and survival from the early 
2000s.  There was a genuine paucity of literature published in the mid 2000s.  
Several articles date from before and around the time of the launch of oral 
therapies (2002-3).  There was then little written on this subject until after 2008.  
This had allowed authors the opportunity to analyse the prescription of oral 
therapies in the longer term.   
 
The lack of published data regarding treatment effects could be due to 
publication bias.  We have seen in several studies that the treatment effect 
seems to be minimal for the PAH-CTD patients.  It is possible, even likely, that 
other articles have not reached publication, as they were neutral or even 
negative in outcome.  It is also a possibility that outside of small case-series, 
that little in the way of further exploratory work has taken place in this narrow 
field.  Whilst I have not analysed the studies specifically for this review, a funnel 
plot could have been constructed to assess the likelihood of publication bias.   
 
A combination of the high prevalence and mortality make research into 
treatment strategies for PAH-CTD a priority.  Such research may investigate 
new treatment modalities or enhance our understanding of the currently 
available options and how these should be best employed. 
2.4.1.1 Bosentan 
Bosentan is an orally active, non-peptide, dual competitive endothelin 1 (ET) 
receptor antagonist.  It exerts its action by blocking both ETa and ETb receptor 
subtypes.  It is licensed for the treatment of PAH on the basis of the 
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BREATHE-1 study (Rubin LJ, 2002) to improve exercise capacity and 
symptoms in patients with WHO functional class III.  Efficacy has been shown 
in:  
•   Primary (idiopathic and heritable) PAH  
• PAH secondary to scleroderma without significant interstitial     
pulmonary disease  
• PAH associated with congenital systemic-to-pulmonary shunts and 
Eisenmenger's physiology  
ET1 has been shown to have a pathogenic role in PH through its role in smooth 
muscle proliferation and vasonconstriction.  Both IPAH and CTD patients are 
known to have high plasma concentrations of ET1.  By antagonising the ET1 
receptors, bosentan has been shown to decrease inflammatory reactions, 
prevent the increase in permeability of pulmonary vessels and have anti-fibrotic 
properties (Channick et al., 2001). 
The evidence for bosentan comes from the BREATHE-1 trial (Rubin LJ, 2002).  
This treated 213 patients with IPAH or PAH-CTD in WHO class III or IV.  This 
double-blinded, placebo controlled study 16 week study randomised patients to 
receive either placebo or bosentan (125mg or 250mg) twice daily.  An extension 
study of a further 12 weeks was available to patients completing the original 
study.  Of the 144 patients in the active arms, only 33 had PAH-CTD (22%).  
The primary endpoint for the study was change in exercise capacity as 
measured by 6MWD.  The patients with PAH-CTD demonstrated a 3-metre 
improvement compared to a 40-metre decline in the placebo arm.  This 
suggests that treatment with bosentan is likely to arrest deterioration rather than 
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induce significant improvement, as measured by exercise capacity.  However, 
approximately a quarter of the 33 PAH-CTD patients improved from WHO class 
III to WHO II during the 16 weeks.  This suggests that exercise capacity may 
not necessarily correlate with functional status in PAH-CTD.  Some trends to 
improvement have been shown in patients with PAH WHO functional class II 
(Galiè N et al., 2008).  However, further work is necessary to validate this as the 
trial failed to reach statistical significance. 
A retrospective study in a small group (n=23) was conducted, evaluating 
bosentan in PAH-SSc over an eighteen month period (Joglekar et al., 2006).  
Outcome measures chosen were WHO FC and haemodynamics.  The groups 
showed stability and tolerability.  However the use of repeat haemodynamics  
does not ideally inform us regarding function.  As discussed elsewhere, 
haemodynamics and function are not well linked in PAH-SSc.  
Williams (2006) conducted a longitudinal study of 92 consecutive patients with 
PAH-SSc.  A historical control group of 47 patients received supportive 
treatments only (diuretics, digoxin, oxygen and warfarin).  The outcomes of this 
group were compared to 45 patients treated with bosentan.  Survival at one and 
two years was better in the bosentan-treated population.  In addition, 
haemodynamics (as measured by pulmonary vascular resistance at right heart 
catheterisation) increased in the historical group but remained stable in the 
bosentan group.  Albeit in a small group, this is interesting haemodynamic data 
because it suggests that even on treatment, pressures are kept stable rather 
than improved.  This mirrors the exercise data shown in the sub-group analysis 
of the BREATHE-1 study (Rubin LJ, 2002); where an increase of 3 metres was 
seen on treatment against decline on placebo.  Girgis (Girgis et al., 2005) found 
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similar but slightly better survival figures, although they examined a smaller 
population.  Regardless of which is closer to reality for the overall PAH-CTD 
population, the data is supportive of treatment over historical controls of 
untreated patients described by Koh et al (Koh, 1996).  Such small 
improvements could be the reality of treatment, although because benefits in 
IPAH are so much better, one can deduce that attempts have been made, most 
recently by Denton (2006), to perform a subgroup analysis of the pivotal clinical 
trials and their open label extensions involving bosentan in PAH-CTD.  They 
note that no in-depth analysis has been conducted specifically for the subset of 
PAH-CTD.  Their analysis looked at the pivotal trials.  This study will be the first 
work to compare two active treatments in a large group in clinical practice, with 
incident cases. 
 
The only attempt to quantify bosentan’s impact on quality of life was an open-
label trial described by Keogh (2004).  The group demonstrated improvements 
at three and six months on SF-36 (a QOL questionnaire) scores in bosentan 
patients.  41% of the sample,  (n=73 of 177) had PAH-CTD. 
 
Bosentan is also indicated to reduce the number of new digital ulcers in patients 
with systemic sclerosis and ongoing digital ulcer disease (SPC, 2012b).  A 
single patient case study (Yagi et al., 2010) documented how bosentan was 
prescribed to a patient with SSc and digital ulceration, but without 
haemodynamic evidence of PAH.  The bosentan improved her digital pain and 
Raynaud’s phenomenon but did not heal the ulceration.  In terms of PAH 
measurement, her exercise capacity remained unchanged and exercise-
desaturation improved.  This is clearly only a single case and given the high 
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cost of the agent (~£22,000 p.a.) we are not able to prescribe to all SSc 
patients, but it may hint that bosentan could delay or prevent development of 
PAH symptoms in this group.   
2.4.1.2 Sildenafil 
Sildenafil exerts its action via selective inhibition of cGMP-specific PDE5 (SPC, 
2012a).  This extends the life of the circulating cGMP in the PA smooth muscle 
cells resulting in vasodilatation.  Due to the proliferation of PDE5 receptors 
(primarily in the penis and lung), PDE5 inhibitors are relatively selective 
pulmonary vasodilators that only minimally decrease systemic blood pressure 
(Michelakis et al., 2003).   
It is licensed for the treatment of adult patients with PAH classified as WHO 
functional class II and III, to improve exercise capacity.  Efficacy has been 
shown in IPAH and PAH-CTD (SPC, 2013). 
In the case of sildenafil, the only placebo controlled RCT study published is the 
SUPER-1 study (Galiè, 2005).  This is the seminal study for sildenafil.  On the 
evidence of this study, sildenafil was licensed in the UK and Europe.  PAH-CTD 
was diagnosed in 84 (30%) of the 278 patients (Galiè, 2005).  This proportion is 
representative of that seen across the seminal papers used for licensing of the 
other treatments: nebulised iloprost, sitaxentan (now withdrawn) and 
ambrisentan (Barst, 2006, Galiè, 2008, Olschewski H, 2002, Rubin LJ, 2002). A 
systematic review of the data was published by Lee (2005). 
 
The main problem with post-hoc subgroup analyses for PAH-CTD patients is 
that effects seen in relatively small groups may not translate to relevance in 
clinical practice.  In the example of the sildenafil study (Galiè, 2005) there were 
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only 63 PAH-CTD and only 30 PAH-SSc patients treated with active drug.  
These are very small numbers to base meaningful conclusions regarding 
efficacy on, given the small treatment effect.  Overall the average improvement 
in 6MWD was 45 metres at 20mg three times daily dosage.  Surprisingly, the 
improvement shown globally by the study for PAH all comers was also borne 
out in the post-hoc sub-group analysis of the PAH-CTD group.  It is an 
important difference compared to the bosentan data, where mere stabilisation 
was recorded.  In addition to improvement in exercise capacity, improvements 
in WHO functional class and improvements in haemodynamics were seen in the 
sildenafil treated group. 
 
Despite the licensed dose being 20mg tds, the SUPER-1 study did show that 
secondary endpoints were improved by escalating doses.  As a consequence of 
this, along with associated safety being confirmed, some centres have 
escalated Sildenafil to supra-licensed doses, as part of clinical practice. 
 
The licensing status of sildenafil has not changed despite the findings of the 
long-term extension study, the SUPER-2 study (Rubin et al., 2011).  Hence 
there is 16-week and long-term data to support efficacy and tolerability at higher 
doses, albeit not in the study’s primary endpoint of changing 6MWD.  Over 80% 
of patients completing the 3-year study were prescribed 80mg tds. 
 
The long-term survival data for sildenafil in PAH-CTD is derived from the 
SUPER-2 study.  Three-year survival estimates in this study show an improved 
rate in IPAH compared to PAH-CTD (81 vs. 72%).  This is not as marked a 
difference as might be expected from other work.  Improvement in WHO 
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function class from III to II has been correlated to survival in IPAH patients.  
This correlation has not yet been noted for PAH-CTD patients. 
 
Indeed across both the sildenafil and bosentan studies, whilst some results 
have shown statistically significant improvements in the treated groups, other 
results have indicated merely a trend towards improvement.  As a 
consequence, there is a widely held view amongst the authors that further 
studies are warranted. 
 
Thus, there is little in the literature to statistically confirm which, if any, oral 
treatments are clinically effective.  Any trend towards improvement shown by 
both sildenafil and bosentan in the PAH-CTD population may reflect their ability 
to stabilise the condition.  Little is written specifically on the clinical value of 
disease stability.  However, small sub groups contain too small a sample group 
to power a statistical analysis and thus are at risk of a higher chance of a type-II 
(β) error.  Such an error is seen when the apparent difference between treated 
and placebo groups is potentially large enough to be clinically important, but not 
large enough to be statistically significant.  It raises the question as to whether 
the similarity between groups is due to ineffective treatment, lack of statistical 
power or an element of each.   
 
Various publications from European centres have used the concept of “treating 
to target” and “goal orientated therapy”.  Both concepts imply dissatisfaction at 
stability as they recommend the addition of extra therapies until certain 
objective measures are met, for example walking certain distances or improving 
functional classes.  However, these approaches have not been formally 
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validated in any guidelines and are not employed in the UK.  They are also 
more difficult to use in the PAH-CTD group due to the difficulty in hard 
functional endpoints being harder to attain and hence the targets are less 
meaningful. 
 
Reassuringly, safety and efficacy are demonstrated for all treatments.  
Unfortunately studies specifically designed to examine treatment outcomes in 
PAH-CTD have not been performed therefore the evidence is limited.  Whilst 
this may be sufficient to justify prescription, we have no evidence to support one 
treatment over another for this particular group. 
 
2.5 Reporting standards 
In addition to searching the literature for articles clinical relevant to the research, 
several references were identified to aid an accurate, thorough and systematic 
write-up.  As a new researcher, standards and guidelines describing good 
practice in authorship were vital to the learning process and the evolution of the 
thesis. 
 
The appropriate choice of research design is made on the basis of the 
hypotheses being tested.  The documentation of the study, be it in article, 
dissertation or thesis format should include certain elements of the work.  These 
critical elements are vital for the reader to gain confidence in the robust 
approaches taken in answering the question. 
 
In recent times there have been a number of international statements written, 
with precisely these aim of improving the quality of reporting in research.  More 
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prominent examples are the TREND (Transparent Reporting of Evaluations in 
Non-randomised Designs) (Des Jarlais et al., 2004) Statement, the STROBE 
(Strengthening the Reporting of Observational Studies in Epidemiology (von 
Elm et al., 2007) Statement and the CONSORT (Consolidated Standards of 
Reporting Trials) (Moher D, 2001).  In addition to these reporting guidelines, the 
ISPOR (International Society for Pharmacoeconomics and Outcomes 
Research) has published good research practices for non-randomised studies 
(Johnson et al., 2009, Berger et al., 2009, Cox et al., 2009). 
The TREND statement was published in the American Journal of Public Health 
at a time when evidence-based practice was emerging, albeit slightly behind 
other branches of medicine.  Whilst this research is not drawn from public 
health, there are inevitable parallels that can be drawn across any non-
randomised evaluations.  The guidelines concern themselves with very 
transferrable qualities such as research design, sample size and methods for 
adjusting for bias. 
 
Whilst a digest of these statements is not made in this review, the themes, 
checklists and guidance have all been given thorough attention during the 
course of this study and the guidelines followed in the documentation of the 
findings.   
 
2.6 Chapter Summary 
Chapter 2, the literature review, has systematically reviewed the currently 
available evidence.  The process of reviewing the literature highlights the lack of 
good quality evidence on which to base prescribing guidelines.  The use of 
small number case series, sub-group analysis and open label work is a 
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consequence of the few RCTs performed in this rare disease.  Clinician 
experience and practice adds to confidence in prescribing agents where little 
evidence exists, but it is hoped that practice research such as this study will 
produce additional evidence to educate and influence future guidance. 
In the specific area of PAH-CTD, we not only lack prospective RCT data on 
medicine efficacy, but also a better understanding of the preferred outcome 
measures.  Although exercise capacity has been the primary outcome measure 
for both of the pivotal licensing RCTs of bosentan and sildenafil in PAH-CTD, 
there are problems in assessing patients who may have overlapping 
musculoskeletal conditions on the basis of how far they walk in a given time 
period.  As such, in addition to traditional use of functional endpoints, this study 
will explore treatment effects from a different perspective; the time spent on 
therapy and their impact on survival.  In addition to the difficulties in applying 
endpoints, there are inescapable differences between the recruited cases in 
RCTs and those prescribed for in the clinic setting.  Robust observational 
research data to support and enlighten prescribing is needed.  This should 
include different patient groups and different durations of study.  Where life-long 
expensive treatments are being licensed on the basis of short-term studies, 
extra evidence is necessary to demonstrate longer-term prescription. 
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Chapter 3 – Aims and Objectives 
3.1 Introduction 
Since 2002, the most commonly prescribed agents for the treatment of PAH-
CTD both in the UK and worldwide have been bosentan and sildenafil.  The 
main supportive data for the use of each agent in this particular aetiology is 
provided by meta-analyses and systematic reviews.  However, much of the 
work reviewed is taken from data graded as lower quality.  This is because the 
work incorporates open label or small and/or non-randomised cohorts.  The only 
randomised controlled trial data comes from sub-group analysis from the two 
licensing studies.  In terms of the change in the primary outcome measure of 
both the SUPER-1 (sildenafil) and BREATHE-1 (bosentan) studies, the result of 
the sub group analyses is inconclusive.  If success is judged by a statistically 
significant improvement offered by these agents over both the trial duration (16 
weeks) and in the longer term (at one and two years), then neither should be 
endorsed.  At best, one can conclude on the basis of maintenance of baseline 
or modest increases in functional ability (measured by walk test and functional 
class) that these both agents are responsible for disease stabilisation, as we do 
not see the deterioration witnessed in the placebo arm.  However, the numbers 
in the sub-group do not power the study to make definite conclusions.  By 
analysing the effects seen in a bigger cohort in a different patient population 
(incident as opposed to prevalent cases), it is hoped that this study may assess 
the treatment effect in real-life. 
 
In 2008, English NHS commissioners and clinicians collectively authored the 
national commissioning policy.  In an attempt to standardise prescribing of 
complex treatments for PH patients across the six nationally designated 
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specialist centres, guidance was written indicating which therapy should be 
prescribed first line for each aetiology of PH. 
 
Whilst the recommendations within this policy rightly prioritise licensed agents, 
this could not be to the exclusion of off-licensed and unlicensed treatments.  In 
PH, where there are so few options available, to restrict prescribers to purely 
licensed usage would almost inevitably deny sick patients effective treatment.  
Whilst there may not be supportive evidence in the form of RCTs, my 
experience suggests that PH specialists use the treatments, indeed treatment 
classes interchangeably in the search for a well tolerated, effective, tailored 
management plan.  It is acknowledged that treatment should be reserved for 
PH groups 1 and 4.  Beyond this it is accepted that treatment with targeted 
therapy may be detrimental.  Within groups 1 and 4, however, each class is 
recommended for use by the international guidance including combining two or 
more agents (McLaughlin et al., 2009b, Members et al., 2009, Authors/Task 
Force et al., 2009) from different classes to elicit a response. 
 
Hence, not only is it impossible to restrict the guidance to licensed therapies, 
there are occasionally instances when off-label and unlicensed treatments are 
used ahead of licensed options.  This forms a routine part of prescribing for 
PAH patients.  Tailoring their management plan to suit their lifestyle reflects the 
importance of patient-led decision making.  This is more often an issue with 
complex prostanoid therapy but may also play a part in deciding the most 
appropriate oral agent for each case.  For example, when the routine blood 
tests needed to ERA safety monitoring could present a challenge. 
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The absence of RCT data to support the use of some therapies means that they 
remain unlicensed for this condition in the UK.  This status varies across Europe 
and the World, with some agents being approved elsewhere, for example by the 
Food and Drugs Administration (FDA) in the US, despite no authorisation in the 
UK.  This situation is not unique to PAH but adds to the discrepancy between 
treatment algorithms that can be used. 
   
In the absence of any data demonstrating superiority of one agent over another, 
the decision about first-line treatment is based on a combination of cost and 
available data.  In the case of PAH-CTD, the commissioners and clinicians 
endorsed bosentan as the first line choice (for 2008 NCP see Appendix 4).  This 
decision is open to challenge on several fronts.  Firstly, as discussed in the 
literature review the evidence for bosentan is no stronger than for sildenafil.  
Indeed if we were to examine the change in primary outcome measure for both 
studies (exercise capacity) in isolation, then sildenafil showed a greater 
magnitude of improvement, although the sub-groups were too small to show 
statistical significance.  In the case of treating PAH in general, however there is 
evidence to support both agents in the form of randomised multi-centre placebo 
controlled clinical trials (RCT) (Rubin LJ, 2002) (Galiè, 2005). 
 
Denton’s analysis (Denton CP, 2006) of the pivotal clinical trials and their open-
label extensions focused on bosentan specifically in PAH-CTD but across the 
two studies reviewed, there was a total of only 66 patients.  His work confirmed 
that bosentan was beneficial in the short term (16 weeks).  Data presented by 
Pope et al at the American College of Rheumatology meeting (Pope, 2007) may 
not have been randomised or blinded, but may provide useful comparative data 
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for my population in terms of the relative prevalence of specific CTD diagnoses 
e.g. systemic sclerosis, SLE etc.  The authors also looked at survival at two 
years.  Unfortunately there is no similar published long-term work describing the 
sildenafil experience. 
3.2 Aims and objectives 
My study recruits from one of the largest single-site PAH-CTD populations in 
Europe.  It is hoped that analysis of this large cohort will address the gap in 
evidence supporting the use of the two agents most commonly prescribed for 
this aggressive aetiology; sildenafil and bosentan.  This will be achieved by 
testing the null hypothesis of the study that bosentan demonstrates no greater 
benefit to PAH-CTD patients than sildenafil.   
 
Building on the structure of the BREATHE-1 bosentan RCT as the basis for my 
study, I aim to examine the recommendations of the national commissioning 
policy based on the experience in the Sheffield population.   
3.3 Study aim: 
To evaluate the influence on outcomes of monotherapy with either bosentan or 
sildenafil in treatment-naïve patients diagnosed with PAH-CTD at the Sheffield 
Pulmonary Vascular Disease Unit (SPVDU).  The review commences with the 
first patient to be given either agent until a census date for inclusion of 1st 
February 2010.   
 
The related research question is “Did the NCP’s recommendation for the use of 
first-line bosentan in PAH-CTD patients influence positive outcomes for 
patients?”  
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Objectives: 
 Assess the change in primary outcome measure from the RCT, which is 
change in exercise capacity as measured by change in walk test 
distance. 
 Assess the change in WHO functional class. 
 Assess the change in BORG breathlessness scores. 
 Assess each group according to duration of treatment with monotherapy.  
It is intended that this marker of treatment satisfaction will be used as a 
surrogate marker of both disease stabilisation and medication tolerance. 
 Assess each group in terms of overall survival.  This will be used as an 
intention to treat measure. 
 Assess the total recruited cohort in terms of survival at annual intervals. 
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Chapter 4 – Methodology and methods 
 
After a brief introduction, the methodology chapter is divided into 6 key areas: 
methodology development, pilot study, patient selection, data sources, data 
synthesis and statistical analysis.  Each of these will be discussed in turn.  The 
sub-sections discuss the theoretical aspects that need to be considered 
together with the practical methods undertaken in the course of this study to 
apply these theories. 
 
4.1 Introduction and Methodology Development 
When seeking answers to clinical queries and developing research ideas, it is 
easy to focus heavily on the randomised controlled trials (RCT) as being the 
highest quality evidence and the preferred method of trial design.  There are 
obvious advantages to the RCT and the quality of the evidence produced.  
These are well documented (Phillips B, 2009).  The strength of the RCT lies in 
establishing whether or not an intervention has an effect or no effect.  Through 
the process of randomisation, the effect of confounding variables is minimised.  
These can never be completely ruled out as they may occur unexpectedly.  
Sub-groups are generated that are comparable for factors that may influence 
the outcome.  Hence any change in the outcome measure should not be 
caused by something other than the intervention itself.  This inevitably gives the 
statistical analysis more validity.  The RCT results may be subsequently used 
as data for a meta-analysis, or systematic review (SR). 
 
A SR may be of value where several RCTs have produced conflicting results or 
shown trends rather than statistically significant results.  By analysing all of the 
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RCTs investigating similar treatment effects, a more powerful or definitive 
conclusion may be drawn.  Such conclusions may be seen in the results of the 
statistical analysis.  Small studies grouped together may confirm a statistically 
significant improvement where individual works may have been clinically 
important but failed to reach significance.  It may be feasible that the treatment 
effect itself is greater when measured over several trials and that certain trials 
have under-estimated the effect of interventions.   
 
Alternatively, confidence intervals may be reduced by a decreased likelihood 
that the parameter will fall outside the 95% or 99% limit.  SRs have also been 
employed to examine effects seen in one or more studies, but not in others 
examining similar interventions.  For example, the recent Cochrane review of 
ERAs in PAH (Liu C, 2013).  SRs may elicit different conclusions to those made 
from the original RCT data, but populations recruited to the SR’s constituent 
RCTs must ideally be homogeneous.  As heterogeneity between the groups is 
likely given variations in inclusion/exclusion criteria and outcome measures, the 
results may not be directly comparable without modification to the statistical 
methods applied.  A test applied to compare for heterogeneity between 
treatment effects seen in different studies is the Cochrane Q test.  Another 
statistical measure, the I2 test describes the total variation across different 
studies and assesses if this is due to heterogeneity or just chance (Higgins JP, 
2003).  Both have been recently employed in a recent meta-analysis of RCTs in 
PAH (Galie et al., 2009), the first to show the benefit of treatments to patients in 
terms of mortality and morbidity. 
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Setting up an RCT to meet the aims of this study may not be the best solution.  
Indeed there are already results published from RCTs for both of the treatments 
(sildenafil and bosentan) and the diagnosis (PAH-CTD) in question in my study.  
Hence it is vital to reinforce the justification behind performing further analysis 
and research into similar outcome measures.  Herein lies one of the major 
criticisms of RCTs; the RCT will have been very specifically designed to deliver 
the answer to the question as to whether a given intervention makes any 
difference to patients.  In the case of the comparative trials (Rubin LJ, 2002, 
Galiè, 2005) for this study, the question asked is whether the prescription of 
drug therapy improves outcome measures at a given time point (sixteen 
weeks).  The same RCT will not be able to confirm that the treatment effect is 
sustained over the longer term.  The extension study and subsequent long-term 
data is open-label and hence open to bias, but this is true of all current long-
term data in PAH.  It will also not be able to inform regarding the treatment of 
patients other than those meeting the entry criteria.  Hence, as the incident 
population being diagnosed daily in the specialist centre is somewhat different 
to the prevalent patients recruited to the studies, the results may not always be 
100% applicable to clinical practice. 
 
Another reason why an RCT may not be possible is financial; it is an extremely 
costly exercise to undertake an RCT.  This limits the use of such a trial in a 
single, or even multi-centre study in the absence of sponsorship from the 
pharmaceutical industry.  A recent US estimate put the cost of bringing a new 
drug to market at over $1bn.  To summarise, an RCT would not be a suitable, 
practical or feasible methodology to test this study’s hypothesis.  Indeed, 
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evaluating guidance introduced in 2008 at this stage cannot be done with any 
prospective methodology.   
 
With the benefit of hindsight, financial resources and clinical justification for 
evaluating its effect, a prospective piece of work similar to this study could have 
been undertaken at the time.  In addition, had such a trial been organised at the 
time of the guidance introduction, an element of patient satisfaction or other 
qualitative research could also have been included.  As discussed, the EBM 
triad refers not only to clinical evidence and clinician expertise but also a 
component of patient expectation (Sackett DL, 2000). 
 
Indeed if PAH-CTD had a better survival rate, it may have been possible to 
enhance the quantitative findings of this study with a qualitative element.  For 
example, opinions could have been sought retrospectively from those treated 
with each agent on their experience with that treatment, its efficacy, toxicity, 
burden of monitoring and overall perceptions either by interview or 
questionnaire.  It was sadly not possible or meaningful at this stage given the 
proportion of the overall study cohort that was still alive, as a result of the life-
shortening nature of the condition.  (Only 66 (27%) out of 247 patients were 
alive on 31st December 2012, the time of performing the data analysis.)  
Bearing in mind that the average return rate from a questionnaire led study in a 
meta-analysis is approximately 20% (Kelley et al., 2003), the qualitative arm 
would have typically analysed responses from approximately only 50 patients).  
In addition, the likelihood is that such a trial would not have been possible 
without involvement from the two pharmaceutical companies involved and 
hence it would have been most unlikely.   
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The absence of pharma-derived funding could be argued as desirable when 
examining treatment effects.  The lack of sponsorship would help researchers 
with the issue of publication bias.  Opportunities for such research in PAH could 
be driven by support from the Pulmonary Hypertension Association or national 
initiatives such as the Health Technology Assessments Programme (part of the 
National Institute for Health Research). 
 
Having ruled out the feasibility of qualitative methods to assess the impact of 
guidance introduced in 2008, a quantitative retrospective approach was 
essential.  There are obvious criticisms of retrospective work that must be 
acknowledged and respected.  These include the potential for bias and will be 
discussed as part of the study limitations later.  However for this study, given 
the quality of historical documentation, as judged by the work published on the 
ASPIRE registry data (Hurdman et al., 2011, Hurdman et al., 2012) it was felt 
there was sufficient validity and reliability within the study to demonstrate the 
impact of the NCP’s introduction.   
 
Having decided on the retrospective approach, it was necessary to utilise the 
most appropriate form of evaluation.  Different models of evaluation can be 
applied depending on the subject of the study.  In the case of this study, the aim 
is to assess the impact of a health policy, the NCP.  This study is using 
retrospectively gathered quantitative data for the evaluation.  The study will 
compare the outcomes of patients commenced on different treatments, before 
and after the introduction of the NCP.  The control or untreated group is taken 
from the BREATHE-1 study.  This group is used to demonstrate the likely 
outcome of not initiating any treatment.   
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According to Øvretveit, (1998), evaluations can broadly be classified into one of 
four categories: experimental, economic, developmental and managerial.  This 
evaluation best fits the description of “Quasi-Experimental”.  The study is not 
geared up to measure cost effectiveness.  It may transpire that there becomes 
an obvious cost advantage to one or other treatments once the data is 
analysed, but the concept of cost effectiveness in PAH has never been proven 
or applied successfully.  With such limited prognosis and expensive costs of 
therapies, evidence would suggest that NICE could not make PAH therapies fit 
the model of the £30k per Quality Adjusted Life Year (QALY) when it embarked 
on the technology assessment. 
 
The study does not collect any qualitative data such as patient satisfaction 
questionnaires.  This is due to the retrospective nature of the work.  Indeed 
patient satisfaction data is not widely published around PAH therapies in any 
context.  In summary, we are not studying the impact of the NCP from either an 
economic or developmental perspective.   
 
This study could potentially be labeled as a “managerial” evaluation.  It does not 
aim to be of interest purely from a managerial perspective, but the conclusions 
and recommendations may have a significant contribution to make in the 
planned review of the NCP.  It is anticipated that this study will be of most 
interest to clinicians and those making prescribing and treatment decisions. 
 
It is important to clarify that this study is assessing the impact of the NCP 
through understanding which of the treated groups (if either) faired best.  
Discovering equivalence will be a useful finding in itself, due to the lack of 
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previous comparative studies published.  The study will not be sufficiently 
powered to make judgment on the use of the treatments in other circumstances, 
or other elements of the NCP. 
 
To reiterate the main study objective, the focus of the evaluation can be 
described as the answer to this question; “Did the NCP’s recommendation for 
the use of first-line bosentan in PAH-CTD patients translate into positive 
outcomes for patients?”  Using the outcome measures validated in published 
RCTs (Galiè, 2005, Rubin LJ, 2002), this evaluation compares those treated 
prior to the NCP and those after its inception.  A key factor will be how closely 
matched the pre and post groups are.  As with any comparative study, if the 
groups are heterogeneous, it will be more difficult to conclude that differences in 
the outcomes are down to the intervention.  This only becomes clear once 
analysis is underway. 
 
4.2 Validity and Reliability 
Understanding the various types of validation used in research and ensuring 
this study met expectations of both validity and reliability would justify the choice 
of methodology.  Being satisfied that the data collection employed in the study 
satisfied each key point below confirmed that an appropriate method had been 
identified.  Potential threats to both reliability and validity occur throughout the 
study.  A rigorous approach to the methods and findings is necessary to have 
confidence that the interpretations of the data are appropriate.  Definitions and 
description of validity and reliability were found in texts by Øvretveit (1998) and 
Balnaves (2001). 
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4.2.1 Validity 
This refers to the extent that the findings are representative of a wider 
population.  Do the tests used to assess treatment effects adequately measure 
this?  There are several types of validity and each must be addressed in the 
study design to maximise the quality of the outcome data. 
These are summarised under the following categories; 
 Content validity – Does the measure comprehensively assess all that 
needs to be measured? 
 Face validity – Does the data gathering method appears to measure 
what it claims to measure? 
 Criterion validity – Does the data gathering method produces data that 
correlates with data from another validated method? 
 Construct validity – Does the tool or measurement fully identify or 
measure the variables? 
The threats to validity and the strategies necessary to address these challenges 
are described below. 
 
Ensuring that the results of this study are valid is difficult on two levels.  Firstly, 
as discussed in Section 2.4, there is considerable debate (Denton et al., 2011), 
(Kowal-Bielecka et al., 2008) in the literature regarding the appropriate endpoint 
measures for all research into PAH-CTD patients.  It is acknowledged that this 
group will not perform as well in functional tests.  This is because functional 
class, exercise capacity and to a lesser extent pulmonary function scores may 
reflect as much on the activity of the CTD as the PAH.  As such none of these 
measures are specific enough to describe the PAH component in isolation.  The 
most recent prospective RCT to investigate this population (in the course of a 
wider PAH licensing study) uses Time To Clinical Worsening (TTCW).  The far 
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more complex TTCW endpoint (defined in Section 2.3.2) was not feasible to be 
used in this study in terms of data collection, as all the information necessary 
was not available.  However, it is accepted that the endpoints being collected 
were the gold standard (albeit potentially flawed) until recently.  In addition, 
whilst TTCW is a more in-depth way of assessing disease progression it is not 
reproducible in everyday clinical practice.  Hence more routine measures such 
as exercise capacity and functional class are still used on every visit. 
 
Secondly, as this is a retrospective trial design, it will be subject to the usual 
validity challenges in terms of the scale of missing data.  How much of the data 
would be missing, poorly recorded and inaccurate remains a challenge for all 
observational studies.  Within our service, various published work has been 
written concerning baseline characteristics of our cohort.  This gave confidence 
that the information was retrievable, validated and accurate for the baselines.  
Whether the follow up data points would be similarly obtainable remained 
unanswered prior to the data collection.  However, by accessing data from 
electronic databases, it was relatively easy to find missing source data using 
electronic filters.  These missing points could be manually searched as part of 
the data cleaning.  The quantity and impact of missing data can be minimised 
and statistically accounted for, but it will inevitably affect the validity of 
conclusions drawn. 
 
In an attempt to maximise criterion validity, the study recorded validated 
endpoints mirroring those collected in the prospective RCT for bosentan (Rubin 
LJ, 2002).  By collecting retrospectively, we do not affect the type of data used 
but it can nevertheless be related to data collected prospectively by the RCT.  
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Whilst not universally employed, the ISWT has been shown as a valid measure 
of exercise capacity (Elliot, 2004, MacSween et al., 2001, Pepera et al., 2010, 
Wise and Brown, 2005).  The ISWT has been shown to have predictive 
reliability (Elliot, 2004) despite being less widely used than the 6MWD.   
 
To maximise construct validity a range of endpoints have been chosen.  As a 
result, the conclusions do not rely completely on one outcome measure.  In 
doing so, the study has construct validity – the ability of the tool or 
measurement to identify or measure variables.  Judgments are based on 
correlations from other works using the measurement tool.  Whilst no product 
licences are based on ISWT, it is a validated measurement of exercise capacity. 
 
Potentially the most important of all these considerations is ensuring external 
validity, otherwise known as generalisability.  This is in contrast to the 
categories of internal validity that have been discussed.  These are concerned 
with the extent to which the method measures the treatment effect seen in PAH-
CTD patients.  External validity is concerned with the extent to which the 
findings can be applied to the wider population outside of the sample.  As the 
intention is for outcomes to influence and enlighten future prescribing guidance, 
the outcomes must be applicable to the populations of PAH-CTD patients 
managed elsewhere.  Assuming that the SPVDU PAH-CTD population is 
representative and given that the entire caseload was recruited if suitable, 
external validity will be ensured. 
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4.2.2 Reliability 
The reliability of the data collection method was assured, as the retrospective 
approach allowed the opportunity to capture all available information for each 
case from existing sources.  There would be consistency if the same methods 
were repeated with different treatments, a different investigator or different time 
frame.  An extraction from electronic database with subsequent manual data 
cleaning would not suffer from the same variance of data as for example 
interviews.  In this way, there was confidence that the method would minimise 
systematic bias.  It was difficult to rule out random bias, primarily as a 
consequence of poor data quality, incomplete recording or inadequate filing.  As 
the data being analysed was recorded in the course of everyday NHS clinical 
practice one would hope that records would be comprehensive but the reality is 
unfortunately different.  With any prospective work, either randomised or non-
randomised, the investigator is in some control of the data being collected.  A 
data collection form could be used in order to ensure that all required 
information was gathered and that gaps or missing values can be rectified very 
shortly after collection.  Such quality measures are not available for 
retrospective work. 
 
In summary, a retrospective, observational case-control evaluation model was 
chosen for this study.  This was accepted as a reliable method of investigating 
validated endpoints and would adequately test the study hypothesis.  It was felt 
that there was strong construct and internal validity to reduce error and bias and 
thus influence the conclusions.  External validity was assumed but could not be 
guaranteed. 
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4.3 Consent and confidentiality 
As there is no active participation aspect either in person at clinics or 
admissions or by letter, consent was not sought from any individuals.  All of the 
data that was needed to analyse was collected routinely as part of each and 
every clinical review that the patient attended in our clinic.  This issue had been 
discussed and resolved with the ethics committee at the time of the original 
submission by SPVDU.  It was agreed by the Ethics Committee that for 
retrospective research such as this, consent would not be necessary.  This 
agreement can be applied to this study.  I have attached the ethics approval 
letter for the over-arching study “STH 14169 – Improving the investigation of 
Pulmonary Hypertension” as Appendix 5.  It is worth emphasising also that in 
this population of a disease with such an effect on life expectancy, there will be 
a significant proportion of deceased patients, from whom consent could not be 
sought.  I acknowledged that if, as a result of this work, any prospective work 
arose then full consent would have to be sought. 
 
4.4 Ethical considerations  
This study is a retrospective analysis of data routinely captured during patients’ 
visits.  As such, I did not in any way affect the level, quality or nature of the care 
given to the patients.  This piece of research was covered by a previously 
attributed ethical approval.  This previously awarded ethical approval allowed 
for all retrospective work carried out on the PAH patients within the Sheffield 
centre, subject to any new researcher’s name being added to the programme 
(See Appendix 6).  I have attached the original letter and also the minutes of a 
subsequent meeting summarising the ethics committee’s position on future 
research, consent and the addition of additional researchers to the project.  This 
research study was being conducted as the second part of the DPharm course.  
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Ethical approval from the University of Bradford was not necessary as it was 
covered by the NHS ethics agreement.  All data collected was anonymised 
throughout.  Any records containing patient identifiable data (PID) was kept 
according to STH policy (See Appendix 7) and procedure and in accordance 
with the specific conditions as detailed in the ethical approval. 
 
4.5 Pilot Study 
Once it was decided that a retrospective observational case-cohort study would 
be the chosen methodology, a smaller scale data collection was undertaken.  
The aim of this piece of work was to confirm that data would be complete and 
rigorous enough for the larger study.  Whilst the registry data had been 
published in terms of baseline characteristics and survival, no attempt had been 
made to relate the data to side effects, discontinuation or treatment effects.   
 
The pilot study recruited 101 patients with PAH from a total of 113 patients who 
had been prescribed ambrisentan at the census date.  Patients with CTEPH 
(and any other aetiologies not included in the product license) were excluded.  
The patient group was characterised in terms of aetiology, functional class, 
haemodynamics, baseline exercise capacity and rationale for prescription.  This 
latter characteristic was important for ambrisentan as the NCP listed it as a 
second choice ERA behind bosentan.  It was useful to understand and describe 
the clinical circumstances in which the agent was being used in clinical practice. 
 
Duration on treatment, side effects (which may or may not have led to 
discontinuation), results of LFT and FBC monitoring and all-cause mortality data 
was also recorded.  According to the SPC (SPC, 2011), ambrisentan appears to 
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have a lower incidence of LFT abnormality than bosentan, so it was of particular 
interest to see if our incident population demonstrated similar characteristics to 
the prevalent patients recruited to the licensing RCT.  The results of the pilot 
work were disseminated at a poster presentation at the American Thoracic 
Society meeting, San Francisco (Hamilton, 2012).   
 
This was a useful exploratory learning exercise in several key ways:  
 Which sources of data could be accessed? 
 What data was likely to be available and from which sources (and indeed 
of what quality it is recorded)? 
 What quantity of missing data points could be expected? 
 How much time would need to be allocated to the data collection for the 
main study? 
 What level of data cleaning would be necessary? 
 
For each of the above factors, the pilot study was an essential part of the 
methodology development.  It gave invaluable insight with regard to key 
elements of the main study. 
 
It was reassuring that data was, in general readily obtainable, albeit from a 
variety of existing sources and needed significant reformatting and cleaning in 
order to be fit for analysis.   
 
One significant difference between this pilot and the main study was the period 
(and duration) of interest.  Ambrisentan was introduced in 2009 (as opposed to 
2002 for bosentan).  This difference may prove to be significant in terms of data 
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retrieval.  For the pilot study, most of the patients were still alive, most were still 
on treatment and all of their clinic letters were available.  This may not be the 
case for the earliest patients (commenced bosentan or sildenafil therapy circa 
2002). 
 
There was also an issue in the collection of the exercise capacity data.  The 
problem was not in terms of completeness, for it was clear that all patients were 
asked to try and undertake an ISWT on each visit.  However it was evident that 
the timing of attendances was not as tightly routine as with those patients in 
RCTs.  It was clear that in the course of clinical practice in our busy centre, that 
the “windows” of time for collecting data points would need to be considerably 
wider than initially expected.  For example, some patients prescribed 
ambrisentan as a consequence of LFT abnormality on bosentan were not seen 
in the SPVDU around or at the time of commencement of therapy.  This meant 
that we had to take the baseline readings as being those from the visit previous 
to ambrisentan being introduced.  Similarly first follow-up data was not present 
for the typical 16 week follow-up visit between 15 and 17 weeks (105-119 
days).  In terms of the pilot study, the first follow-up slot would be in the range 
56-224 days in order to maximise recruitment and minimise missing data points.   
 
The adoption of similar windows was a necessary strategy when it came to the 
PAH-CTD group in this study too.  It became clear that if strict windows of time 
akin to those in the RCTs, few, if any patients would have data to analyse, yet 
the majority of those patients were still alive and on treatment.  Compromising 
on the time windows was deemed worthwhile to improve the robustness of the 
data.  After all, the results of this study would be derived from, and have 
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implications for everyday clinical practice.  As the shifting of patient attendance 
due to both patient and organisational factors is part of real life, such a 
compromise was easily justified.  When this approach was taken to the PAH-
CTD group along their treatment journey, it did mean that some patients’ first 
follow-up was only several days before others’ one-year data.  However this 
would be inevitable whenever the timelines are drawn up. 
 
The ambrisentan pilot did not look at data beyond first follow-up as there was 
not sufficient patient numbers with long-term experience at the census date.  
However for the small group available, it was clear that the one and two year 
follow-up data would not necessarily fall at 52 and 104 weeks, but within a 
window of time either side of the date.  This was helpful as it introduced an 
unforeseen amendment to the plan for follow up dates.  In planning the 
structure of this study, windows for 1 year (day 253-504 and 2 year (day 646-
814) follow up were strategically selected to maximise recruitment without being 
irrelevant to the time point.  It was fully anticipated in a study analysing 
monotherapy in treatment naïve patients with PAH-CTD that groups at these 
time points might have small numbers.  In the event we had a total of n=90 
(36% of total) at 1 year and n=56 (22%) at 2 years.   
 
4.6 Data sources  
This study analyses data collated from primary sources.  These are defined for 
the purposes of research as documents written during the time under study.  
This is contrasting with secondary sources, which is defined as an interpretation 
or analysis of the primary data.  As our patient population had been 
systematically reviewed over the period of study, there would be a vast amount 
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of primary data recorded and accessible.  These data sources are often 
overlooked and are of potentially huge value if they are complete and robust 
enough to be interrogated thoroughly.  Retrospective review can inform 
researchers and clinicians greatly.  Systematic review of primary sources can 
give insight into the beneficial (or otherwise) effect of management strategies to 
date.  In addition they can provide clues and information regarding unwanted 
events and how these may be best avoided in the future.   
 
However, as with any collation of existing data “primary” sources, whilst the 
content may be available and of considerable value, it is invariably in the wrong 
format, order or location.  In addition, someone else will have collected the data 
for another purpose.  Lack of accuracy is one of the biggest challenges facing 
the investigator when conducting a retrospective analysis (Nagurney et al., 
2005). 
 
Capturing the data for the purposes of this study presented me with exactly 
these challenges.  I had confidence that the patient group had been 
systematically worked up previously in the context of the development of the 
ASPIRE registry (Hurdman et al., 2011).  However as this was a registry of 
baseline characteristics only, there were ongoing concerns that needed to be 
addressed in order to have full confidence in the suitability, quality and quantity 
of data available for analysis. 
 
The data were captured in the course of routine clinical practice in a busy and 
expanding unit.  The implication of this was that data may be not have been 
recorded and inputted accurately due to time and staffing pressures.  The most 
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obvious example of this was noted in the documentation taken from the medical 
notes and typed letters (discharge summaries and outpatient clinic letters).  It 
was noticeable that the quality of the data recorded in the letters has vastly 
improved over time.  Additionally, the most recent documentation was both 
more thorough and easier to locate.  For the patients started on treatment the 
longest time ago, there was a high probability that the patients would now be 
deceased.  In this instance their notes were archived to microfiche and there 
was by no means any certainty that the specific data needed for the study 
would still be accessible.  However, where critical data points were not available 
from currently available sources, the microfiche was explored.   
 
With this previous work in mind, I had some confidence in the quality and 
completeness of the earlier patients’ data as these have been double-checked 
by previous investigators from our centre.  It was also reassuring that whatever 
data I needed from these patients, it would be in the registry if it were still 
accessible. 
 
Data regarding the dates of patients’ visits to the SPVDU was recorded in the 
Trust’s “Patient Centre” (PC).  This is the patient data management software.  It 
has details of current patient demographics, appointments, attendances, 
admissions and waiting lists.  This superseded the previous software (PAS) in 
2009. 
 
Clinical information was extracted from the ASPIRE registry data.  The registry 
contained most of the necessary baseline haemodynamics, PFTs and ISWT 
data.  Certain follow-up information was also evident.  Anything missing from 
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the electronic extraction had to be searched for by hand from primary sources.  
The ASPIRE registry only recorded the WHO class at diagnosis.  This was not 
the point at which treatment was initiated for some patients with very mild 
disease who had been successfully identified via an early referral or screening 
protocol.  For this minority, the medical notes were interrogated to find out the 
WHO class at the point of treatment commencement. 
 
Data for the medication histories was corroborated from two sources and 
synthesised into a usable summary.  The PH clinical pharmacy team have built 
and maintained a database detailing every patient who has been commenced 
on treatment for PAH at the SPVDU since 2002.  This is a live document that is 
regularly and routinely updated.  As such, it contains the vast majority of the 
information required to map a patient’s “treatment journey”.  However for data 
rigour, this was checked against the information contained in discharge 
summaries and outpatient clinic letters for accuracy.  Two important elements 
were known to be missing from the treatment database; diagnosis and rationale 
for stopping (where the pharmacy team had not been specifically notified).  The 
first element, diagnosis is absent due to the fact that this database was never 
designed or intended to link aetiology with treatment.  This information was 
being recorded elsewhere.  Rationale for stopping was erratically recorded, as 
this information was not always available to the pharmacy team for every 
patient at the time the database was updated with a stop date.  Where 
discontinuation rationale was absent, medical records or letters were 
interrogated in an attempt to avoid crucial missing data points. 
 
  115 
From March 2013, all the information being collected for this study is being 
centralised into “Infoflex”.  Infoflex is a comprehensive patient data 
management software tool that has been customised for many clinical areas 
across the Trust (pulmonary hypertension included).  Its system of interlinked 
databases will in future allow for clearly written queries to be run in order to 
generate data similar to that which has been collected for this study.  The main 
challenge to the investigator of potential future studies will be the quality of 
data.  There are threats to data quality in both original data input and validating 
the migration of the data into Infoflex from previously used secondary sources.  
As discovered in the course of this study, obtaining usable data from numerous 
independent sources relies on the accuracy of multiple individuals entering the 
original data (hence a high propensity for error).  Not only this, but it must also 
be validated as data fit for purpose. 
 
In addition to the locally held Infoflex system, there is a national PH audit 
dataset, currently being transitioned to the NHS Information Centre in Leeds.  
Data from all patients in the UK is entered into the database.  The purpose of 
this is similar to the local Infoflex system (indeed some of the data captured in 
Infoflex is uploaded into the national database).  It is anticipated that over time, 
commissioners and clinicians will be able to extract important data regarding 
outcomes form this dataset.  Such outcomes will be invaluable in reinforcing the 
evidence for treating PAH using high cost medicines.  The key to its success 
will be clear definitions, a dictionary and glossary to ensure that, with so many 
individuals in so many centres inputting, data quality is maintained.  One of the 
major concerns with the outgoing national data capture platform was the lack of 
such a glossary or help manual.  As a result, it is possible that some centres will 
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have misunderstood the requirements of certain fields and unintentionally 
entered data incorrectly.  Although a user group was established to try and 
cope with such challenges, the reality of trying to capture this volume of 
information without any resource attached is that staff are given data input roles 
additional to their other work and that accuracy is not prioritised ahead of the 
workload. 
 
4.7 Data Cleaning 
Once the study entry criteria were decided upon, there followed a period of data 
collection, then intense reformatting and cleaning to ensure the data was 
rigorous and fit for analysis.   
 
Detailed description of the steps taken in MS Excel and MS Access to clean the 
data has been included as Appendix 8. 
 
4.8 Patient identification 
As outlined in the introductory chapters, there are two main challenges facing 
the investigator of treatments for this rare disease.  Firstly numbers of cases 
suitable for inclusion and secondly the small treatment effect size seen in the 
licensing studies. 
 
In order to meet the aims and objectives outlined the robust methodology set 
out first and foremost to maximise the sample.  Maximising the sample and 
recruiting from every patient meeting the entry criteria would give the sample 
strong external validity and hence be representative.  Hence optimising overall 
(and by virtue sub-group) recruitment was a priority.   
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A broad inclusion criteria was used, whilst keeping it as comparable as possible 
with that used in the bosentan BREATHE-1 study (Rubin LJ, 2002).  The 
placebo arm of the BREATHE-1 trial was used as the control group for this 
study.  At the outset it was only possible to estimate the effect size based on 
those described in the BREATHE-1 and SUPER-1 trials.  As already noted, 
there was a larger change in exercise capacity seen in the PAH-CTD group in 
the SUPER-1 than BREATHE-1 study.  However given the numbers of patients 
in the sub-groups, it is unclear whether the groups were matched for 
comparison.  That said, the very least that can be expected from treating 
prevalent treatment-naïve cases is disease stabilisation at 16 weeks.   
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Inclusion criteria: 
 Treatment-naïve patients with a diagnosis of PAH-CTD made by the 
SPVDU. 
 Commenced on oral monotherapy treatment with either sildenafil or 
bosentan. 
 Patients commenced on therapy prior to licensing, as part of named-
patient, compassionate use programmes were included to maximise 
recruitment, provided they had the appropriate diagnosis. 
 Commenced before 01.02.2010.   
This date was significant as it was also the end of recruitment to the 
ASPIRE registry.  In order to maximise the follow-up duration of those 
patients initiated on treatment after the introduction of the National 
Commissioning Policy (NCP) in April 2008, the study has a census date 
of 1st November 2010.  Hence, whilst new treatment starters were not 
included after February, treatment effects were recorded for a further 
eight months.  All patients still on treatment at the census date were 
nominally given this as a discontinuation date for the purpose of data 
analysis. 
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Exclusion criteria: 
 Patients commenced on any other PH targeted therapy (prostanoids, 
ambrisentan, sitaxentan, or any combination of two agents). 
 Patients referred to Sheffield on treatment (hence not diagnosed by 
our centre). 
 Patients prescribed either sildenafil or bosentan for treatment of 
Raynaud’s phenomenon who were subsequently diagnosed with 
PAH. 
 
This study follows on from both the ASPIRE registry (Hurdman et al., 2011) and 
also the work by Condliffe et al. (2009) in characterising the patient group in the 
SPVDU.  As part of describing the PAH-CTD population across all UK centres, 
data presented by Condliffe and colleagues reviewed all incident cases with this 
specific diagnosis up to June 2006.  The ASPIRE registry recorded all patients 
of all aetiologies seen by the SPVDU up until February 2010. 
 
Patients with the diagnosis of PAH-CTD were identified from the overall 
ASPIRE registry (Hurdman et al., 2011).  These were cross-referenced against 
the treatment database to identify all those with the correct diagnosis that were 
prescribed targeted drug therapy.  Targeted therapies are those agents 
specifically prescribed for the treatment of PAH.  These will include the other 
PDE5 inhibitor (tadalafil), the other ERAs (sitaxentan, ambrisentan) and 
prostanoids (treprostinil, and iloprost -both nebulised and intravenous). 
 
As part of the data collection for the ASPIRE registry, supportive as well as 
targeted therapies, for example warfarin, were recorded.  These are of no 
consequence here as this study looks specifically at two orally active targeted 
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therapies.  For the purpose of this study, supportive therapies have been 
regarded as benign background treatments that have no impact on outcome 
measures.  They are likely to be prescribed across all-comers but none are 
proven to be beneficial in impacting the outcome measures assessed in the 
study.  It was assumed that these would not find the treatment effects noted 
from the targeted therapy and that their prescription was likely to be equal 
across the cohort. 
 
In addition, treatments prescribed for the CTD component of a patient’s 
condition, for example prednisolone, were also noted but ignored for this study.  
Lastly the use of calcium channel blockers was noted for ASPIRE.  These 
agents are commonly prescribed within the CTD population at standard doses 
for the treatment of Raynaud’s phenomenon.  Whilst it is acknowledged that 
calcium channel blockers are of therapeutic value at high doses in IPAH, there 
is no evidence that they can be beneficial if employed in this way for PAH-CTD.  
As a result of both these factors, they have been ignored for the purpose of this 
analysis.  Hence in building up each patient’s treatment journey, wherever 
these supportive treatments were recorded, they have been ignored.  Only 
targeted PAH therapies have been used to form the treatment journey.   
 
It was important to build a patient treatment journey so that it was possible to 
record dates and reasons for all dose changes and discontinuations.  It also 
enabled at-a-glance to visualise and understand the patient’s history.  For 
example a patient may have commenced bosentan, then switched to sildenafil 
or alternatively commenced sildenafil, had the dose escalated twice up to a 
maximum of 100mg tds then received the addition of a second treatment. 
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The rearranged treatment journeys were checked to ensure that patients in the 
final set had either sildenafil or bosentan in their first episode.  Patients with 
targeted therapy other than bosentan or sildenafil as their first episode were 
excluded from the study.  However, it was vital not to exclude patients with 
other targeted therapy as a subsequent episode, hence as 2nd, 3rd, 4th or 5th 
change.  These episodes would be vital to the study as this addition or 
substitution would mark for them the monotherapy end date. 
 
One of the outcomes to be reported is the time on monotherapy.  This is simple 
to measure for bosentan as patients almost always start on 125mg twice daily 
(bd) and stay on that dose.  For sildenafil, the picture is not so clear as it was 
the accepted clinical practice to escalate the sildenafil dosage, sometimes to 
100mg three times daily (tds) over time before adding or switching to other 
treatments.  Thus, this study needed to be thorough enough to catch all patients 
who had a dose escalation, as these remained on monotherapy albeit at supra-
licensed doses.  For the analysis and statistics, it was necessary to break the 
sildenafil cohort into two groups; firstly a group where the experience was 
based purely on the time at licensed doses (i.e. up to 25mg tds).  Once the 
dose was escalated, this was treated as the end of their monotherapy episode.  
A second group of sildenafil patients included experience to their ultimate 
monotherapy dose.  This may have been 50mg tds or 100mg tds.  Some went 
to 100mg tds then came back down to 50mg tds.  In all these examples, 
provided a second treatment was not added, it was treated as a sildenafil 
monotherapy episode.  In the analysis, it would be of interest to see if the group 
prescribed only the licensed dose do any differently from the group whose 
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doses were escalated.  This comparison mirrors the SUPER-1 (Galiè, 2005) 
and more recent long term SUPER-2 (Rubin et al., 2011) studies. 
 
The rationale for treatment discontinuation was recorded.  This would provide 
useful data that could show whether one or other treatment would subject 
patients to a particular problem, for example whether a higher proportion of 
patients experience intolerable side effects or more died on one or the other 
treatment. 
 
Discontinuation prior to first follow up was of particular interest.  Information on 
those who stopped before review may elicit an insight into the reasons some 
patients stop after a very short time.  For those who died on bosentan prior to 
review, further investigation to the individual cases would be necessary but if 
even partly predictable due to the patient factors, bosentan represents a costly 
intervention with a long onset of beneficial effect and perhaps one best avoided 
in favour of a quicker acting agent in these patients for whom a rapid response 
is necessary. 
4.9 Patient Cohorts 
Once the data was cleaned, translated, and double-checked, the cohorts for 
comparison were applied and the patients coded into one or more groups for 
statistical analysis.  These cohorts can be summarised as: 
1. “Headline” Groups – those where the main interest will be placed and 
with numbers sufficient to draw conclusions from the dataset 
a. All sildenafil patients at all doses commenced at any time 
b. All bosentan patients at all doses commenced at any time 
c. All patients that commenced treatment prior to the NCP 
  123 
d. All patients that commenced treatment in accordance with the 
NCP 
e. Sildenafil patients treated to licensed doses 
f. Sildenafil patients treated to supra-licensed doses 
2.  “Supporting” groups – those smaller groups which may elicit useful 
findings albeit with limited numbers 
a. Bosentan patients commenced pre-NCP 
b. Bosentan patients commenced in accordance with NCP 
c. All patients with a diagnosis of PAH-CTD (SSC) 
d. All patients with a diagnosis of PAH-CTD (Other) 
4.10 Statistical Analysis 
4.10.1 Missing Data 
As data was recorded for clinical purposes, therefore it was almost inevitable 
that some fields would not be identifiable.  Methods previously discussed were 
employed to minimise the quantity of missing data.  However some 
measurements were indeed not available. 
 
Early work undertaken prior to the main study hinted at the difficulty of 
retrospective studies with regard to missing data.  The audit characterising the 
early experience with ambrisentan for PAH (Hamilton, 2012) gave some insight.   
This has been discussed in depth in Section 4.5 
 
Whilst adapting the approach to follow up intervals would allow for the best 
recruitment of patient numbers, there was nothing that could be done 
retrospectively regarding completeness of the clinical records.  A degree of 
incomplete data should be anticipated when undertaking this type of research 
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or audit, however the quantity cannot be pre-empted.  Had BORG been the 
most crucial marker for the study, such a proportion of missing data (42% at 
baseline) would have rendered the study impossible.  What is striking is how 
poorly recorded this test was in the same population for whom “missingness” of 
other data points was not really a major problem. 
 
In order to quantify and evaluate the impact of the missing data, a strategy was 
developed to distinguish “user missing” from “system missing” values.  These 
are terms utilised within SPSS and it is vital to understand the meaning of these 
terms.  In general terms, missing values were identified as instances where the 
dataset did not have a value for a given variable at any review point.  Such 
instances may occur when a patient was on treatment but either did not attend 
for follow up (reason unknown to the investigator) or there was no walk test or 
WHO class recorded for their visit.  For the purposes of data analysis these 
were identified to SPSS as “user missing”.  This is in contrast to the “system 
missing” data points created where patients had discontinued treatment and 
hence were no longer of interest to the study.   
 
In terms of classification of the user-missing data, there are broadly three 
categories (RUBIN, 1976).  These are: 
1. Missing completely at random (MCAR) – where the probability of 
missingness is independent to any characteristic of the cases, for 
example, the sheet recording the ISWT distance is lost before being filed 
in the notes or recorded electronically.  When data is MCAR, so is the 
subset of cases affected. 
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2. Missing at random (MAR) – a more general assumption that the missing 
variable depends purely on other observed variables, that is, the reason 
for the missingness is related to the case’s characteristics 
3. Missing not at random (MNAR) – Where the probability depends on 
something that is not observed and recorded.  For example where the 
lack of an ISWT distance was due to the patient not being able to afford 
to travel to the appointment. 
 
Usually, missing data are not MCAR or MNAR (Donders et al., 2006).  Although 
the overall prevalence was only 11% for ISWT and 15% for WHO classes, list 
wise deletion of incomplete cases would have resulted in 53 cases being lost 
from the cohort.  Given the small numbers available this would not have been 
sustainable in terms of meaningful analysis.  Indeed assuming that the data 
was not MAR either, then analysis of complete cases is no longer unbiased.  
Additionally, all simple techniques for handling missing data, for example mean 
of the observed values or last observation carried forward give biased results 
(Donders et al., 2006).   
 
In addition, as the missing ISWT values are numerical, replacing the missing 
with worst-case scenario (WCS) values was not feasible (unless zero was input 
for all), because there is no way of estimating a WCS for each case. 
 
As a consequence of this finding, imputation by more complex methods was 
necessary to ensure the optimal statistical power and representativeness of the 
results.   
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Several options are available to replace the missing values in order to analyse a 
“complete” data set giving a more powerful analysis.  One of the more popular, 
multiple imputation was used in this study.  Multiple imputation aims to allow for 
the uncertainty about the missing data by creating several different plausible 
data sets.  Analysis is displayed as a combination of the results obtained from 
them.  The use of multiple imputation in medical research has been well 
documented (Mackinnon, 2010). 
 
SPSS is able to carry out this imputation procedure.  It carries out a two-stage 
process.  Firstly multiple (m=5 chosen for this dataset and is the most popular) 
model datasets are created based on observed values of predictor variables.  
The user has the opportunity to specify all variables (described in SPSS as 
constraints) on which the model should be based.  It is advisable to use as 
many potentially relevant variables as possible.  This reduces the chance of 
values being imputed that sit outside the ranges seen in the observed cells.  It 
also allows for variables to be included which may have relevance to the 
missingness but are not necessarily important to the hypothesis testing.   
  
The imputation must account for all uncertainty in predicting missing variables 
by inserting appropriate variability into the missing values, as we do not know 
the true values of the missing data (Sterne et al., 2009). 
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For this study, the following constraints were employed in generating the 
imputed values: 
Table 8 – Constraints used for multiple imputation by SPSS 
Age Gender 
Diagnosis code CTD Type 
Presence / absence of pulmonary 
fibrosis 
Treatment dose group 
Pre / Post NCP group Monotherapy group 
Duration on Max Monotherapy Survival 
Pulse Ppa (Mean Pulmonary Artery 
Pressure) 
Rpa (Mean Right Atrial Pressure) Cardiac Output 
Cardiac Index PVR 
PCWP MVo2 
Baseline ISWT distance Baseline WHO functional class 
 
The investigator is able to reset the random number generator (based on 
Mersenne Twister model) (Matsumoto and Nishimura, 1998).  It is also possible 
to set maximum number of case draws (for this analysis n=200) and the 
parameter draws (n=2). 
 
Additional effort is taken to ensure that the values imputed by the program fit 
possible values for the variable in question.  Hence for the ISWT distance, it 
was important to limit the values to a minimum of zero, rounded to the nearest 
ten.  Whilst this narrows the possibilities for the random number generator, it 
does ensure “possible” results are imputed by SPSS. 
The output for all analysis carried out using multiple imputation datasets 
includes information additional to standard SPSS outputs analysing single data 
sets.  This additional information contains a parameter estimate (the average 
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estimate from the 5 datasets) and the Standard Error (based on the average 
plus an estimate of the added uncertainty that comes from the imputed data). 
 
4.10.2 Choice of statistical tool for monovariate analysis 
The study design originally planned to use pairwise statistical testing to analyse 
the changes from baseline to T1 of the scale dependent variable, change in 
walk test distance.  However on deciding the tool to use, there were several 
factors to consider ensuring that pairwise comparison was the most appropriate. 
 
The scale data collected is a measure of walk test distance measured in metres 
by the incremental shuttle walk test (ISWT).  Other data collected involves 
ordinal data describing WHO functional class.  Depending on each patient’s 
maximal duration of monotherapy, there are up to three time points for analysis.  
These time points are first follow up (T1), approximately one year (T2) and 
approximately 2 years (T3).  However, due to high discontinuation rates (mostly 
due to death), group sizes at T2 and T3 are relatively small and may not be of 
sufficient size for statistical analysis.  In addition, non time-specific overall 
markers have been noted as all cause mortality and duration on maximal 
monotherapy (both in days). 
 
The first quality that the test of choice needed to possess was to be applicable 
to the dataset.  Data was collected in this study to test the hypothesis in a non-
randomised trial design.  Consequently, the tests to analyse the data needed to 
be appropriate for this particular type of work.  It is suggested that tests for 
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randomised samples are not always ideal for non-randomised and vice versa 
(Britton A, 1999).  Several tests could each have staked a claim to being able to 
give meaningful results from the data collected. 
 
Secondly, and most importantly in terms of making findings relevant to practice, 
the test would ideally produce a result set that was comparable to other similar 
work.  For this study, all procedures undertaken in all the clinical studies 
conducted for regulatory approval in patients with PAH were scrutinised.  
Particular interest was placed on those measuring the effects seen in PAH-
CTD.  Although the choice of endpoints can be debated as previously 
discussed, the method of assessing response was relevant. 
 
Results of licensing studies for all current PAH treatments looking at changes in 
exercise capacity have been reported using the pairwise t-test.  This would be 
selected because it is widely understood and very commonly used among 
researchers.  It is a powerful test, given the assumptions of the test being met.  
In the t-test, each case is its own control so within-subject differences can be 
limited.  The result is a smaller error term and hence larger t value.  This may 
often allow for smaller numbers in the study.  It would be of particular value in 
this study where group size was not always large. 
 
With these qualities in mind and in order to be satisfied that pairwise analysis 
via t-tests was the optimal route, other options were explored.  With the benefit 
of statistical advice, it was suggested that simply comparing the means might 
not adequately account for bias introduced by covariates.  For example, that the 
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change in walk test seen at T1 may be influenced by the baseline walk test 
distance.  A test that would take account of this is ANCOVA (analysis of 
covariance).  This seemed a very logical option, as there was good clinical 
rationale to believe that baseline walk test distances may influence future 
changes. 
 
On further investigation, ANCOVA seemed a possibly viable alternative but as a 
regression model, certain assumptions needed to be satisfied.  The 
assumptions needed not to be violated so that the test achieved the goal of 
correcting or controlling for the influence of the covariate.   
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The assumptions of the ANCOVA test are: 
1. Normality of residuals (error terms – but not necessarily the independent 
or covariate values) 
2. Homogeneity of variances 
3. Homogeneity of regression slopes 
4. Linearity of regression 
5. Independence of error terms. 
This test can be performed within SPSS, as a general linear model (GLM).  The 
first part of the sequence tests whether or not an interaction between the 
covariate and factor exists.  From this it is necessary to test the homogeneity of 
the covariate parameter estimates across levels of the factor.  When ISWT data 
at first follow up from the collected set was put through this initial test, the 
interaction term was significant (p=0.002).  This indicated the covariate 
parameter estimates are not homogenous.  In ANCOVA, if this assumption is 
violated, it amounts to having an interaction between the covariate (baseline 
distance) and the grouping variable (treatment option). 
   
The model could in theory still be used, but understanding the outcomes is not 
straightforward.  A positive interaction between the variables reinforces the view 
that this test may be useful, however the lack of homogeneity of variance 
between the groups was less helpful.  Any pursuit of this route would mean that 
clear comparable results would not be possible.  The significant interaction 
meant that the difference between treated groups would change for different 
values of baseline ISWT distance. 
Despite violation of one of the assumptions it would appear to have been a 
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possible way of analysing the data.  However on further exploration of the 
technical challenges posed by interpreting results of ANCOVA tests, further 
issues were uncovered that required consideration.  The use of ANCOVA as 
opposed to simple analysis of change scores (SACS) by, for example, using the 
t-test is much debated in the literature (Holland, 2005, Locascio and Cordray, 
1983). 
    
The correct application of ANCOVA and interpretation of the results (as with all 
statistical analysis) requires a level of understanding of what the coefficients 
and tests represent.  By way of further explanation, ANCOVA models “control 
for” the variance in the independent variables that are associated with the 
dependent variable and then examines the residuals.  Consequently each 
coefficient and test is difficult to interpret outside the context of this set of 
variables and their interrelationships.  This in itself does not preclude using the 
test but moreover suggests that interpreting and describing the outcomes may 
be complex.   
 
Further discussion in the literature questioned the use of ANCOVA in the 
particular circumstances of this dataset.  Miller and Chapman (Miller and 
Chapman, 2001) argue that it is absolutely inappropriate to control for non-
independent covariates that are related to both the independent and dependent 
variables in an observational (non-randomised) study.  Other work reinforces 
this view (Van Breukelen, 2006); that by applying this method to testing non-
randomised groups there is a higher risk of bias.  Inherent to the non-
randomised structure is the possibility that the covariate is linked to both the 
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dependent and grouping variable.  To put this in the context of this study, 
patients may have been assigned a particular treatment in part due to their 
baseline walk test.  This covariance may not be overcome by the test and the 
test may indeed remove, in part at least, the treatment effect noted. 
 
As described above, an extensive investigation into the concept of ANCOVA, 
weighing up the advantages and disadvantages of the test was conducted; 
culminating with running the test with a sample of data from the set was carried 
out.  To summarise, it was acknowledged that attempting to control for 
covariance needed further exploration.  An interaction between the covariant 
and the dependent variables was noted but not all of the assumptions of the 
test could be met with the data collected.  In a Health Technology Assessment 
(HTA) (Britton A, 1999) authors found that adjustment for differences at 
baseline in non-randomised studies often changed the effect size, but not 
significantly.  Importantly the direction of change was inconsistent.  With 
reproducibility and universal translation of the results of the study of key 
importance, as stipulated above, an alternative needed to be found.   
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It seemed logical that if the results of this study were going to be compared to 
other work in PAH investigating treatment effect then similar outcome measures 
reported in similar terms would be helpful.  Outcomes from regression are more 
difficult to make direct comparisons against.  This led to a consideration of a 
simpler statistical test based on pairwise comparisons at the monovariate 
analysis stage.   
With reducing the impact of confounders in mind, the possibility of transforming 
the data to percentage rather then arithmetic change was considered.  Had the 
test lent itself to this idea then it may well have dealt with the issue in a 
straightforward way.  However, implicit in the ISWT is the concept of an 
incremental test.  Hence a 20% improvement seen at follow up may represent 
different levels of clinical change depending again on the baseline.  For 
example a 20% improvement on a baseline of 100 metres is very different to a 
similar proportional improvement seen on a baseline of 500 metres.  In addition, 
with a notable number of patients failed to make one complete shuttle (10m), a 
baseline of 0m was noted.  A percentage improvement from 0m or indeed a 
change from baseline to 0m at their follow up would not be possible. 
In conclusion, monovariate analysis via pairwise t-tests on the data as the 
method of analysing change from baseline was decided upon.  With this in 
mind, the first important step was to obtain descriptive statistics on the groups 
at baseline, to test for normality and distribution.  The histogram, P-P plot and 1 
sample K-S tests were all applied to assess if the data was normally distributed 
or not. 
 
Having established the distribution of all variables, the appropriate pairwise 
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testing methods was applied.  In order to describe baseline characteristics, 
scale variables of age, haemodynamics, WHO functional class and baseline 
ISWT distance was noted.  Comparisons between the groups were made to test 
for differences prior to treatment.  To compare ISWT distances at each review 
time point with that recorded at baseline, within case comparisons (paired 
samples) used either the Paired t-test (parametric) or Wilcoxon signed-rank test 
(non-parametric).  Between groups analysis used the independent samples t-
test (parametric) or the Mann-Whitney U Test (non-parametric). 
 
Comparing the proportions of the groups in WHO functional classes used the 
Chi square contingency tables.  These are an example of statistical cross-
tabulations.  They are used to discover if there is a relationship between two 
categorical variables.  In order for this to be an appropriate test to use, the data 
must pass two assumptions: 
 The two variables must be ordinal or nominal (i.e. categorical data, for 
example WHO functional class) 
 The two variables should consist of two or more categorical, independent 
variables (for example, gender) 
 
4.10.3 Time to event analysis 
Once the baseline and pairwise testing was completed, further endpoints were 
investigated by appropriate statistical analysis.  To describe the effect of the 
groups on “all cause mortality” the data was plotted via Kaplan-Meier curves.  
These curves assess time-to-event endpoints.  For this, the original dataset was 
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revisited to confirm which of the patients were alive at the census date (thus for 
SPSS, event single value=0) and who was deceased prior to the census date 
(event single value=1).  Kaplan-Meier curves were also used to describe other 
time-to-event endpoints; maximum time on monotherapy (on monotherapy at 
date of death or census date, event=0) versus discontinued monotherapy 
(event=1). 
 
Plots were prepared comparing groups and the statistical significance 
associated with the lines was measured using the log rank test.  The null 
hypothesis being tested in these curves is that the survival curves do not differ.  
The p value indicates the probability of the survival curve for one group being 
more extreme than the other.  The assumption of the test is that the survival 
distributions are the same between groups. 
 
4.10.4 Predictors of events 
Whilst time-to-event analysis may have elicited clues as to differences between 
the dependent variable groups, their significance in any causal effect needed 
further investigation.  The association between explanatory variables and 
survival rate was assessed through monovariate and subsequent multivariate 
analysis.  Cox proportional hazards regression analysis, also known as Cox 
regression analysis, was employed for this stage. 
All collected explanatory variables were tested using the analysis.  Categorical 
variables were added, noting the reference category within each variable to 
enable correct interpretation of the output.  The hazard ratio (HR) and 
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corresponding 95% confidence intervals was noted along with the relevant p-
value.  Significance of p=>0.2 in the univariate testing ensured that the 
particular variable was entered into the multivariate analysis.  The only 
exception to this was explanatory variables deemed to be co-linear, as only one 
of these was considered in further analysis. 
 
The HR indicates the level of risk of explanatory variables on; in this case, all 
cause mortality.  HRs greater than 1 indicate an increased risk for those with 
the characteristic, and a reduced risk for those with a ratio less than 1.  The 
hazard ratio represents the increased risk for every unit or level increase in the 
explanatory variable, for example years of life when analysing age. 
 
Where variables were identified through Cox Regression to have an 
independent association with the outcome in question (TOM or all-cause 
mortality), they were explored quantitatively.  The aim was to ascertain a signal 
value at which the variable became significantly involved.  For example if age 
was found to be associated with TOM, above which age would we be 
particularly concerned that TOM may be reduced?  This exercise is best 
achieved by plotting a Receiver Operator Characteristic (ROC) curve.  This 
graph plots the fraction of true positives out of the positives vs. the fraction of 
false negatives out of the negatives. 
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4.11 Chapter Summary 
The methods chapter has described all the steps taken in the process of this 
research.  The chosen methods aim to demonstrate the effect of using first line 
oral monotherapy for PAH-CTD patients.  This effect has been measured both 
functionally via exercise testing and WHO classification.  Comparison of the 
agents’ impact on TOM and survival has been analysed.  Assessment of the 
independent predictors of TOM and survival has been covered using all 
independent variables collected.  This thorough analysis of both the major 
headline groups and also sub-groups of clinical interest will make good use of 
the wide range of data captured. 
 
The methods have been chosen to ensure a rigorous approach, reduce or 
eliminate bias and minimise the impact of confounders on the outcomes.  
Methods for guaranteeing reliability and validity were covered in Section 4.2.  
The detailed data collection, cleaning and formatting was a lengthy process, 
indeed taking far longer than was either anticipated or desired.  As with any 
quantitative research, the statistical methods to test the hypothesis are of 
paramount importance in order to ensure that the outcomes are both accurate 
and representative.  These were covered in depth in Section 4.10 together with 
the approaches taken to handle missing values. 
 
Having spent time discussing these methods and statistical tests, the results 
follow neatly on during the next chapter. 
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Chapter 5 – Results 
5.1 Introduction 
 
This chapter summarises the findings of the research.  It begins in Section 5.1.1 
with an outline of the major statistical issues and the handling of missing data.  
Following this insight into the data analysis, the chapter progresses with 
descriptive sections regarding the overall cohort’s characteristics (Section 5.2).  
Section 5.3 examines the small group of patients who did not continue their 
initial monotherapy even until their first follow up.  Finally in terms of describing 
the smaller sub-groups of note, a comparison of those who remained on their 
monotherapy at their two-year review is made (Section 5.4).  Sections 5.5 and 
5.6 detail the outcomes of the statistical analysis of the rest of the cohort; the 
treated groups who were followed up over time. 
 
5.1.1 Statistical Issues 
All statistical analysis was performed using PASW Statistics v20 (SPSS, 
Chicago, IL, USA). 
 
The study did not select a sample of cases out of a large population.  Instead it 
examined consecutive incident cases from a registry.  All patients in the registry 
were included provided they met the entry criteria.  Hence the group is entirely 
representative.  Findings relate directly to the treatment-naïve monotherapy 
patients identified at SPVDU. 
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5.1.2 Missing values 
The haemodynamic data needed for this study is derived from the results of 
RHC studies.  Typically in previous published works, for example RCT trial data, 
only certain haemodynamic markers are quoted for the purposes of disease 
characterisation and severity or prognosis estimations.  It is rare to find the full 
range of measurements documented.  This study uses these same, frequently 
quoted markers.  The following Table illustrates both the complete list of values 
recorded during routine RHC studies currently performed at the SPVDU, 
together with the haemodynamic measurements as researched for this study. 
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Table 9 – Comparison between haemodynamic parameters recorded in 
routine clinical practice vs. those regularly reported in pharmacological 
studies 
Routinely recorded Used in this study 
Pulse Pulse 
Supplemental Oxygen Systemic O2 Sats 
Systemic O2 Saturations Pra 
Systemic systolic blood BP Ppa 
Systemic diastolic BP PCWP 
Mean Systemic BP CO 
Pra CI 
Right Ventricular systolic pressure PVR 
PA systolic pressure  
PA diastolic pressure  
Ppa  
PCWP  
CO 1  
CO 2  
CO 3  
Mean CO  
CI  
Total Pulmonary Resistance  
Pulmonary Vascular Resistance  
Systemic Vascular Resistance  
O2 saturation in Superior Vena Cava  
O2 saturation in Inferior Vena Cava  
O2 saturation in RA  
O2 saturation in RV  
O2 saturation in PA (baseline)  
Fick CO  
Fick CI  
Fick PVR  
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Of the specific parameters in the second column of the Table, a total of 94% of 
data points were completely recorded.  This indicates that from 1,976 potential 
values from the 247 patients, 1,856 were present and validated as correct.  The 
proportion of missing data from the additional unquoted haemodynamic data 
was not quantified.  Indeed in this study the haemodynamic data is purely used 
for diagnostic purposes.  Only 1 of the 247 patients (0.4%) did not have a 
baseline diagnostic RHC performed at SPVDU.  In this exceptional instance a 
diagnosis was made on the basis of non-invasive investigations.   
 
In 168 patients (68%) the baseline RHC was performed within 7 days of the 
treatment commencement date.  Only 19 patients (4%) had their baseline RHC 
performed more than three months before starting treatment. 
 
For characterising baseline haemodynamic parameters, SPSS excluded cases 
list wise where patients were missing values.  No attempt to impute these (or 
indeed any baseline parameters) has been made. 
 
Pulmonary function test data was available for the majority of patients.  Only 12 
of 247 patients (5%) were missing FEV1 or FVC predicted values.  34 of 247 
patients (13%) were missing TLCO measurements. 
 
Baseline ISWT data was not available for 26 of 247 patients (10%).  As 
discussed in the methodology, the decision was taken to exclude these from the 
exercise analysis.  In the rest of the dataset, ISWT distance data was 
unavailable for 11% of follow up data points.  This comprised 37 out of a total of 
320 values. 
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Baseline WHO functional class analysis was available for 100% of patients 
recruited to the study.  However, although all the patients were attributed a 
WHO functional class at baseline for treatment commencement, a total of 53 
WHO measurements were not noted across the treatment journeys.  The two 
most common reasons for this are either the WHO was not clearly documented 
either in the notes or on the discharge/clinic letter or alternatively that the 
patient’s appointment date fell outside of the time windows. 
 
BORG breathlessness scores performed at the time of the ISWT were poorly 
recorded.  Baseline scores were absent for 194 of 247 cases.  As with other 
baseline parameters, no attempts to impute values were made.  Indeed with 
such a degree of missingness, use of predefined methods of data imputation 
would not have been appropriate.  Unfortunately the proportion missing at 
baseline was typical across the follow up time points.  As a result, this marker 
was not used in the statistical analysis as a useful endpoint. 
5.2 Recruited sample 
 
286 patients were identified from the ASPIRE registry (Hurdman et al., 2011) 
with a diagnosis of PAH-CTD.  Of these, 247 were identified as meeting all of 
the study inclusion and exclusion criteria.  By definition therefore, the Sheffield 
Pulmonary Vascular Disease Unit (SPVDU) made a diagnosis of PAH-CTD by 
right-heart catheterisation and commenced oral monotherapy with bosentan or 
sildenafil in 247 treatment naïve patients during the census timeline.  The 
ASPIRE registry includes incident cases diagnosed by the SPVDU from 
February 2001 onwards.  However, timescale for inclusion to this study only 
dates back as far as either treatment became available (2002).   
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The first patient suitable to be included in the study commenced treatment on 
1st May 2002.  The census (final) date for inclusion into the registry (and 
therefore this study) was 1st February 2010.  All patients in the registry were 
followed up to 1st November 2010.  All patients had a baseline measurement of 
WHO functional class.  In the context of the study, baseline is taken as being 
the date of treatment commencement as opposed to initial diagnosis.  However, 
for the majority of patients this is likely to be very similar.  The majority of 
patients (n=221, 89%) also had baseline exercise capacity assessed by 
incremental shuttle walk test (ISWT).   
 
Maximum follow up duration was 2183 days with a mean of 462 days.  This was 
measured by the time patients spent on maximal monotherapy doses.  Across 
the group the maximum survival was 2896 days with a mean of 835 days.  This 
is based on all-cause mortality figures but it is vital to note that some patients 
may have discontinued monotherapy before this time and either had additional 
treatments added, switched to alternative monotherapy or discontinued for 
other reasons. 
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Figure 2 – Numbers and diagnoses of patients enrolled into the study and 
followed up at each interval. 
 
Notes: MCTD = mixed connective tissue disease; UCTD = undifferentiated connective tissue 
disease; DM/PM = dermatomyositis/polymyositis; RA = rheumatoid arthritis; SLE = systemic 
lupus erythematosus 
 
  
Did not satisfy entry, prescribed :
1st line Prostanoid n=23
1st line Oral combination n=4
1st line Prostanoid + sildenafil combination n=1
1st line Ambrisentan n=1
1st line Sitaxenten n=1
Sildenafil  for raynauds phenomenon n=1
Referred to SPUDU on treatment n=6
Enrolled into clinical trial n=1
Treatment not started n=1
Diagnosis breakdown :
PAH-CTD (SsC) n=187
PAH-CTD (Other) n=60
MCTD n=11
UCTD n=-11
PM/DM overlap n=10
RA n=11
Sjogren's Syndrome n=1
SLE n=10
Others n=6
Co-existing pulonary fibrosis n33
Bosentan 125mg bd          n=144 Sildenafil         n=103
Licensed dose      
(25mg tds)   
n=46
Maximum doses (up to 100mg tds) n=57
Diagnosed with CTD-PAH at SPVDU and commenced 
treatment     n=286
Satisfied entry criteria                             n=247                                                                                                                                                           
First follow up                                                  n=224
One year follow up review                      n=109
Two year follow up review                 n=58
Discontinued before first follow up n=23
Discontinued between first follow up and one year n=115
Discontinued between one year and two year n= 51
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5.2.1 Patient breakdown 
The baseline demographics of the total recruited population are described 
below  
Table 10 – Baseline characteristics of the total recruited population 
(n=247) 
Characteristic Mean (SD) or 
* Median (IQ range) 
Age, years 64.5 (11.4) 
Female, % 202 (82) 
Pulse, bpm 82 (14) 
Ppa, mmHg 41.5 (12.0) 
Rpa, mmHg 7.9 (5.2) 
CO, L/min 4.9 (1.4) 
CI, L/min/m2 2.9 (0.7) 
PVR, dyn/s/cm-5 517 (427)* 
PCWP, mmHg 9.2 (4.2) 
MVO2, % 65.5 (7.9) 
WHO I/II/III/IV, % 0 / 4 / 91 / 5 
ISWT, m 100 (135)* 
FEV1 predicted (%) 72.9 (20.2) 
FVC predicted (%) 83.5 (24.1) 
TLCO predicted (%) 37.5 (11.2) 
Notes – Values represent mean (standard deviation) or percentage unless otherwise indicated 
(*Median (interquartile range) 
 
Definition of abbreviations: Ppa, mmHg = mean pulmonary artery pressure, Rpa, mmHg = mean 
right atrial pressure, CO, L/min = cardiac output, CI, L/min/m
2 
= cardiac index, PVR, dyn/s/cm
-5
 
= pulmonary vascular resistance, PCWP, mmHg = pulmonary capillary wedge pressure, MVO2, 
% = mixed venous oxygen saturation in the pulmonary artery, WHO I/II/III/IV = World Health 
Organisation functional class, ISWT, m = incremental shuttle walk test, FEV1 predicted (%) = 
Forced expiratory volume, FVC predicted (%) = Forced expiratory volume, TLCO predicted (%) 
= Transfer factor 
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5.2.2 Treatment breakdown 
The split of patients across the oral monotherapy options is shown in Table 4; 
Table 11 – Breakdown of patients prescribed each treatment option during 
the two policy eras (n=247) 
 Pre-NCP Post NCP 
Sildenafil to lic. dose* n (%) 33 (32) 13 (13) 
Sildenafil to max dose n (%) 49 (47) 8 (8) 
Sildenafil (total) n (%) 82 (79) 21 (21) 
Bosentan n (%) 104 (73) 40 (27) 
Notes: 
 Licensed dose indicates those patients treated up to sildenafil 25mg tds 
 Maximum dose indicates those patients treated with supra-licensed doses – up to 
maximum tolerated doses.  These may be 50mg or 100mg tds. 
 
5.2.3 Discontinued before first follow up 
Of 247 patients enrolled into the study, 39 patients (16%) had their licensed 
dose treatment discontinued before their first scheduled follow up visit.  This 
sub-group’s haemodynamic characteristics did not differ significantly from the 
rest of the cohort.  The only two parameters showing a statistically significant 
difference between the sub-groups who failed to stay on treatment long enough 
to be reviewed and the rest was baseline ISWT and TLCO.  The baseline ISWT 
distances were significantly different (60m vs. 120m p=0.004).   
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Table 12 – Comparison between characteristics of the sub-group who 
discontinued licensed dose prior to 1st follow up (n=39) with those seen at 
first follow up (n=208). 
 Discontinued 
licensed dose 
prior to 1st follow 
up (n=39) 
Seen at 1st follow 
up (n=208) 
P value 
Age (yrs) 68.5 (11.1) 64.2 (11.5) 0.098 
Baseline ISWT (m) 60.0 (95)* 120.0 (140)* 0.004 
Survival (days) 697.4 (657.7)* 838.9 (564.2)* 0.145 
PVR (dyn/s/cm-5) 574.0 (657)* 507.0 (398)* 0.304 
Rpa (mmHg) 6.0 (7) 7.0 (7) 0.895 
Ppa (mmHg) 41.7 (12.4) 41.6 (11.4) 0.926 
CO 4.4 (1.4) 4.9 (1.4) 0.086 
CI 2.7 (0.7) 2.9 (0.7) 0.210 
PCWP 9.3 (3.8) 9.4 (4.3) 0.581 
MVO2 (%) 66.6 (11) 67.5 (10) 0.091 
Pulse (bpm) 81 (14) 83 (21) 0.610 
FEV1 predicted (%) 70.4 (20.9) 73.3 (20.1) 0.461 
FVC predicted (%) 83.3 (28.3) 83.6 (23.3) 0.95 
TLCO predicted (%) 33.1 (12.5) 38.1 (10.9) 0.044 
Baseline WHO 
(II/III/IV) % 
 
2.5 / 87 / 10 
 
4 / 92 / 4 
 
0.195 
 
The group exhibited a non-statistically significant (NS) difference in mean 
survival as the rest of the cohort.  (698 vs. 839 days p=0.145).  However, we 
would not expect 25% mortality within two months of starting PAH medication.    
 
The biggest reason to discontinue licensed dosage is the escalation to higher 
doses, shown in Table 6.  The data establishing the specific reason why this 
group had their licensed dose monotherapy discontinued ahead of their first 
follow up is shown in Table 6.  
  149 
Table 13 – Reason for license dose discontinuation prior to 1st follow up 
(n=39) 
Reason for discontinuation Frequency (%) 
Additional oral therapy 1 (2.5) 
Additional prostanoid 1 (2.5) 
Adverse Effects 10 (25) 
Death 10 (25) 
Dose change 16 (41) 
Ineffective 1 (2.5) 
 
Note – Dose change simply means that these patients were increased from 
25mg tds sildenafil to 50mg tds.   
 
Table 7 takes this logic to the next step by removing dose change and looks at 
the 23 patients who failed to make it to first follow up on any treatment.  It is 
now possible to revisit the difference between this group and the rest of the 
cohort.  An element of caution is needed as n=23, so the statistical power is not 
evident to make judgments with certainty. 
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Table 14 – Comparison between characteristics of the sub-group who 
discontinued licensed dose prior to first follow up (excluding dose 
changes) (n=23) with those seen at first follow up (n=208). 
 Maximal dose 
discontinued prior 
to 1st follow up 
(n=23) 
Seen at 1st 
follow up 
(n=208) 
P value 
Age (yrs) 70.0 (10.2) 64.0 (11.5) 0.017 
Baseline ISWT (m) 65.0 (123)* 120.0 (140)* 0.054 
Survival (days) 75.0 (873)* 734.0 (708)* <0.0001 
PVR (dyn/s/cm-5) 619.0 (633)* 508.0 (400)* 0.382 
Rpa (mmHg) 6.5 (9) 7.0 (7) 0.796 
Ppa (mmHg) 41.0 (13.4) 41.7 (11.3) 0.995 
CO 4.21 (1.2) 4.99 (1.4) 0.027 
CI 2.64 (0.6) 2.91 (0.7) 0.100 
PCWP 10.2 (4.1) 9.3 (4.2) 0.341 
MVO2 (%) 62.1 (11.9)  66.1 (7.2) 0.282 
FEV1 predicted 
(%) 
76.3 (21.9) 72.6 (20.0) 0.430 
FVC predicted (%) 94.1 (27.8) 82.5 (23.5) 0.040 
TLCO predicted 
(%) 
36.7 (12.2) 37.6 (11.2) 0.742 
Baseline WHO 
(II/III/IV) % 
 
0/91/9 
 
4/92/4 
 
0.453 
 
As expected, once we take those patients who were subject to a dose increase 
out of the equation, the proportion of patients dying increases greatly and 
survival is now significantly different between the groups (75 vs. 734 days 
p=<0.0001).  Also different between the groups is FVC % predicted 94.1 vs. 
82.5 (p=0.04) although counter-intuitively, the group discontinuing before follow 
up had higher FVCs.  Walk distance becomes slightly less statistically 
significant (65 vs. 120m p=0.054).  A breakdown of the rationale for 
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discontinuing maximal monotherapy prior to an initial follow up now breaks 
down as seen in Table 8. 
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Table 15 – Reason for maximal dose discontinuation prior to first follow 
up (n=23) 
Reason for discontinuation Frequency (%) 
Additional oral therapy 1 (4) 
Additional prostanoid 1 (4) 
Adverse Effects 10 (43) 
Death 10 (43) 
Ineffective 1 (4) 
 
All 10 patients experiencing side effects not only finished on their licensed 
dosage but stopped monotherapy altogether.  Of this 10, seven patients 
switched to an alternative whilst three received no further therapy. 
5.2.4 Discontinuation due to adverse effects 
Of the two monotherapy options, the following Tables show the breakdown of 
adverse drug reactions causing discontinuation. 
5.2.4.1  Bosentan  
 
Table 16 – Side effects noted in bosentan treatment arm, which led to 
discontinuation. 
Bosentan Frequency Per cent 
Adverse 
effect 
LFT abnormality 16 76.2 
Anaemia 1 4.8 
Feels less well / 
lethargy 
2 9.5 
Oedema (Pulmonary) 2 9.5 
Total 21 100.0 
 
Outside LFT abnormality (a known problem in this class of agents) (Hoeper, 
2009), bosentan appears well tolerated with a low overall discontinuation rate 
due to adverse effects.  Data for LFT abnormality is robust, as a consequence 
of all patients prescribed ERAs submitting regular blood samples to Sheffield.  
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An audit performed in 2009 suggested the majority of patients submitted bloods 
in accordance with the product licence for monitoring.  More recent changes to 
the system, notably the use of the electronic database “Infoflex” to store results 
and send reminders when samples appear overdue has improved our 
compliance to >90%.  
 
5.2.4.2  Sildenafil 
 
Table 17 – Side effects noted in sildenafil treatment arms, which led to 
discontinuation. 
Sildenafil Frequency Per cent 
Adverse 
effect 
Headache 2 20.0 
Visual disturbance 2 20.0 
Feels less well / 
lethargy 
4 40.0 
Oedema (Peripheral) 1 10.0 
Tremor 1 10.0 
Total 10 100.0 
 
The proportion of permanent discontinuations seen in the group who stopped 
prior to their first follow up, was not replicated in the main treated cohort.  Of 
those patients who continued on treatment until at least their first review, only 
19 (8.5%) discontinued monotherapy as a consequence of unwanted side 
effects or inefficacy and did not switch to an alternative agent. 
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5.3 Still on monotherapy at 2 years 
 
Table 18 – Comparison of the characteristics of the group retained on 
monotherapy at 2 years vs. the rest of the cohort 
 
This group had a much higher ISWT baseline than the cohort average.  This did 
not however translate into different proportions in each functional class.  Also 
evident was improved oxygenation and reduced PVR.  There was no 
statistically significant difference in pulmonary function parameters or age on 
commencement. 
  
 On at 2 years 
(n=56) 
Rest of cohort 
(n=191) 
P value 
Age (yrs) 62.8 (11.6) 65.0 (11.4) 0.230 
Baseline ISWT (m) 120 (125) 80 (140) 0.006 
PVR (dyn/s/cm-5) 450 (375) 547 (483) 0.05 
Rpa (mmHg) 7 (5) 7 (7) 0.648 
Ppa (mmHg) 39.0 (11.2) 42.1 (12.1) 0.086 
CO 5.1 (1.4) 4.9 (1.5) 0.313 
CI 2.9 (0.7) 2.9 (0.7) 0.648 
PCWP 9.1 (3.7) 9.3 (4.4) 0.727 
MVO2 (%) 69.5 (8) 66.6 (11.7) 0.06 
Pulse (bpm) 82.0 (12.6) 84.7 (14.9) 0.232 
FEV1 predicted (%) 74.3 (21.1) 71.3 (21.8) 0.385 
FVC predicted (%) 84.4 (24.4) 82.0 (26.1) 0.573 
TLCO predicted (%) 36.2 (14.9) 32.9 (15.8) 0.184 
Baseline WHO 
(II/III/IV) n= 
2 / 46 / 1 7 / 180 / 11 0.674 
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Table 19 – Comparison of the group retained on monotherapy at 2 years 
vs. those who died before first follow up 
 
Note the very small numbers in the RIP pre follow up group (n=10).  This group 
may be too small to make definitive conclusions on the basis of.  However if the 
assumption is made that the data was validated, it is a useful illustration of the 
difficulty faced by prescribers on initiation of therapy.  Significant differences are 
seen in all pulmonary function parameters.   
 On at 2 years 
(n=56) 
RIP pre follow 
up (n=10) 
P value 
Age (yrs) 63.3 (11.2) 71.7 (8.9) 0.230 
Baseline ISWT (m) 120 (125) 150 (260) 0.952 
PVR (dyn/s/cm-5) 471 (375) 393 (498) 0.552 
Rpa (mmHg) 7 (5) 6 (6) 0.644 
Ppa (mmHg) 37.6 (10.2) 38.6 (13.4) 0.788 
CO 5.0 (1.1) 5.5 (1.8) 0.312 
CI 2.9 (0.6) 3.1 (0.7) 0.422 
PCWP 9.4 (1.9) 9.4 (1.9) 0.368 
MVO2 (%) 69.5 (8) 70.6 (12.5) 0.901 
Pulse (bpm) 82.0 (12.6) 85.8 (12.4) 0.416 
FEV1 predicted (%) 71.6 (19.9) 91.2 (13.4) 0.006 
FVC predicted (%) 82.1 (23.6) 107.2 (17.0) 0.003 
TLCO predicted (%) 33.5 (17.5) 41.7 (7.1) 0.021 
Baseline WHO 
(II/III/IV) n= 
3 / 51 / 2 1 / 9 / 0 0.987 
  156 
5.4 Treated cohort 
After 39 patients had failed to stay on the licensed dose, and 23 patients 
stopped monotherapy altogether prior to a follow up assessment, the remaining 
221 patients stayed on monotherapy for review at one or more reassessment 
dates. 
 
To maximise recruitment and ensure that statistical power was optimised, the 
windows for follow up were considerably wider than those used in a prospective 
RCT.  As a result, first follow up visits were taken as shown in Table 16. 
Table 20 – Mean duration to follow up appointments 
Visit Time window (days) Mean duration to follow 
up (days) (SD) 
First follow up (T1) 56-252 138 (43) 
One Year follow up (T2) 253-504 355 (59) 
Two Year follow up (T3) 646-814 724 (44) 
Note – day 0 = day commenced treatment. 
Although the windows of opportunity to capture follow up information were 
deliberately wide, the mean durations noted are very close to ideal review 
points.  The interval to T1 is slightly longer than the sixteen weeks used in the 
RCT, the intervals to 1 and 2 years are virtually perfect.   
In order to understand and test the study’s hypotheses via commonly used 
outcome measures, comparisons were made between results from sub-groups.  
The main groups for analysis are: 
1. All patients treated pre NCP vs. All patients treated in accordance 
with the NCP (Groups contain patients treated with different 
medication). 
2. All patients treated with sildenafil vs. All patients treated with 
bosentan 
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(Groups contain patients treated at different time points). 
3. All patients treated with sildenafil at licensed dose vs. All patients 
treated with sildenafil to maximum tolerated doses   
(Groups contain patients treated at different time points). 
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5.4.1 Baseline parameters 
Table 21 – Comparison of the baseline parameters divided by policy era 
 
This data compares the characteristics of the cohorts treated either side of the 
introduction of the NCP.  Note the difference in Ppa.  This was an isolated 
finding and in isolation is unlikely to be clinically important.  Similarity across the 
other parameters including exercise capacity or pulmonary function tests at 
baseline demonstrates the homogeneity of the groups for comparison.   
  
 Pre NCP 
(n=186) 
Post NCP 
(n=61) 
P value 
Age (yrs) 64.7 64.3 0.858 
Baseline ISWT (m) 115 (140) 120 (170) 0.698 
PVR (dyn/s/cm-5) 495 (425) 547 (458) 0.063 
Rpa (mmHg) 7 (6) 9 (10) 0.067 
Ppa (mmHg) 40.8 (11.8) 44.0 (11.2) 0.002 
CO 4.9 (1.5) 4.9 (1.4) 0.649 
CI 2.9 (0.7) 2.9 (0.7) 0.918 
PCWP 9.5 (4.2) 9.2 (4.6) 0.355 
MVO2 (%) 67.6 (9.4) 65.4 (14.4) 0.179 
Pulse (bpm) 82.8 (14.0) 85.6 (14.7) 0.276 
FEV1 predicted (%) 73.3 (19.6) 71.6 (22.1) 0.588 
FVC predicted (%) 84.3 (23.4) 81.1 (26.1) 0.380 
TLCO predicted (%) 37.5 (11.8) 37.1 (9.2) 0.798 
Baseline WHO 
(II/III/IV) % 
 
4 / 92 / 4 
 
4 / 88 / 8 
 
0.394 
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Table 22 – Comparison of the baseline characteristics divided by 
treatment choice – bosentan vs. sildenafil (all doses) 
 
Whilst age and baseline exercise capacity did not differ significantly, the group 
treated with bosentan had significantly worse haemodynamics (in all areas 
except PCWP) than the group treated with sildenafil.   
  
 Bosentan 
(n=144) 
Sildenafil 
(n=103) 
P value 
Age (yrs) 64.2 (10.3) 65.1 (13.0) 0.525 
Baseline ISWT (m) 100 (110) 105 (160) 0.680 
PVR (dyn/s/cm-5) 634.0 (459) 441.0 (336) 0.001 
Rpa (mmHg) 8.0 (8) 7 (5) 0.016 
Ppa (mmHg) 43.3 (12.6) 39.2 (9.5) 0.001 
CO 4.6 (1.5) 5.3 (1.5) <0.001 
CI 2.7 (0.7) 3.0 (0.7) 0.001 
PCWP 9.4 (4.5) 9.4 (3.8) 0.662 
MVO2 (%) 64.3 (8.7) 67.6 (6.1) 0.004 
Pulse (bpm) 85.0 (9.5) 83.0 (14.4) 0.260 
FEV1 predicted (%) 74.9 (19.2) 70.0 (21.2) 0.067 
FVC predicted (%) 86.5 (22.1) 79.6 (26.2) 0.037 
TLCO predicted (%) 37.1 (10.4) 37.9 (12.4) 0.576 
Baseline WHO 
(II/III/IV) % 
 
3 / 92 / 5 
 
4 / 91 / 5 
 
0.912 
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Table 23 – Comparison of the baseline characteristics divided by sildenafil 
dose (licensed dose vs. sildenafil at higher doses) 
 
 
Several parameters are noted to be more severe in the group who had their 
doses escalated beyond licensed doses.  Notably lower transfer factor, 
increased hypoxaemia, higher baseline pulse and a lower baseline exercise 
capacity. 
 Sildenafil -
licensed dose 
(n=46) 
Sildenafil – max 
monotherapy 
dose (n=57) 
P value 
Age (yrs) 66.0 (14.0) 64.5 (11.7) 0.998 
Baseline ISWT (m) 130 (140) 90 (170) <0.001 
PVR (dyn/s/cm-5) 383.5 (304) 444.0 (341) 0.86 
Rpa (mmHg) 6.5 (5) 7 (5) 0.362 
Ppa (mmHg) 38.4 (9.5) 39.9 (9.5) 0.804 
CO 5.4 (1.5) 5.2 (1.5) 0.201 
CI 3.1 (0.7) 3.0 (0.8) 0.061 
PCWP 9.8 (3.7) 9.0 (6) 0.049 
MVO2 (%) 70.5 (7) 67.0 (8) 0.009 
FEV1 predicted (%) 69.3 (22.6) 69.5 (22.2) 0.970 
FVC predicted (%) 80.35 (29.1) 77.7 (25.7) 0.631 
TLCO predicted (%) 36.6 (16.2) 30.2 (17.6) 0.061 
Pulse (bpm) 80.8 (13.4) 84.7 (14.8) 0.002 
Baseline WHO (II/III/IV) 
(%) 
 
2 / 93 / 5 
 
5 / 90 / 5 
 
0.870 
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5.5 Outcome Measures comparisons 
 
The treated cohort groups have been compared both between groups and 
within groups on the basis of four distinct outcome measures.   
These are: 
1. Change in exercise capacity as measured by ISWT 
2. Change in WHO functional class 
3. Time on monotherapy  
4. All cause mortality. 
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5.5.1  Change in exercise capacity 
 
This was measured by noting arithmetic change from baseline to first follow up 
ISWT distance. 
 
5.6.1.1.  Pre vs. Post NCP (all comers) 
 
Table 24 – Data showing change in ISWT from baseline to first follow up 
(Pre vs. Post NCP) 
 
 
 
 
 
 
Not
es 
– 
the imputed mean change is the result of the multiple imputation exercise.  This 
shows that the change Pre NCP may be an under-estimate and the post 
change an over-estimate, based on the relative proportions of missing data. 
 
The relative increase in variance shows the effect of the imputations on the data 
ranges. 
 
Relative efficiency is a decimal representing the imputation model’s confidence 
in estimating representative results after imputing missing values.  Hence the 
closer to 1.0, the more accurate we may believe the results to be.   
These notes are relevant to similar Tables throughout Section 5.6.1. 
 
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T1 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Pre NCP 
(Raw) 
100 
(n=166) 
5.9 
(n=122) 
0.85    
(Imputed)  8.92  0.155 0.171 0.970 
Post NCP 
(Raw) 
120 
(n=55) 
-19.63 
(n=27) 
    
(Imputed)  -9.03  0.450 0.685 0.917 
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Figure 3 – Boxplot showing the change in ISWT from baseline to 1st follow 
up (Pre vs. Post NCP) 
These results show that patients treated in accordance with the NCP from 2008 
see a very slightly negative change from baseline (NS).  Whilst there were 
isolated differences between the characteristics of the groups at baseline, they 
did appear to be generally well matched.  This would therefore suggest that 
there is either a characteristic of the group that was not captured/measured or 
that prescribing in accordance with the NCP did not result in ISWT 
improvement, however the result was not statistically significant. 
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Table 25 – Data showing change in ISWT from baseline to 1-year follow up 
(Pre vs. Post NCP) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Boxplot showing the change in ISWT from baseline to 1-year 
follow up (Pre vs. Post NCP) 
 
This shows no difference between the groups and a significant dropout of 
patients by 1 year.  However as seen in the monotherapy comparison, the 
absolute change in walk from baseline to 1 year is greater than that seen at 1st 
follow up (Non-significant, NS). 
  
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T2 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Pre NCP 
(Raw) 
100 
(n=166) 
18.78 
(n=74) 
0.951    
(Imputed)  20.90  0.140 0.152 0.973 
Post NCP 
(Raw) 
120 
(n=55) 
16.36 
(n=11) 
    
(Imputed)  22.17  0.173 0.194 0.966 
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Table 26 – Data showing change in ISWT from baseline to 2-year follow up 
(Pre vs. Post NCP)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Boxplot showing the change in ISWT from baseline to 2 year 
follow up (Pre vs. Post NCP) 
The suggestion from the imputed values in the very small post NCP group at 2 
years is that the collected data may over-estimate the effect size.  However it is 
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T3 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Pre NCP 
(Raw) 
100 
(n=166) 
14.89 
(n=45) 
0.874    
(Imputed)  14.43 
(n=51) 
 0.101 0.107 0.980 
Post NCP 
(Raw) 
120 
(n=55) 
5.00 
(n=4) 
    
(Imputed)  -21.2 
(n=5) 
 0.179 0.201 0.965 
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encouraging to see disease stability for those remaining on monotherapy as 
long as 2 years. 
 
 
Figure 5 – – Median ISWT distances at each time point (Pre vs. Post NCP) 
Whilst again the n decreases over time and there is a wide variance particularly 
at 1 year, the graphs demonstrate a trend of improvement over time to 1 year 
where the peak median ISWT distance is seen, both pre and post NCP.   
 
 
Figure 6 – Median change visualised by group (Pre vs. Post NCP) 
  
  167 
5.6.1.2.  Bosentan vs. sildenafil 
 
Table 27 – Data showing change in ISWT from baseline to 1st follow up 
(bosentan vs. sildenafil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Boxplot showing the change in ISWT from baseline to 1st follow 
up (bosentan vs. sildenafil) 
Despite a wide range of responses to treatment, the median change in ISWT 
seen at first follow up was 0 (zero) metres in both groups, with no difference 
between the groups 
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T1 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Bosentan  
(Raw) 
115 
(n=118) 
-2.07 
(n=87) 
0.489    
(Imputed)  0.14 
(n=102) 
 0.133 .144 .974 
Sildenafil 
(Raw) 
120 
(n=83) 
5.97 
(n=62) 
    
(Imputed)  12.14 
(n=72) 
 .439 .657 .919 
  168 
Table 28 – Data showing change in ISWT from baseline to 1 year 
(bosentan vs. sildenafil) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Boxplot showing the change in ISWT from baseline to 1 year 
follow up (bosentan vs. sildenafil) 
 
The figures from 1 year follow up are similar to that seen at first follow up in 
terms of mean change from baseline.  This remains not significantly different 
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T2 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Bosentan  
(Raw) 
115 
(n=118) 
10.47 
(N=43) 
0.327    
(Imputed)  13.78 
(n=45) 
 0.026 0.026 0.995 
Sildenafil 
(Raw) 
120 
(n=83) 
38.81 
(n=43) 
    
(Imputed)  28.36 
(n=45) 
 0.207 0.239 0.960 
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between the groups with the median change again being 0 (zero) metres.  
However a point of note is the mean changes are numerically larger than at first 
follow up.  This suggests that for those patients able to remain on monotherapy, 
maximum benefit as measured by walk test may be seen after 16 weeks. 
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Table 29 – Data showing the change in ISWT from baseline to 2-year 
follow up (bosentan vs. sildenafil) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Boxplot showing the change in ISWT from baseline to 2 year 
follow up (bosentan vs. sildenafil) 
 
It is at this time point (albeit with small cohorts) that we see the first difference 
between the groups approaching statistical significance (p=0.065).   
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T3 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Bosentan  
(Raw) 
115 
(n=118) 
-18.70 
(n=23) 
0.065    
(Imputed)  -10.56 
(n=25) 
 0.028 0.029 0.994 
Sildenafil 
(Raw) 
120 
(n=83) 
43.08 
(n=26) 
    
(Imputed)  28.84 
(n=31) 
 0.226 0.265 0.957 
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Figure 10 – Comparison of median ISWT distances at each time point.  
(bosentan vs. sildenafil) 
Note that although the n decreased over time, the median walk test distance 
improved from first follow up to 1 year in both treatment groups. 
 
 
 
Figure 11 – Median change visualised by group (bosentan vs. sildenafil) 
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5.6.1.3.  Sildenafil licensed dosage vs. maximal monotherapy dose 
 
Table 30 – Data showing the change in ISWT from baseline to 1st follow up 
(sildenafil dosage groups) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Boxplot showing the change in ISWT from baseline to 1st 
follow up (sildenafil dosage groups) 
There was little difference between the groups at this time point.  Median 
change was again 0 (zero) metres.   
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T1 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Licensed 
dose 
(Raw) 
130 
(n=43) 
9.09 
(n=22) 
0.731    
(Imputed)  13.93 
(n=27) 
 0.453 0.692 0.917 
Maximal 
doses 
(Raw) 
90 
(n=49) 
4.25 
(n=40) 
    
(Imputed)  11.07 
(n=45) 
 0.124 0.134 0.976 
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Table 31 – Data showing the change in ISWT from baseline to 1-year 
follow up (sildenafil dosage groups) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Boxplot showing the change in ISWT from baseline to 1 year 
(sildenafil dosage groups) 
The group retained on licensed dose at 1 year showed a NS numerical 
improvement in walk.  The distribution of the values was non-parametric and 
there was a positive skew leaving the median change at 0m.  
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T2 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Licensed 
dose 
(Raw) 
130 
(n=43) 
60.77 
(n=13) 
0.194    
(Imputed)  53.14 
(n=14) 
 0.08 .084 .984 
Maximal 
doses 
(Raw) 
90 
(n=49) 
11.38 
(n=29) 
    
(Imputed)  17.16 
(n=31) 
 0.339 0.445 0.937 
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Table 32 – Data showing the change in ISWT from baseline to 2-year 
follow up (sildenafil dosage groups) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – Boxplot showing the change in ISWT from baseline to 2-year 
follow up (sildenafil dosage groups) 
A similar pattern to that seen at 1 year emerges here:  NS significant 
differences between groups or baseline values.   
Group Baseline 
ISWT 
distance 
(m) 
Mean 
change at 
T3 (m) 
P= Fraction 
missing 
info 
Relative 
increase 
variance 
Relative 
efficiency 
 Multiple imputation 
 Licensed 
dose 
(Raw) 
130 
(n=43) 
78.57 
(N=7) 
0.629    
(Imputed)  53.78 
(n=9) 
 0.093 0.098 0.982 
Maximal 
doses 
(Raw) 
90 
(n=49) 
30.00 
(n=19) 
    
(Imputed)  18.64 
(n=22) 
 0.289 0.359 0.945 
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Figure 15 – Showing median ISWT distances at each time point (sildenafil 
dosage groups) 
 
 
Figure 16 – Median change visualised by group (sildenafil dosage groups) 
For the first time in the exercise analysis, there is a genuine plateau seen in 
treatment effect in the licensed dose group from baseline to 1 year follow up, 
with a modest increase seen at 2 years in the very small group.   
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5.5.2  Change in WHO functional class 
The following pie charts illustrate the distribution of patients in each of the 
functional classes at baseline.  Note that no patients are WHO functional class 
(FC) I.  Only very few are in WHO FC II.   
 
 
Figure 17 – Pie charts illustrating baseline proportions of each group by 
WHO functional class 
This analysis found showed no change either between or within groups over 
time.  As with exercise capacity, the groups showed no overall differences in 
terms of WHO functional class change at baseline or over time.  The n 
decreased with time as expected, but the overall proportion of patients in each 
functional class did not alter.   
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5.5.3 Time on monotherapy 
This was quantified using a “time to event method” on Kaplan Meier curves.   
5.5.3.1 Pre vs. Post NCP 
 
 
 
Patients at risk 
   186       92          52          27           11  3 Pre NCP 
    61       20           5     Post NCP 
 
Figure 18 – Kaplan Meier survival plot of duration of monotherapy 
between policy eras 
 
This curve shows a statistically significant reduction in time on monotherapy 
since the introduction of the NCP in 2008. 
  
P=<0.0001 
Pre NCP 
Post NCP 
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5.5.3.2 Bosentan vs. sildenafil 
 
 
Patients at risk 
   143            56              22           13             5     2     Bosentan 
   103            56              35           14             6     1     Sildenafil 
 
Figure 19 – Kaplan Meier survival plot of duration of monotherapy 
between monotherapy options    
Patients treated with sildenafil remain on monotherapy significantly longer than 
those on bosentan.  Further analysis via Cox regression is necessary to 
understand the causative relationships between the choice of therapy versus 
the other confounding variables.   
  
Sildenafil 
P=0.005 
Bosentan 
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5.5.3.3 Sildenafil Doses 
 
 
 Patients at risk 
      46  20             10      1         0        Licensed dosing 
      57            36             26            13         5        Maximal dosing 
 
Figure 20 – Kaplan Meier survival plot of duration of monotherapy 
between sildenafil dose options    
There is a NS difference in TOM between the two sildenafil groups.   
  
P=0.148 
Maximal dosing 
Licensed dosing 
  180 
5.5.4 All cause mortality 
 
All cause mortality is shown on the following Kaplan-Meier curves.   
5.5.4.1.  Pre vs. Post NCP 
 Patients at risk 
   186                106                  33                    10  Pre NCP     
    61                 17      Post NCP 
 
Figure 21 – Kaplan Meier survival plot of all cause mortality across policy 
eras    
 
There is no difference between these curves.   
P=0.686 
Post NCP 
Pre NCP 
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5.5.4.2.  Bosentan vs. sildenafil 
 
 Patients at risk 
      144         61        18      8           Bosentan 
      103         62  15      2  Sildenafil 
 
Figure 22 – Kaplan Meier survival plot of all cause mortality across 
monotherapy options    
 
This data shows a statistically significant difference in all cause mortality 
between the group treated with sildenafil and bosentan, with those on sildenafil 
demonstrating better survival.  Further analysis via the Cox regression is 
necessary to determine the relative importance of these factors in the overall 
survival and whether choice of monotherapy was a significant factor in these 
curves. 
The other obvious question in analysing this graph is the component of the 
survival that may be attributed to the treatment.  For example was a brief period 
P=0.006 
Bosentan 
Sildenafil 
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on oral monotherapy followed by a longer course of IV prostanoids?  Although 
the sildenafil group show an improved survival, it was necessary to exclude the 
fact that patients had received initial sildenafil for a relatively short time in their 
overall treatment journey, followed by a long.  To account for this, a time on 
monotherapy: survival time percentage was calculated.   
  
Table 33 – Proportion of total time on treatment comprised by the episode 
on each monotherapy 
Agent Time on therapy: 
survival (proportion) 
P= 
Sildenafil 0.86 0.013 
Bosentan 0.66  
 
Calculated by: Time on monotherapy agent 
    Total treatment journey time 
 
This demonstrates that patients receiving sildenafil monotherapy first line spend 
a higher proportion of their overall treatment journey on this agent than those 
started with bosentan. 
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5.5.4.3.  Sildenafil doses 
 
 Patients at risk 
     46          24  6      1     Licensed dose  
     57                    38  9      1    Maximum doses 
Figure 23 – Kaplan Meier survival plot of all cause mortality across 
sildenafil dose options    
There is no significant difference in survival seen in the groups treated at 
licensed dose or maximal monotherapy.   
  
P=0.903 
 
Licensed dose 
 
Maximal doses 
 
  184 
5.5.4.4.  Overall 1 and 2 year survival 
 
Following Condliffe et al.’s (2009) attempts to demonstrate how survival had 
improved in the “modern treatment era”, correspondence was seen in the 
literature (Girgis et al., 2009) questioning the representativeness of the data.  In 
order to generate data from this study’s dataset to be a useful and valid 
comparative, analysis of survival was performed at 1, 2 and 3 years.   
 
In these incident cases with PAH-CTD on monotherapy with bosentan or 
sildenafil the survival estimates are 82% at 1 year, 66% at 2 years, 49% at 3 
years, 30% at 4 years, 26% at 5 years, 24% at 6 years and 15% at 7 years.  
The longest surviving case in the cohort was alive at 7.9 years. 
 
There was not felt to be value in plotting the overall survival figure by treatment 
as these analyses have already been discussed in Section 5.6.4.2.  The current 
study examined monotherapy only so will not answer the question regarding 
monotherapy vs. combination therapy but will add important numbers of 
incident, treated cases to the literature as a guide of survival. 
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5.5.5 Cox Regression analysis 
5.5.5.1 Time on monotherapy (TOM) 
 
Table 34 – Cox regression analysis of causative factors for TOM 
 
  Univariate analysis Multivariate analysis 
Variable n= Hazard Ratio P= Hazard Ratio P= 
Age 247 1.009 (0.993, 1.025) 0.260   
Baseline WHO II/III  
IV 
198 
49 
 
Reference 
0.711 (0.459, 1.099) 
 
0.124 
  
Gender 
F 
M 
 
202 
45 
 
Reference 
1.030 (0.650, 1.633) 
 
 
0.900 
  
Pra 238 1.019 (0.984, 1.055) 0.301   
Ppa 242 1.017 (1.002, 1.032) 0.025   
CO 231 0.855 (0.744, 0.984) 0.029   
CI 222 0.706 (0.537, 0.926) 0.012 0.709 (0.533, 0.943) 0.018 
PVR 228 1.001 (1.000, 1.001) 0.006   
MVO2 235 0.978 (0.954, 1.002) 0.068   
Pulse 224 1.008 (0.994, 1.022) 0.260   
PCWP 235 0.959 (0.915, 1.005) 0.078 0.949 (0.904, 0.997) 0.037 
Baseline ISWT 221 0.999 (0.998, 1.001) 0.317   
FEV1 % predicted 238 1.005 (0.996, 1.013) 0.278   
FVC % predicted 238 1.005 (0.997, 1.012) 0.231   
TLCO % predicted 238 0.995 (0.984, 1.006) 0.366   
Diagnosis 
SSc 
Other CTD 
 
187 
60 
 
Reference 
1.223 (0.801, 1.868) 
 
 
0.350 
  
Pulmonary Fibrosis 
Absent 
Moderate to severe 
 
185 
33 
 
Reference 
1.277 (0.730, 2.232) 
 
 
0.392 
  
Monotherapy 
Bosentan 
Sildenafil 
 
144 
103 
 
Reference 
1.692 (1.168, 2.452) 
 
 
0.005 
 
Reference 
1.533 (1.014, 2.320) 
 
 
0.043 
Sildenafil dose 
25mg 
Maximal 
 
46 
57 
 
Reference 
1.534 (0.819, 2.875) 
 
 
0.181 
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Following univariate analysis with all collected baseline parameters entered, 
those with a p-value of <0.2 were considered to be entered into the multivariate 
analysis. 
 
Variables considered being co-linear, for example cardiac index and cardiac 
output were not both selected. 
 
The results show that all haemodynamic parameters except Pra and the choice 
of treatment are associated with time on monotherapy in the univariate analysis. 
The multivariate analysis informs us that having taken account of all the other 
associated factors, choice of monotherapy, CI and Wedge pressure are 
independent predictors of time on monotherapy. 
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5.5.5.2 All cause mortality 
 
Table 35 – Cox regression analysis of causative factors for all-cause 
mortality 
 
  Univariate analysis Multivariate analysis 
Variable n= Hazard Ratio P= Hazard Ratio P= 
Age 247 1.019 (1.003, 1.033) 0.018   
Baseline WHO II/III  
IV 
198 
49 
 
Reference 
0.396 (0.272, 0.577) 
 
<0.001 
Reference 
0.580 (0.350, 0.959) 
 
0.034 
Gender 
F 
M 
 
202 
45 
 
Reference 
1.139 (0.732, 1.722) 
 
 
0.563 
  
Pra 238 1.042 (1.009, 1.076) 0.011   
Ppa 242 1.014 (1.000, 1.028) 0.055   
CO 231 0.707 (0.619, 0.806) <0.001   
CI 222 0.588 (0.457, 0.765) <0.001   
PVR 228 1.001 (1.000, 1.001) <0.001   
MVO2 235 0.943 (0.923, 0.963) <0.001 0.955 (0.932, 0.979) <0.001 
Pulse 224 1.018 (1.004, 1.031) 0.012   
PCWP 235 0.992 (0.950, 1.037) 0.733   
Baseline ISWT 221 0.995 (0.993, 0.997) <0.001 0.997 (0.994, 0.999) 0.006 
FEV1 % predicted 238 0.997 (0.990, 1.005) 0.439   
FVC % predicted 238 0.999 (0.992, 1.005) 0.725   
TLCO % predicted 238 0.985 (0.975, 0.995) 0.005   
Diagnosis 
SSc 
Other CTD 
 
187 
60 
 
Reference 
1.207 (0.811, 1.795) 
 
 
0.353 
  
Pulmonary Fibrosis 
Absent 
Moderate to severe 
 
185 
33 
 
Reference 
0.552 (0.357, 0.852) 
 
 
0.007 
  
Monotherapy 
Bosentan 
Sildenafil 
 
144 
103 
 
Reference 
1.64 (1.151, 2.338) 
 
 
0.006 
  
Sildenafil dose 
25mg 
Maximal 
 
46 
57 
 
Reference 
1.037 (0.576, 1.868) 
 
 
0.903 
  
 
There were multiple parameters shown to be associated with mortality 
according to the univariate analysis.  Again at this stage, the choice of therapy 
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agent was significant.  However when entered into multivariate analysis, three 
factors are independent predictors of all-cause mortality in this group: baseline 
WHO class IV, MVO2 and baseline ISWT. 
 
Having established these independent predictors, I analysed these signals 
further.  Unfortunately the use of ROC curve analysis did not give a definitive 
curve to indicate a strong signal value.  As a consequence I pursued the matter 
by splitting the group via the median.   
 
Patients at risk 
     106        46   11              3    1   Low 
     113         71  21   7    4   High 
 
Figure 24 – Survival of the cohort split by the median baseline ISWT 
distance (+/-100m) 
I was able to demonstrate a significant difference between the groups above or 
below the median baseline ISWT distance.  The Kaplan Meier curve above 
P=0.001 
 
>100m 
baseline ISWT 
<100m 
baseline ISWT 
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(Figure 25) shows a significant difference between those patients having a 
baseline test above or below this figure. 
 
Unfortunately, the Kaplan Meier plot of survival predicted by mixed venous 
oxygen saturations with lines derived by splitting via the median was not 
significantly different.   
 
Patients at risk 
    197     107    29    10    WHO II/III 
     48         16    4     0    WHO IV 
 
Figure 25 – Survival of the cohort split by WHO Class (II/III vs. IV) 
 
This very obviously shows the impact of baseline WHO Class on survival 
(p<0.001).  A statistically significant difference is seen between those who are 
initiated treatment whilst in WHO FC II or III versus those who are WHO IV on 
commencement. 
P=<0.001 
 
WHO II/III 
 
WHO IV 
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Chapter 6 – Discussion 
 
Having tested three distinct hypotheses against four endpoints, the results have 
been described in Chapter 5.  Four key findings were identified from the multiple 
analyses performed.  In addition to these key findings, there is some discussion 
around the results found that did not reach significance.  Of similar interest are 
the comparisons, which showed no difference between treatments or eras. 
 
The key findings of the study can be summarised as: 
 
1. Both sildenafil and bosentan monotherapy successfully maintained 
disease stability up to 2 years. 
(See Section 5.5)   
2. Patients continue sildenafil monotherapy longer than bosentan after all 
other baseline characteristics are accounted for.  
(See Section 5.5.3.2) 
3. Treatment with sildenafil conveys a significant survival advantage, 
although with other baseline characteristics accounted for choice of 
monotherapy does not independently predict mortality. 
(See Section 5.5.5.2) 
4. Baseline ISWT distance independently predicted survival however 
change in walk at follow up did not. 
(See Section 5.5.5.2) 
 
The following discussion chapter covers firstly the recruited sample and then 
each outcome measure being tested.  The results from the groups are in turn 
put into context. 
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6.1 Recruited sample 
This thesis summarises the retrospectively collected data on the largest group 
of treated PAH-CTD patients from a single centre examined longitudinally in 
terms of monotherapy treatment effects.  To facilitate this the entire 
systematically phenotyped cohort of treatment-naïve patients with PAH-CTD 
diagnosed at the SPVDU (between 2002 and 2010, n=286) was considered for 
my study.  Of these, 247 patients met the specified entry criteria.  I have 
followed up this group for the entirety of their first line oral bosentan or sildenafil 
monotherapy journeys; at first follow up, then one and two years.  Given the 
practicalities and constraints of NHS clinical practice, the mean intervals 
achieved by the time windows employed seemed very satisfactory timings at 
which to review response and also to be able to relate the findings to those 
noted in previous work. 
 
It was implicit that all the data would be representative of the SPVDU 
population, in that all eligible patients rather than a sample have been recruited.  
Hence the data presented is deterministic rather than probabilistic. 
 
The sample recruited was similar in terms of proportions of diagnosis seen in 
previous work.  There was an expected dominance within this PAH-CTD group 
of those with PAH-SSc.  The proportion of patients with significant co-existing 
lung disease in the study population is lower than that from the national dataset 
compiled by Condliffe (2009).  This is largely predictable as there is little 
evidence for PAH treatments being of significant benefit in this group of 
patients.  Indeed a recent study investigating ambrisentan (a newer ERA) 
showed a deleterious effect in Idiopathic Pulmonary Fibrosis (Raghu et al., 
2013) and was terminated early for fears of disease progression on treatment.  
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It is not currently certain whether this is a class effect but there is little 
supportive data for using other pulmonary vascular therapies (Furuya and 
Kuwana, 2011) in patients with significant co-existing pulmonary fibrosis.  The 
presence of even a small proportion of these patients within the study cohort is 
representative of uncertainty at diagnosis regarding the relative clinical 
importance of the vasculopathy versus that of the fibrotic component of the 
patient’s breathlessness. 
 
In earlier UK prescribing guidelines (Forum, 2004) applicable in the early to mid-
2000’s, patients managed by SPVDU were only eligible to receive treatment if 
they exhibited haemodynamic signs of severe disease.  These were (one of) 
Rpa ≥ 10mmHg, CI ≤ 2.1 L/min/m2, and MVO2 ≤ 63%.  On the basis of this 
cohort’s average, these patients have severe disease as characterised by 
hypoxaemia but their pressures are not as high as those seen typically in other 
forms of the disease.  These old criteria are no longer applied to treatment 
eligibility but they remain a useful benchmark in describing disease severity. 
 
When the haemodynamics for the sub-groups were analysed, some 
unexpected differences were noted: 
1. Ppa was higher in the group treated Pre-NCP vs. that of 2008 onwards.  
This was an isolated finding and in isolation is unlikely to be clinically 
important. 
2. Haemodynamic difference was noted between the bosentan and 
sildenafil groups.  Treatments were not deliberately initiated on the basis 
of haemodynamic disease severity.  Prior to the NCP (2002-8) clinical 
and patient preference influenced the choice of agent used.  Since the 
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introduction of the policy in 2008, patients with PAH-CTD were 
prescribed bosentan as first line therapy for PAH-CTD.  This marked 
difference between the baseline groups is a significant confounding 
feature.  It demonstrates that patients prescribed bosentan had more 
severe disease.  This made interpretation of the results more difficult as 
the groups were not equal at baseline in this respect.  That said, it is 
interesting that the more severe haemodynamic parameters at baseline 
seen in the bosentan group did not correlate with either a significantly 
reduced baseline value for WHO FC or ISWT relative to the sildenafil 
group. 
 
RHCs are not routinely repeated in clinical practice in Sheffield.  This is due to 
both clinical appropriateness and service capacity reasons.  However this may 
not necessarily be representative of clinical practice at other units.  The 
exceptions to this general principal in Sheffield are in the event of diagnostic 
uncertainty or evidence of deterioration which cannot obviously be attributed to 
PAH.  In these cases it may not be possible to re-evaluate the response to 
treatment without using haemodynamic markers.   
 
Repeat RHCs have been a feature of several RCTs for PAH therapies.  These 
include the sildenafil SUPER-1 (Galiè, 2005) trial which evaluated 
haemodynamics at follow up as a secondary endpoint.  In contrast, the 
BREATHE-1 (Rubin LJ, 2002) study for bosentan did not measure 
haemodynamic response. 
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Changes in functional markers; namely exercise capacity (as measured by 
ISWT) and WHO functional class were noted at each time point.  Other 
endpoints were employed to assess treatment effects; time on monotherapy 
and all cause mortality.  These other endpoints were chosen as means of 
measuring the impact of treatment without using the functional markers which 
have been shown as questionable in this aetiology of the disease (Denton et al., 
2011).   
 
Time to clinical worsening (TTCW) has been proposed as a more meaningful 
outcome measure for RCTs (Denton et al., 2011) but it is not feasible to employ 
this composite endpoint in the clinic setting.  As such, functional tests coupled 
with the emergence of more sophisticated non-invasive imaging techniques 
(e.g. MRI) remain the favoured options.   
 
Time on monotherapy was used as a validated (Lieberman et al., 2005, 
Deslandes et al., 2009) surrogate for patient and clinician satisfaction with 
treatment.  It has not been used to my knowledge in the area of PAH before but 
useful parallels of context here hinted of its applicability in an area where hard 
endpoints are in question.  All cause mortality was also studied; mortality status 
was ascertained via the National Health Service enhanced reporting service 
death report as in some cases specific cause of death could not be established 
from our records. 
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6.2 Change in exercise capacity 
Both sildenafil and bosentan maintained exercise capacity for those patients 
staying on monotherapy up to two years (n=56).  At no timepoint did the cohorts 
either significantly improve or deteriorate. 
 
It can be seen from the t-tests that exercise capacity does not change across 
time when we compare any of the groups.  All of the between-group and within-
group analysis showed a NS median change of 0m.  Whilst this does not imply 
improvement over time for these treated cases, it is possible to have done so if 
we had used a placebo control arm.  If we wanted to make any estimation of 
placebo-corrected treatment effect, the only point of reference data available 
comes from the sub-groups within the RCTs (Galiè, 2005, Rubin LJ, 2002).  
Albeit in prevalent cohorts, the placebo arms of PAH-CTD patients in RCTs all 
deteriorated prior to 12-16 week reviews.  Whilst improvement has to be the 
ultimate goal, arresting deterioration and inducing stabilisation of a progressive 
disease is in most circumstances a first goal of treatment and a clinically 
relevant marker.  As this study examined incident cases, relating treatment 
effects to previous work is difficult. 
  
The fact that I found no difference between the monotherapy groups is of 
interest.  The study was not designed to confirm that the treatments would be 
equally efficacious, but there have been very few head-to-head studies 
comparing the two most prescribed agents in PAH-CTD patients.  The SERAPH 
study was comparative but only recruited two PAH-CTD patients (Wilkins et al., 
2005).  As both agents are widely used I did not necessarily expect to find huge 
differences in efficacy as these may have already become evident over time in 
clinical practice.  Sildenafil has a quicker onset of action, we would expect to 
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note some benefit after 4-6 weeks compared with 6-8 for bosentan.  As a 
consequence, we may have expected to see better figures at first follow up for 
the sildenafil groups.  This is not borne out in my data.  Additionally, the 
baseline haemodynamics showed the bosentan group had more severe 
disease hence the groups are heterogenous at baseline in this respect. 
 
In a meta analysis of RCT data, Avouac noted this absence of clinically relevant 
improvement as measured by exercise capacity when looking specifically at 
PAH-SSc patients (2008).  This study and the data presented by Avouac 
examined similar numbers albeit in different trial settings.  A more recent meta 
analysis suggested that ERAs may be a less effective choice in PAH-CTD 
(Kuwana et al., 2013).    
 
It is easy to overlook the clinical importance of disease stability in the short and 
long term for these patients.  With PAH-CTD being the most aggressive form of 
the disease and oral monotherapy suspected to be less effective for certain 
cases than either combination therapy or prostanoids use, these are useful 
findings. 
 
Continuous IV epoprostenol remains the only agent to demonstrate benefits in 
improving 6MWD in PAH-SSc (Badesch et al., 2000) albeit versus placebo.  No 
study has been published comparing IV epoprostenol to more commonly 
prescribed oral therapies. 
 
The introduction of the NCP did not make any net difference to ISWT.  When 
the group treated in accordance with guidance vs. the group treated prior to the 
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policy was compared, there was no difference.  This vindicated the clinical 
decision-making beforehand as being as effective as that suggested by the 
approach of the guidance.  That said, the guidance was not originally intended 
to improve prescribing within the specialist units.  Moreover it was put in place 
to guide non-specialists, ensure equity across England for patients and 
eradicate some historic challenges in obtaining funding from commissioners.  
The proportion of both sildenafil and bosentan prescribed before and after only 
altered slightly but nevertheless statistically significantly across the policy 
inception (p=0.001).  The bosentan share of prescribing increased by 
approximately 6% with sildenafil falling by the same amount.   
 
There was also no difference between the two groups of patients prescribed 
different doses of sildenafil.  The correlates well to the RCT data from the 
SUPER-1 study.  It seems from that trial that although higher doses have been 
shown to improve other endpoints, exercise capacity does not significantly 
improve with dose escalation.  Sildenafil is only licensed at 20mg tds, however 
all patients in the long term extension study were escalated to higher doses 
(Rubin et al., 2011).  It is important to bear in mind that doses would be 
escalated as a result of clinical need in this study as opposed to study protocol.  
It is reasonable to assume that doses were only escalated in those patients who 
had either demonstrated a lack of benefit, ongoing worsening symptoms or 
whose disease trajectory was of rapid decline. 
 
It would have been logical to suggest that the maximum dose group may have 
displayed less response at first follow up than those maintained on 25mg 
throughout monotherapy.   However the median time to dose escalation from 
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25mg was 224 days (IQ range 113-482).  This is towards the end of the window 
used for first follow up visits (day 84-256) and beyond the mean interval (day 
138).  Approximately one third of patients had their dose escalated by day 145, 
i.e. 1 week after the mean first follow up review.  Another third had increased 
their dose by 1 year. 
 
It is difficult to relate the findings to the long-term extension of the RCT for 
several reasons.  Firstly SUPER-2 was not purely for PAH-CTD patients, 
second patients were allowed to add a second treatment if deterioration was 
seen and also these were prevalent cases.  My study looked at incident cases 
purely on monotherapy.  At the point of any deterioration when a second 
treatment was added, they were assigned a discontinuation date for 
monotherapy. 
 
This study used the ISWT test as the measure of exercise capacity.  As 
previously discussed (Section 2.4.1) this is an entirely different way of 
measuring exercise capacity to the traditionally ubiquitous 6MWD.  A recent 
publication has alluded to the fact that a dynamic exercise may be more 
meaningful in predicting clinical events and outcomes (Naeije et al., 2013).  
Denton (2011) and Avouac (2010) have discussed the limitation of using 
exercise capacity as measured by 6MWD for PAH-CTD.  Very few centres use 
the ISWT in the context of PAH and whilst the problems of assessing outcome 
in CTD patients by exercise is clearly fraught with potential issues, I was able to 
show that baseline ISWT distance was an independent predictor of mortality in 
this group. 
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Although limited by missing data, the BORG scores that were captured in our 
database suggested that breathlessness was not the major source of limitation 
to completing the ISWT at first follow up.  Mean post exercise BORG score = 
4/10 (n=114). 
6.3 Change in WHO functional class 
This study illustrated stability in WHO functional class in all analyses up to 2 
years.  This was true of both between group and within group comparisons.  
These are useful data that as with exercise testing, a picture of no overall 
change represents confirmation of disease stability on treatment.  This period of 
stability gives no direct implication to quality of life, which is deemed by patients 
to be the most important goal of treatment.  However if patients are functionally 
stable for extended periods, it is hard to imagine (or even suggest) that their 
overall quality of life will be deteriorating. 
 
The difficulty for prescribers is being able to confidently select those who may 
do well on monotherapy and in whom disease will stabilise.  My attempts to 
contrast the worst sub-group (i.e. those who died before their 1st follow up on 
treatment) with the groups who stayed on monotherapy at two years proved to 
be inconclusive.  It is worth remembering that the RIPs were a very small group, 
so drawing conclusions cannot be achieved with certainty.  That said, there 
were no useful markers found in one group and not the other.  This is obviously 
a curious finding, implying that explanatory variables were not collected by this 
study, or the group was too small . 
 
Interestingly, previous studies investigating bosentan have been able to 
demonstrate an improvement, which is not noted here (Launay et al., 2010, 
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Denton et al., 2008, Denton CP, 2006).  This may be explained by differences 
in the populations used.  In the long-term sildenafil data (Rubin et al., 2011), 
nearly 50% of those completing the study at 3 years had improved their 
functional class, but that was not purely recruiting PAH-CTD patients.  In 
addition there was a higher proportion in FCII at baseline (39% vs. 4%) and 
lower percentage in FCIV (3% vs. 5%) than in my cohort.  The proportion of 
PAH-SSc was substantially lower (14% vs. 74%) in the RCT than in the group 
recruited in for this study.  Indeed given the UK prevalence data on the CTD 
population presented by Condliffe and colleagues (2009) both the FC and 
disease breakdown in the sildenafil RCT cohort appear far from representative.  
Both of these factors are vitally important in contextualising the findings and 
relating my data.  It is well recognised that PAH-SSc is the most limiting of the 
CTDs so with such difference in the baseline characteristics of the groups, it is 
not unexpected to see disparity in the outcomes. 
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6.4 Time on monotherapy 
 
TOM may represent a useful measure of treatment effect in PAH and 
specifically PAH-CTD.  TOM was calculated for each patient and some 
differences between the groups were found. 
 
TOM was significantly greater before the introduction of the NCP in 2008.  The 
implication of this finding is that patients initiated since 2008 had monotherapy 
discontinued either by addition of second treatment or through switching to 
alternatives.  This may have been a predictable finding if data was collected 
across the introduction of the more recent NCP.  Whilst the “second generation” 
policy in 2011 (see Appendix 9) allowed for easier access to combination 
treatment, the 2008 policy simply defined the limited circumstances in which it 
would be reimbursed.  Even after the 2008 policy, clinicians regularly had to 
pursue lengthy documentation on an individual case basis to add therapies.   
 
The potential explanation may lie not in combinations but in choices of 
monotherapy options.  Ambrisentan was added to the armoury in 2009 bringing 
the total number of options to six.  This would be particularly attractive as an 
alternative to the bosentan patients who had shown therapeutic benefit but 
experienced abnormal LFTs.  For this set of patients it would seem a logical 
approach to continue ERA. 
 
TOM was also significantly increased in the sildenafil patients across as 
compared to the patients receiving bosentan.  The explanation for this may be 
two-fold: 
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 The bosentan group had more severe disease at baseline as measured 
by haemodynamics (see results Table 13).  It is feasible to suggest that 
these more severe patients are less likely to respond to treatment and 
are likely to either die more quickly or be reviewed more regularly and 
have changes to their therapy as a consequence of lack of response..  
Both features may explain the findings of the study. 
 Bosentan has only one routinely prescribed effective dose.  In rare 
instances, patients are prescribed 62.5mg or 250mg bd long term.  
However the entire recruited cohort was prescribed 125mg bd.  This ‘flat-
dosing’ structure means that dose titration as seen with sildenafil is not 
practiced.  As such, addition or switching to an alternative is the only 
option in apparent treatment failure. 
 
The comparison between the sildenafil dosage groups showed no difference.  
From this we can deduce that the dose escalation is effective in prolonging 
TOM.  By increasing the dose to 50mg tds or 100mg tds, it is possible to 
postpone or even rule out the need for addition or switching of therapy.  It 
reinforces the data that sildenafil is well tolerated and that adverse effects 
leading to discontinuation are not dose-related.  This study suggests that 
patients able to tolerate sildenafil but who may show a sub-optimal response 
can have doses safely increased.  The net result is that their TOM is not 
significantly different from those who respond to 25mg dosing. 
 
Using time on monotherapy was by no means an attempt to suggest that 
monotherapy is preferable to combination therapy.  Data on combination 
therapy either in the context of goal orientated therapy or treating to target is 
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evolving.  Oral combination use is currently being evaluated in the context of a 
large RCT.  Given the current paucity of vital evidence to support routine 
combination prescribing, monotherapy remains the regimen used in 60-70% 
cases in both the SPVDU and the UK (HSCIC, 2013).   
 
There are now more therapeutic options for PAH than ever before.  Treatment 
naïve patients prescribed initial monotherapy have more options available to 
them either as additional or alternative treatment.  As a consequence, patients 
failing to respond to initial monotherapy are entirely different to those failing to 
respond to continuous IV infusion of prostanoids.  For these cases, there may 
be few (if any) untried alternatives.    Interpretation of this novel endpoint needs 
to be done in the context of the patient in question, but these findings suggest 
that in certain cases, monotherapy is safe and effective in the long term.   
 
When analysing both groups in terms of discontinuation, results show that both 
treatments are very well tolerated.  Relatively few patients (<10%) withdraw 
from treatment as a consequence of ADRs.  The biggest single contributor of 
ADRs is the LFT abnormality associated with bosentan.  The LFT abnormality 
prevalence is broadly in keeping with previous data, but lower than the higher 
range of suggested figures (Gabbay, 2007, Rubin LJ, 2002).  This is especially 
encouraging in the CTD population where there are multiple co-morbidities.  
Following discontinuation of 1st line monotherapy, only 19 (8.5%) stopped as a 
consequence of ADRs or inefficacy and did not switch to an alternative agent. 
 
In comparing the group discontinued prior to 1st f/u, most licence doses were 
stopped for dose changes, after which those patients may have remained on 
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treatment for longer periods.  This may have been as a result of inadequate 
clinical response or a planned increase due to rapid deterioration prior to 
initiation of therapy. 
 
When the factors affecting TOM were analysed via Cox Regression the results 
were insightful.  Following univariate analysis, Baseline WHO, Ppa, CO, CI, 
PVR, MVO2, Wedge and choice of monotherapy were all shown to be clinically 
relevant.  After parameters not deemed to be co-linear were entered into the 
multiple regression, CI, wedge and choice of monotherapy were found to be 
independent predictors of TOM.  Sildenafil patients were likely to spend longer 
on monotherapy (HR1.533, p=0.032) than bosentan patients.  This takes 
account of all the confounding variables. 
 
Experience in the SPVU suggest that the complexities of prostanoid treatment 
options coupled with dexterity issues suffered by the PAH-CTD group often 
make delivering these advanced options challenging.  Physicians may be 
hesitant to initiate IV or other complex options because of concern for increased 
infection, medication side effects or perceived risk of pulmonary oedema related 
to diastolic dysfunction or the relatively higher prevalence of pulmonary-
venoocclusive disease in these patients (Chung et al., 2010).  As such, despite 
rapidly progressive PAH symptoms, oral therapy may be the ceiling option for 
some in this cohort.  Of the 247 patients studied in the study, only 12 had 
prostanoid added to their monotherapy.  None were switched from oral 
monotherapy to prostanoid monotherapy. 
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6.5 All-cause mortality 
In this study, survival estimates were identified as 82% at 1 year, 66% at 2 
years, 49% at 3 years, 30% at 4 years, 26% at 5 years, 24% at 6 years and 
15% at 7 years.  (See Section 5.6.4.4) 
 
This correlates well at 1 year with recent published work (Rubenfire et al., 2013) 
where the 1 year survival was estimated at 84%.  The data generated by my 
study appears worse than the US set with increasing years.  However the 
inclusion criteria are not identical, with their set including all monotherapy starts.  
As a result, patients indicated for prostanoid first line or other oral therapies 
were included.  The use of first line prostanoid may account for the difference. 
 
The introduction of the NCP in 2008 did not affect mortality according to the 
findings in this study.  This is in part reassuring since important long-term 
studies and evidence has been published since its introduction, where less was 
known when drawing up the guidance pre 2008.  The data from recent 
publications is clear that not only does survival remains very low, particularly in 
the SSc group but that modern treatments have had little impact on this 
outcome measure in this aetiology. 
 
When I compare the survival curves for the two treatment options, the 
confounding feature that patients in the bosentan group had more severe 
disease as defined by haemodynamic parameters makes interpretation of the 
results more complicated.  Thus, the sildenafil group showed a definite survival 
advantage but it is not possible to attribute this difference purely to choice of 
treatment because of the baseline characteristics.  The Cox proportional 
hazards model was used to determine the relative risks of mortality.  Across the 
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entire cohort the haemodynamic features noted as significantly worse in the 
bosentan than sildenafil groups were tested.  Although found to be clinically 
relevant, only MVO2 was found to be an independent predictor of mortality.   
 
The prescribed dose of sildenafil was also not found to be associated with 
survival.  No difference was noted in the Kaplan-Meier curves between licensed 
or maximal doses.  There is no helpful reference point for comparison for the 
sildenafil dose survival because the sample in the SUPER-2 is heterogenous 
from this cohort due to different patterns of diagnosis, severity and functional 
ability.   
 
From the comparison of baseline features between those discontinued prior to 
1st follow up vs. the rest of the cohort, mean survival was not affected.  It can be 
suggested from this that tailoring treatment to the individual is key to successful 
outcome.   
 
It is also considerable that whilst the patients on increased doses of sildenafil 
appear to have more severe disease at baseline and are functionally more 
limited as seen by decreased ISWT, these differences do not manifest 
themselves by way of prognosis.  Hence, some patients may need higher doses 
to live as long as those who demonstrate a symptomatic response at licensed 
doses.  This supports the use of higher doses, albeit outside license.  This may 
be justifiable if other alternatives are contra-indicated and more complex 
prostanoid treatment not feasible. 
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This study found that when taking the recruited cohort as a whole, baseline 
ISWT (HR 0.997, p=0.006), diagnosis in WHO functional class IV (HR= 0.580 
p=0.034) and MVO2 (HR=0.955 p=<0.001) as being independent predictors of 
survival.  Further exploration of these findings demonstrated that survival was 
worse when the group is divided into those whose baseline ISWT was above or 
below the median.  Those patients with a baseline ISWT >100m had 
significantly improved prognosis (p=0.001).  ROC curve analysis was also 
performed but the result was difficult to interpret accurately as this dataset 
proved weak with respect to this test. 
 
It is of clinical value that the ISWT baseline predicts survival in our CTD 
population.  This correlates with previous work carried out in our centre (Elliot, 
2004).  This research analysed various aetiologies.  A baseline ISWT <150m 
correlated with poor prognosis.  It is topical given the conjecture in the literature 
of the correlation between 6MWD and survival (Naeije et al., 2013, Avouac et 
al., 2010). 
 
Poor prognosis as measured by all cause mortality is of concern to all 
professionals caring for PAH-CTD patients.  There are many publications 
describing the mortality noted in this group.  It is clear that despite the ‘modern 
treatment era’, these patients show little by way of improved survival (Rubenfire 
et al., 2013, Condliffe, 2009, Launay et al., 2012, Denton et al., 2008).  Indeed 
survival remains unacceptably poor despite multiple therapeutic options being 
available (Rubenfire et al., 2013).   
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6.6 Strengths and Weaknesses of the study 
6.6.1 Strengths 
As I had access to the ASPIRE registry (Hurdman et al., 2011), I could recruit a 
larger population of PAH-CTD patients than has been looked at before in a 
single study.  I was able to use a dataset that was as complete as could 
reasonably be expected going back 10 years.  The amount of missing data was 
within expectation.  The pilot study gave confidence in building a strong 
methodology to use for a large-scale interrogation of recorded data. 
Also in terms of numbers, the SPVDU has one of the largest treated cohorts in 
any PH unit.  This gave a vast resource of cases to analyse and also 
confidence in the clinical management, that patients would have been 
systematically diagnosed and treated in line with prescribing guidelines as 
appropriate and regularly followed up. 
 
In order to make optimal use of the vast array of data available, several 
endpoints could be used.  Whilst this added to the analysis complexity and 
length, there was the opportunity to corroborate findings of one strand of the 
analysis with another.  Unlike an RCT with one primary endpoint, there was the 
opportunity to examine treatment effect from a variety of perspectives. 
 
This study is the first large head-to-head study (albeit retrospective) conducted 
with these two first-line oral treatments.  Previous comparisons have been 
achieved through meta-analysis or small-scale studies. 
 
I have been able to demonstrate how well tolerated these oral therapies are in 
this particular type of PAH.  The discontinuations from adverse events were 
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similar to those witnessed in the RCTs, however it is suggested that the PAH-
CTD patients may be pre-disposed to an increased risk. 
 
Having followed patients up over eight years, I have been able to study patients 
for longer periods than any of the published open-label extension studies.  This 
gives valuable information on the use of treatments in the long term.  It also 
illustrated the effectiveness of monotherapy for certain cases.  Unfortunately it 
was difficult to generate any signals from the baseline characteristics to guide 
prescribers as to which patients may do better on which treatment.  However 
approximately 20% of the cohort remained stable at 2 years on monotherapy.  
This suggests that combination therapy may not be necessary for all, although it 
is important to note that whilst tolerating treatment, they had not made 
significant improvement, which may have been possible through treatment 
escalation. 
 
6.6.2 Weaknesses 
As with any retrospective work, the main weaknesses are that the study was 
observational, non-randomised and a small proportion of the data was missing.  
Exhaustive steps were taken to minimise both the quantity and the impact of the 
missing data via thorough data cleaning and statistically through multiple 
imputation.  Data regarding survival and TOM will not be affected by missing 
values. 
 
The challenges presented by missing values first appeared early in the data 
collection phase.  One of the first tasks was to obtain a complete history of each 
patient’s episodes with the SPVDU.  These should include outpatient clinics, 
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day-case attendance and both the elective and acute inpatient stays.  However, 
it became clear that attendances to SPVDU had been documented in letters 
that are not listed in PC and vice versa.  It was unknown as to whether this may 
have been due to inaccurate recording at the time or software migration errors 
during the upgrade from PAS to PC.  Whilst it may not be critical to have a letter 
for every date recorded for each patient in PC, as not all attendances in PC 
would warrant a letter.  In summary, as PC could not be regarded as suitably 
reliable in terms of quality of data all attendance information was corroborated 
by two sources.  This was an early but typical example of the extent of data 
cleaning necessary to guarantee rigour in the process.  Throughout the 
collection phase, wherever the slightest doubt arose regarding any values, be 
they dates or physical parameters, at least two sources were used to ascertain 
the correct data. 
 
This very much extended the data collection phase of the project and having 
made assumptions regarding time scales on the basis of the presence of 
complete datasets, added delays.  This reflects naivety on my part and has 
formed a valuable learning experience.  Whilst the data was largely present, 
formatting, correcting and cleaning was more involved than expected. 
It also made the point to me that despite every intention of accurate patient 
phenotyping, systematic data recording and established research programmes, 
each piece of research requires slight variation in output.  Designing, building 
and maintaining a database capable of both capturing data in usable format and 
with the capability of answering specific queries is a major challenge.  In the 
modern NHS, such systems should be possible to meet the needs of research 
beyond RCTs coming to the fore.  There is a challenge for all concerned to 
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ensure data captured in busy clinical practice is accurate, well formatted and 
entered in a timely fashion.  I was acutely aware that after huge amounts of time 
taken to format the data I needed, the resulting Excel sheets may be of little if 
any value to anyone in the future.  The skill of the modern researcher needs to 
be in the analysis of the data, not the merging and reformatting of databases. 
 
Despite statistical attempts to account for confounding variables using 
advanced techniques, the imbalance at baseline of the sildenafil and bosentan 
sub-groups made analysis challenging.  It has resulted in a significant selection 
bias in the sample.  This was purely a chance finding, as the patients were not 
stratified to receive one or other treatment as a result of haemodynamic disease 
severity.  Interestingly though, when multivariate analysis was performed for 
TOM and mortality, none of the haemodynamic characteristics independently 
predicted events, although some were clinically relevant in the univariate model.  
It raises an interesting theoretical question as to whether the results would be 
replicated with groups well matched at baseline. 
The exercise capacity analysis returned non-significant results.  It is important 
to discuss this in the context of the recruited sample.  There was slight benefit in 
the sildenafil cohort without statistical significance.  As the monotherapy groups 
were not matched at baseline, confounding variables make firm conclusions 
impossible.  However as a moot point, well-matched groups showing the effect 
size found would have needed to be far greater in size to reach significance.  
The difference found within groups was far smaller than the average 
improvement in the RCT.  This numerical difference could be consequential of 
using a different test (ISWT vs. 6MWD).  It may also be due to the disease sub 
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group being different to a general PAH population.  The third potential reason is 
statistical power.   
 
Cohen’s Primer (1992) is a recognised tool for exploring post hoc potential 
power issues in studies.  Having recruited the entire population, the maximum 
possible numbers were analysed.  Taking one specific result as an example, the 
effect size found between bosentan and sildenafil at first follow up constitutes a 
small effect size as defined by Cohen: 
(Ma-Mb).  = 0.2 
        σ 
Where Ma-Mb = difference in means, σ = standard deviation 
Based on α  = 0.05 and an effect size (ES)=0.2, the sample would have needed 
394 in each arm to either result in statistical significance, or that the result falls 
into the small β (0.2) chance of a type II error.  In clinical practice for this 
condition, these sample sizes are entirely unrealistic, especially in a single-
centre study. 
 
Where multiple clinicians see patients there is always the chance of disparity in 
practice.  By this I mean that each clinician will practice independently and the 
decision to make a treatment change be multi-factorial.  It is assumed that these 
influences will balance across the population.  It was not possible to have all 
‘monotherapy-ending’ decisions to be blindly reviewed independently for 
consistency.   
 
Also along these lines, the research methodology could have lent itself to 
researcher bias.  As one researcher was solely collecting and analysing the 
dataset, I had to ensure that there was no way I could influence the findings.  
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One of the methods used was blinding myself to outcome measure data.  By 
using only dates of review, with associated results hidden, I was able to 
ascertain the visit of interest from the patient’s history.  It was only after 
selecting the dates of interest that the values were revealed and recorded.  
Hence no possibility of selecting a ’best case’ or ‘worst case’ result scenario of 
any group. 
 
6.7 Meaning of the study 
Following an extensive review of the entire cohort of PAH-CTD patients treated 
with an oral monotherapy of bosentan or sildenafil, some very practically useful 
findings have been made. 
 
To have demonstrated disease stability in a significant proportion of incident 
cases of PAH-CTD to 2 years on monotherapy is clinically important.  PAH-CTD 
is the most rapidly progressing and has the most limited survival of all the sub-
types of PAH (Rubenfire et al., 2013).  We are increasingly using combination 
therapy and there is growing evidence to support this approach.  Instinctively 
the use of two or more agents with complementary mechanisms seems a 
logical approach.  However given the complexity of the agents, the 
polypharmacy and multiple co-morbidities experienced by the PAH-CTD group 
mean that supportive data for oral monotherapy in the long term is reassuring.  
The SPVDU currently manages approximately 60% of patients requiring 
targeted therapies on monotherapy.  These data give evidence that 
monotherapy is safe, well tolerated and effective in the long term for those 
patients not needing escalation of treatment. 
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Through an observational study, it has been possible to show equivalence 
between bosentan and sildenafil in terms of functional change.  This very much 
endorses the decision taken in 2011 when the second NCP was published to 
make sildenafil first line for all types of PAH.  Bosentan was first line for PAH-
CTD from 2008.  However, as sildenafil is now considerably cheaper and these 
findings showing equivalence with bosentan, it may represent a more cost 
effective treatment. 
 
This study shows that some patients do well in the longer term on higher doses 
of sildenafil and vindicates the use of escalation to supra-licensed doses.  Both 
sildenafil and bosentan are well tolerated with a low discontinuation rate 
secondary to side effects.  Clinically the dilemma of whether to increase the 
dose or switch/add in a second therapy remains. 
 
Smaller, prospective work has been previously published (Launay et al., 2010) 
but in many respects (see Section 1.8) these do not accurately represent the 
patients being initiated onto treatment in everyday clinical practice.  PAH 
prescribing guidelines introduced in 2008 in England are based on the findings 
of sub-group analysis from RCT data.  However it is acknowledged that RCTs 
will exclude, consciously or otherwise, some types of patients to whom results 
will subsequently be applied (McKee et al., 1999).  In reviewing clinical practice, 
I have provided evidence beyond RCT data, which adds to previous findings 
(Launay et al., 2010, Hachulla et al., 2009, Fisher et al., 2006, Girgis et al., 
2009) and may be of value to clinicians and commissioners for future revisions 
of national policy. 
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6.9 Unanswered questions and future research 
 
Three factors may effect a change in prescribing practice in the future.  The first 
reason for this is the recent availability of generic sildenafil.  If all the current 
patients were switched, this could be expected to reduce the cost of prescribing 
(albeit off-licence) in the UK by 96%.  It remains to be seen whether these 
significant financial savings (circa £10m per year) will be used to support the 
use of combinations not currently available (triple therapy or ERA + 
Prostanoids) in specified circumstances.  The review of the policy planned for 
later in 2013 will reflect any changes to future practice. 
 
The second factor is the availability of a more stable epoprostenol formulation.  
Current administration of continuous IV infusions of epoprostenol is limiting for 
patients, not least because the agent is only stable for 8-12 hours at room 
temperature (SPC, 2012c).  The new formulation (Veletri®) has extended 
stability data allowing patients the option to only change the syringe once a day.  
Reconstituted syringes will be stable under refrigeration for up to seven days 
(SPC not yet available).  This may have an impact on the uptake and usability 
of epoprostenol for patients with limited dexterity as a consequence of their 
CTD. 
 
Lastly, the results of the AMBITION study will be published.  This study 
examined for the first time in an RCT the effects of first-line combination 
prescribing.  The study describes the use of ERA + PDE5i use in the form of 
ambrisentan and tadalafil.  If this study delivers a positive finding of combination 
prescribing over corresponding monotherapy, the treatment paradigm will no 
doubt shift.  At present, although combination prescribing is slowly increasing, 
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doubts remain over the quality of supporting evidence in the literature (Fox et 
al., 2011). 
 
More work is needed to explore applicable endpoints for this, the most 
aggressive form of a progressive and devastating family of diseases.  Whilst 
much important work is being done to encourage early referral, diagnosis and 
treatment, survival has not fundamentally changed for the better.  RHC remains 
the chosen diagnostic test but non-invasive options are improving, notably 
Magnetic Resonance (MR) imaging.  More work is necessary to develop the 
place of non-invasive investigations in both a diagnostic and prognostic 
capacity.  Limited collection of BORG scores hindered that stream of the 
analysis.  However from the data collected, it was noted that pure 
breathlessness was not the primary reason for most PAH-CTD patients to fail to 
meet the walk test bleep.  This emphasises the impact of the other symptoms of 
PAH-CTD on exercise. 
 
Time on monotherapy (TOM) has not been well described previously in PAH 
studies.  However it has been validated and utilised in the field of psychiatric 
medicine.  There are applicable parallels to be drawn between the two distinctly 
different clinical areas borne out of the lack of reproducible endpoints in 
assessing PAH-CTD patients’ response to treatment.   
 
TOM can be interpreted as a useful composite measure of treatment effect.  It 
neatly integrates patients’ and clinicians’ judgments of efficacy, safety and 
tolerability into a global measure of effectiveness that reflects their evaluation of 
therapeutic benefits in relation to their undesirable effects (Lieberman et al., 
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2005).  Further validation work in this clinical field is necessary to understand 
whether this novel endpoint has a role in research into PAH therapies. 
 
It is hoped that future policy will reflect observational research in addition to the 
data provided by RCTs, because it is very clear that the patients receiving 
prescriptions in clinic are markedly different from the groups in studies.  More 
work like this study in treated populations is necessary to more accurately 
describe the response to treatment in incident cases.  Ideally this work would be 
able to compare different monotherapy options and characterise the growing 
experience with combinations of treatments.  Such work would be of great value 
both to clinicians but also commissioners who face an unenviable task of 
resourcing expensive, sometimes complex treatments and services where 
current evidence is somewhat lacking. 
 
Accurate data capture for the NAPH should be a priority for all centres in order 
to improve for all stakeholders the quality of data available both for clinical and 
academic purposes.  Now that electronic data management is central to clinical 
practice every day, it should be a reasonable expectation that the national 
dataset for a relatively small clinical area be an invaluable bank of in-depth data 
stored in retrievable formats to make studies such as this far less time-
consuming and labour-intensive.  In order to validate guidelines drawn up with 
little RCT data, observational evidence has a vital role to play in ensuring best 
practice.  It should also be possible to demonstrate the positive influence of 
screening tools, comparing current outcomes with historical estimates of 
survival. 
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PAH is an exciting area for pharmacists to work in.  It is rapidly evolving in 
terms of drug developments and clinical interest.  There is a huge potential for 
ongoing translational and practice research for pharmacists in PAH.  With such 
a significant proportion of the PAH management achieved through the patients’ 
pharmaceutical care, we need to use our clinical skills within the context of a 
multi-professional team and develop the quality of observational research to 
improve patient outcomes.   
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Appendix 1 – Embase search strategy  
1.  PULMONARY HYPERTENSION/dt [dt=Drug Therapy] 
2.  PULMONARY HYPERTENSION/dt,pd [dt=Drug Therapy, pd=Pharmacology] 
3.  exp CONNECTIVE TISSUE DISEASE/ 
4.  2 AND 3 
5.  BOSENTAN/ae,ct,ad,cb,cm,do,it,dt,to,ec,po,pr,pe,pk,pd [ae=Adverse Drug 
Reaction, ct=Clinical Trial, ad=Drug Administration, cb=Drug Combination, 
cm=Drug Comparison, do=Drug Dose, it=Drug Interaction, dt=Drug Therapy, 
to=Drug Toxicity, ec=Endogenous Compound, po=Oral Drug Administration, 
pr=Pharmaceutics, pe=Pharmacoeconomics, pk=Pharmacokinetics, 
pd=Pharmacology] 
6.  SILDENAFIL/ae,ct,ad,an,cb,cm,do,it,dt,to,ec,po,pr,pe,pk,pd [ae=Adverse 
Drug Reaction, ct=Clinical Trial, ad=Drug Administration, an=Drug Analysis, 
cb=Drug Combination, cm=Drug Comparison, do=Drug Dose, it=Drug 
Interaction, dt=Drug Therapy, to=Drug Toxicity, ec=Endogenous Compound, 
po=Oral Drug Administration, pr=Pharmaceutics, pe=Pharmacoeconomics, 
pk=Pharmacokinetics, pd=Pharmacology] 
7.  5 OR 6 
8.  4 AND 7 
9.  8 [Limit to: (Publication Types Article or Conference Abstract or Conference 
Paper or Editorial or Journal or Review) and Human and English Language] 
10.  *BOSENTAN/ 
11.  *SILDENAFIL/ 
12.  10 OR 11 
13.  4 AND 12 
14.  13 [Limit to: Human and English Language] 
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Appendix 2 – Medline search strategy 
1.  exp HYPERTENSION, PULMONARY/ 
2.  exp CONNECTIVE TISSUE DISEASES/ 
3.  1 AND 2 
4.  exp RECEPTORS, ENDOTHELIN/ 
5.  bosentan.ti,ab 
6.  4 OR 5 
7.  exp PHOSPHODIESTERASE INHIBITORS/ 
8.  6 OR 7 
9.  3 AND 8 
10.  (pulmonary AND arterial AND hypertension).ti,ab 
11.  1 OR 10 
12.  2 AND 11 
13.  sildenafil.ti,ab 
14.  7 OR 13 
15.  6 OR 14 
16.  12 AND 15 
 
 
 
  
Citations identified from 
literature search (n=179) 
Excluded (n= 172 ) 
Paediatric studies (n=3) 
Duplicate citations (n= 28) 
Reviews and Commentaries  
(n= 47) 
Case-control studies or case 
reports (n= 36) 
Meta Analysis (n= 3) 
Animal or in-vitro models (n= 23) 
Populations were not PAH  
(n= 30) 
Preliminary or subgroup analysis 
of already included or excluded 
studies (n= 2) 
 
Studies included in final 
analysis (n= 7) 
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Appendix 3 – Screening protocol for PH using yearly 
echocardiography and transfer factor is systemic 
sclerosis (Elliot and Kiely, 2004) 
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COMMISSIONING POLICY – TARGET THERAPIES FOR THE TREATMENT 
OF PULMONARY ARTERIAL HYPERTENSION IN ADULTS 
 
1 BACKGROUND 
 
In April 2008 the commissioning of pulmonary arterial hypertension (PAH) 
became the direct responsibility of the 10 Specialised Commissioning Groups 
(SCGs) in England.  These are supra-regional services.  As a consequence it was 
considered beneficial to have a single national commissioning policy operating 
across England. 
 
2 CAVEATS 
 
This is an interim policy pending the publication of the NICE Technology 
Appraisal Guidance due in April 2008.  When the NICE Guidance is published 
the policy will be reviewed. 
 
 The policy has drawn on available clinical effectiveness evidence.  It has also 
taken into account affordability and other priorities of Primary Care Trusts. 
 
 The Consensus Statement, produced by the consultant staff who specialise in 
the care and treatment of patients with pulmonary arterial hypertension has 
been taken into consideration in drawing up this policy.1 
 
 It is anticipated that the national pulmonary arterial hypertension 
commissioning group working under the auspices of the National Specialised 
Commissioning Group will review this commissioning policy on an annual basis. 
 
3 SCOPE OF POLICY 
 
 The policy focuses on the use of the high cost disease targeted therapies in the 
treatment of pulmonary hypertension in adults. 
 
 This commissioning policy needs to be read in conjunction with the national 
service specification for the pulmonary hypertension service. 
 
4 PULMONARY HYPERTENSION 
 
 4.1 Definition 
 
  Pulmonary arterial hypertension (PAH) is a rare disorder of the blood 
vessels in the lung in which the pressure in the pulmonary artery rises 
above normal levels and may become life threatening. 
 
  It is caused by a diverse group of diseases and is characterised by a 
progressive increase of pulmonary vascular resistance leading to right 
                                            
1
 Consensus Statement of the management of pulmonary hypertension in clinical practice in the 
UK and Ireland; Heart, March 2008, volume 94 Supplement 1 
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ventricular failure and premature death if untreated. 
 
 
  PAH is defined as a mean pulmonary artery pressure greater than 
25mm Hg at rest or greater than 30 mm Hg on exercise. 
 
 4.2 Signs and Symptoms 
 
  Pulmonary hypertension is associated with disparate conditions 
including connective tissue disease, congenital heart diseases, chronic 
pulmonary thromboembolism, sickle cell disease, HIV infection, use of 
an appetite suppressant, and liver disease.  If the cause is unknown 
then it is referred to as idiopathic pulmonary arterial hypertension 
(IPAH).  IPAH can occur sporadically or can be familial. 
 
  The cardinal symptom, breathlessness, is shared with many more 
common diseases and the signs of pulmonary hypertension are difficult 
to elicit.  The delay between onset of symptoms and diagnosis is often 
as long as two years.  
 
  In the past, treatments for pulmonary hypertension were limited, but 
now there is a range of drug therapies in use that have been shown to 
improve the outcome of PAH. 
 
 4.3 Incidence and Prevalence 
 
  Lack of systematic and often poor data collection prevents reliable 
estimation of incidence, morbidity, mortality and survival. 
 
  The potential “pool” of patients to be treated is complex and based on 
a number of factors as shown below:- 
 
   
 
Incidence                                                                  Death Rate 
Diagnosis Rate                                                         Transplantation Rate 
Referral Rate                                                            Endarterectomy Rate 
Take on Rate                                                            Withdrawal of Treatment 
Prevalence 
 
 
 
 
 
  The census of patients on treatment at 31 March 2007 identified 1500 
patients UK wide.  The number has doubled over 3 years. 
 
  The pool of patients on treatment continues to grow and has not yet 
reached a ‘steady state’. 
Pool of PAH
patients on drug
treatment 
Changes to natural 
history of the disease as 
a result of treatment i.e. 
increased survival 
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 4.4 Diagnosis 
 
  IPAH is a diagnosis of exclusion. Admission is usually necessary in order 
to carry out a series of investigations regarding cause, baseline 
pulmonary haemodynamics and responsiveness to potential therapy. 
 
 
  The diagnostic evaluation of PAH includes the following: 12-lead 
electrocardiogram, chest radiograph, echocardiogram, 
cardiopulmonary exercise testing (6 minutes walk or shuttle test), 
ventilation perfusion lung scan, high resolution CT scan, CT pulmonary 
angiogram and pulmonary function tests and in selected cases MRI and 
pulmonary angiography.  Liver function and thyroid function studies, 
collagen vascular screen, and HIV antibody are useful in determining 
whether PAH is associated with systemic disorders. 
 
  Diagnosis is made at the time of right heart catheterisation (although in 
very sick unstable patients this may be dangerous and treatment may 
be commenced in the absence of catheter data if other indicators are 
consistent with severe disease).   It is performed primarily to confirm 
the diagnosis of PAH and as indicator of disease severity. 
Cardiopulmonary haemodynamic measurement and vasoreactivity 
testing is performed to help guide therapy in selected patients, and 
decide on the appropriateness of calcium antagonist therapy. 
 
5 TREATMENT CENTRES 
 
 Six centres have been designated by the National Commissioning Group (NCG) 
to provide pulmonary hypertension services for adults.  The centres offer 
investigation and treatment of patients with idiopathic pulmonary 
hypertension, pulmonary hypertension complicating other diseases and 
assessment of response to treatment.   The centres and staff also provide 
support for patients and their families. 
 
 Only the designated centres are able to initiate treatment. 
 
 A service specification including standards for the delivery of care has been 
agreed and each centre is measured against these standards by the National 
Commissioning Group (NCG). 
 
The designated centres are: 
 
  London  Hammersmith Hospital 
 Royal Brompton Hospital 
 Royal Free Hospital 
  Cambridge  Papworth Hospital 
  Sheffield  Royal Hallamshire Hospital 
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  Newcastle  Freeman Hospital 
 
 NB:  Great Ormond Street Hospital is designated to provide pulmonary 
hypertension services for children.  This service is funded centrally by National 
Commissioning Group. 
 
 Each centre has an agreed action plan to enable them to move towards 
meeting all the standards.  
 
 There are discussions in progress to support the development of shared care 
arrangements with appropriate local clinical services.  There are also 
discussions taking place about links with the designated services for grown up 
congenital heart disease. 
6 THE POLICY 
 
 6.1 List of drugs covered and approved doses 
 
Oral Nebulised Subcutaneous Intravenous 
 
 Bosentan 
125mg bd only 
 Iloprost  Treprostinil*  Epoprostenol* 
 Sildenafil 
(Revatio – 20mg tds only 
Viagra 25mg-100mg tds 
only) 
   Iloprost* 
 Sitaxsentan 
100mg od only 
   Treprostinil* 
 
       *  Prostaglandins 
 
 The approximate drug costs are shown below.  Some dosages of some drugs  
will be variable. 
 
 Cost without 
homecare 
Cost with 
homecare 
Bosentan 125mg BD £23,500 £21,000 
Sitaxsentan 100mg £23,500 £21,000 
IV Iloprost £39,000 £37,000 
Nebulised Iloprost 
(Ventafee) 
£32,200 £31,500 
Treprostinil £41,500 £35,200 
Epoprostenol (incl pump) c £35,000 £33,000 
Sildenafil £5,440 - £6,700 £5,000 - £6,700 
 
 Doses above those specified will not normally be funded. 
 
 6.2 Monotherapy 
 
  6.2.1 Monotherapy will be provided for patients as described in 
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Table 1. 
 
   Other conditions are currently excluded.  Any extension to the 
range of conditions will only be considered as a service 
development.  These will be subject to business case assessment 
as set out in Schedule 6 of the NHS Contract. 
 
  6.2.2 Patients only with a functional classification of PAH of stage III or 
stage IV of the WHO modified New York Heart Association 
(NYHA) Classification will be funded.  Patients with functional 
Class I or II on baseline assessment will not normally be eligible 
for funding save in exceptional circumstances (as defined in 
Section 6.4) 
 
  Class I - Patients with pulmonary hypertension but without 
resulting limitation of physical activity. Ordinary physical activity 
does not cause undue dyspnoea or fatigue, chest pain, or near 
syncope. 
 
 
  Class II - Patients with pulmonary hypertension resulting in slight 
limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity causes undue dyspnoea or fatigue, 
chest pain, or near syncope. 
 
  Class III - Patients with pulmonary hypertension resulting in 
marked limitation of physical activity. They are comfortable at 
rest. Less than ordinary activity causes undue dyspnoea, fatigue, 
and chest pain or near syncope. 
  
 
Class IV - patients with pulmonary hypertension with inability to 
carry out any physical activity without symptoms. These patients 
manifest signs of right heart failure. Dyspnoea and/or fatigue may 
be present even at rest. Discomfort is increased by any physical 
activity. 
  It is expected that defining a patient’s functional class will be a 
multidisciplinary team decision. 
 
  6.2.3 Drug doses higher than those specified in Section 6.1 will not 
normally be eligible for funding save in exceptional 
circumstances (as defined in Section 6.4). 
 
 6.3 Dual Therapy 
 
  6.3.1 Dual therapy will only be funded in combinations involving 
sildenafil unless there are exceptional circumstances. 
 
 6.4 Exceptionality 
 
Responsibility for demonstrating exceptionality rests with the requesting 
clinician. 
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  Only evidence of clinical need will be taken into consideration.  Factors 
such as gender, ethnicity, age, lifestyle or other social factors such as 
employment or parenthood will not be considered on grounds of 
equality. 
 
  In order to demonstrate exceptionality the patient: 
 
   Must be significantly different to the population of interest (ie 
patients with pulmonary hypertension and/or the subpopulation). 
 
  AND 
   Be more likely to benefit from this intervention than might be 
expected than other patients with the condition. 
 
  The fact that the treatment might be efficacious for the patient is not, in 
itself, grounds for exceptionality. 
 
  If a patient’s clinical condition matches certain indications which might be 
seen as “accepted” (e.g. the trial indication, the licensed indication, 
anecdotal or routine but unstudied clinical practice) etc) but these 
particular indications fall outside the commissioning policy, the patient is, 
by definition, not exceptional. 
 
  Pre-agreed exceptions for dual therapy in combination, not involving 
sildenafil, are: 
 
  6.4.1 Dual therapy: for patient switching from one monotherapy to an 
alternative monotherapy (up to a maximum of 12 weeks) 
 
  6.4.2 Dual therapy: for patients who have been listed for the following 
surgery may be given additional consideration: 
 
 Heart-lung transplantation 
 Double Lung transplantation 
 Thrombo-endarterectomy (in patients with chronic thrombo-
embolic disease) 
 
  6.4.3 Continuation of existing treatments (including a prostacyclin) for 
patients making the transition from children’s services to adult 
services where it would be inappropriate to change treatments 
only to comply with the commissioning policy. 
 
  6.4.4 Continuation of existing treatments (including a prostacyclin) for 
adult patients (i.e. started prior to the policy being agreed) which 
are not in accordance with the commissioning policy is permitted 
until the patient and their clinician consider it appropriate to 
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stop. 
 
  In those situations where the principle of exceptionality cannot be 
applied (i.e. in situations where there is no reference group such as 
funding requests for very rare clinical conditions or complications) 
then the following will be considered: the nature of the condition, 
the nature of the treatment, consideration of the biological 
plausibility that this treatment might work in this clinical situation, an 
assessment of value for money and prioritisation against other 
competing demands. 
 
 6.5 Clinical Trials 
 
The commissioners will not pick up the funding of patients coming off 
drug company sponsored drug trials / extended access programmes or 
compassionate funding unless prior arrangements have been made. 
 
  It is seen as the responsibility of those initiating therapy to ensure that 
there is either an exit strategy or that ongoing treatment is provided.  
Patients should be fully informed. 
 
  The commissioners will fund patients once the service development has 
been agreed. 
 
 
 
 
 
 
 6.6 Patient Stopping Criteria 
 
The continued use of target therapies will be reviewed on a regular basis.  
The key factors influencing the cessation of treatment will be: 
 
  a) Successful surgery 
  b) Clinically relevant side-effects eg liver function 
  c) Poor/no response to treatment 
 
  Drug therapies may also be withdrawn “at the end of life”. 
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 Pulmonary Arterial Hypertension (IPAH, 
FPAH, Anorexogen-induced, and where 
associated with Portal hypertension or 
HIV infection) 
PAH associated with 
significant venous or capillary 
involvement 
PAH associated with 
connective tissue 
disease 
PAH associated with 
congenital heart disease 
PH due to chronic 
thrombotic and/or 
embolic disease 
First line WHO III/: S 
WHO IV: P 
 
PVOD only: WHO III/IV, S, 
consider surgery 
PCH: no disease targeted 
treatment supported consider 
surgery 
WHO III/IV: B WHO III: B 
WHO IV: B as a bridge to 
transplant 
WHO III/IV: S 
Consider surgery 
Second line/ 
Alternative* 
WHO III: B,P or X 
WHO IV: B 
 WHO III/IV: S, P or X  WHO III/IV: B 
Combination 
 
B+S or X+S  
Patients should be entered into a clinical 
trial where possible 
 B+S or X+S 
Patients should be 
entered into a clinical 
trial where possible 
B+S will be considered as 
a bridge to surgery 
B+S will be considered 
as a bridge to surgery 
Alternate 
combination 
P+S 
Patients must be entered into a clinical trial 
(NB trial participation previously agreed by 
commissioners) 
    
Evidence Few head to head studies, clinical 
consensus only. 
RCT evidence of comparable results 
between S and B (SERAPH) 
RCT and extension evidence of survival 
benefit of S (SUPER-1) 
RCT evidence of functional improvement 
over placebo for B (BREATHE-1) and X 
(STRIDE-1) 
RCT and extension evidence of survival 
benefit of P but no firm evidence of 
relative efficacy of different preparations in 
class 
Some small study evidence of improved 
results in combination of S+B 
 
No published data on use of B 
or X 
Case reports only on S and only 
in PVOD 
No RCT evidence but 
some evidence of 
functional improvement 
on B, X and S 
Long term follow-up data 
is poor. 
Evidence on P is 
equivocal 
No published evidence of 
benefit of combination. 
 
RCT evidence of 
functional improvement 
in WHO III with B 
(BREATHE-5) 
No published evidence of 
benefit of combination. 
 Case reports on distal 
(inoperable) disease 
treated by B 
(BENEFIT). No 
published data on use 
of X. 
B= Bosentan, P= Prostanoids, S= Sildenafil, X= Sitaxsentan OR Ambrisentan 
WHO= Functional classification of PH modified after the New York Heart Association functional classification according to the World Health 
Organisation 1998 IPAH= Idiopathic PAH; FPAH= Familial PAH; PVOD= Pulmonary veno-occulsive disease; PCH= Pulmonary capillary 
haemangiomatosis 
 
* If first line is contraindicated, ineffective in controlling symptoms or poorly tolerated
TABLE 1 
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7 FUNDING APPROVAL 
 
 There will be no requirements to seek commissioner approval prior to the 
commencement of treatment 
 
 BUT 
 
 the release of commissioner funding is dependent on registration of the patient 
on the national database AND provision of the commissioner dataset. 
 
 The commissioner dataset is as follows: - 
 
  Patients NHS number 
  Patients DoB and postcode 
  GP Practice Code 
  Name of drug 
 
 Expected maintenance dose: - 
 
  Cost of drug 
  Starting date for treatment 
  Projected cost to year end 
  Primary diagnosis (i.e. underlying condition) 
  WHO/NYHA Functional Classification 
 
8 MONITORING INFORMATION 
 
 Each centre will need to provide each SCG with a monthly monitoring 
statement covering the following fields: 
 
  ID number 
  Patient Initials 
  NHS number 
  PCT/SCG codes 
  Drug and dose 
  Notification of changes to drugs and dosage 
  Takeoff date 
  Reason for takeoff 
  Monthly cost 
  Annual cost 
 
9 REVIEW 
 
 This policy will be reviewed on an annual basis and/or in the light of any new 
clinical or cost effectiveness evidence. 
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 New treatment regimens will not be considered in year unless there is evidence 
of a sustainable benefit. 
 New drugs coming onto the market may be added to the list in year via the 
commissioners under the following circumstances: - 
 
  If they have the same or greater efficacy than current drugs 
 
 AND 
 
  If they have an equivalent or lower cost to current treatment 
 
10 FURTHER WORK TO BE UNDERTAKEN 
 
 Further work will be undertaken to review/collect cost effectiveness evidence.  
Once this information is available the policy will be reviewed. 
 
 
14 January 2009 (V2 Final document) 
 
Appendix A 
 
POLICY CHANGE PROTOCOL 
 
The key steps in the policy change protocol are as follows: 
 
(a) All requests for changes to the national policy should be made to the lead SCG 
Director in writing. 
 
(b) The change request should clearly set out the evidence supporting the change, 
the anticipated benefits, and any financial implications 
 
(c) Requests from the clinicians should come via the national clinicians group with 
the chair of the group writing formally to the lead SCG Directors. 
 
(d) The lead SCG Director will obtain a public health/specialist pharmacist review of 
the clinical and cost effectiveness and the cost implications. 
 
(e) The original request and the public health/specialist pharmacy opinion will be 
considered by the national PH Commissioners Forum. 
 
(f) The national PH Commissioners Forum will make a recommendation to SCGDN. 
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Appendix 5 -  – Ethics approval letter for the over-arching study 
“STH 14169 – Improving the investigation of Pulmonary 
Hypertension” 
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Appendix 6 – Addition of researchers to existing ethics 
approval 
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Appendix 7 – Notice of substantial amendment 
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Appendix 8 – Data Cleaning – Technical details 
 
The bulk of the clinical data for each patient was kept in the ASPIRE registry 
database, in Microsoft Access® (MS Access) format.  I understood the rationale 
for using MS Access and had a clear understanding of the advantages of the 
program.  However due to my unfamiliarity and despite attempts to query the 
database, it was clear that performing the cleaning in MS Access would be too 
time-consuming and unpractical.  Instead, the data was exported to MS Excel 
(MS Excel).  Within MS Access, each data entry occupied an individually 
numbered row.  In order to view the particular data being studied (for example 
treatment journey, ISWT etc.) as a sequential, chronological timeline, each 
event needed to be recorded in MS Excel as a series of columns going across a 
worksheet.  This would provide the first migration issues that had to be 
addressed. 
Macros were used to aid the data reformatting.  Macros are defined as sets of 
instructions in MS Excel for tasks to perform on a given worksheet or data.  By 
recording or programming certain actions, MS Excel users utilise macros to 
automate repetitive tasks, format data sheets, or perform complex mathematical 
operations.  By using macros, MS Excel users can launch a virtually infinite 
number of tasks and processes with the simple touch of one button, greatly 
speeding complicated spreadsheet work.  In addition, by completing 
rearrangement and other spreadsheet tasks electronically, the chance of 
manual error is eliminated.  This is of considerable value from a data quality 
control perspective. 
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Running the first few patients then double-checking that all the relevant data 
had been translated from columns to rows achieved necessary validation of the 
macro process.  This was an important step in terms of control process to 
ensure that the reformatting would not move data points from one line or 
column to another.   
 
Once the macro was validated as able to carry out the reformatting accurately, it 
eliminated the potential for human error from such onerous reformatting 
processes across so many rows and columns.  After reformatting had been 
completed, a double check was put in place to ensure that all the relevant data 
points had been moved from columnar to row form.  This was necessary in 
order to verify that the macro had worked correctly.  This was achieved using 
the MS Excel COUNTA function, and matching the data columns against the 
number of rows for each patient in MS Access. 
 
As the translations were made from ASPIRE source data into the MS Excel 
worksheets, it became clear that not all of the data was in the correct order.  
Where MS Access had sorted the ASPIRE registry data by patient reference 
number, any line of data without the reference number was placed 
chronologically at the end of that patient’s data.  This inevitably meant that 
some data points were out of chronological sequence and manual 
rearrangement as part of the data cleaning was necessary.  This issue was 
identified with primarily the walk tests but also to a lesser extent the WHO 
classes. 
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COMMISSIONING POLICY 
  
TARGETED THERAPIES FOR THE TREATMENT OF 
PULMONARY HYPERTENSION IN ADULTS 
 
1 BACKGROUND 
 
In April 2008, the commissioning of pulmonary hypertension (PH) 
became the direct responsibility of the 10 Specialised 
Commissioning Groups (SCGs) in England.  These are supra-
regional services.  As a consequence, a single national 
commissioning policy, operating across England, was developed.  
This policy was produced, and now revised, by SCG commissioning 
and public health representatives in collaboration with consultant 
staff who specialise in the care and treatment of patients with 
pulmonary hypertension.  It has drawn on available evidence of 
clinical effectiveness, particularly clinical guidelines published in 
2009 by The Task Force for the Diagnosis and Treatment of 
Pulmonary Hypertension of the European Society of Cardiology 
(ESC) and the European Respiratory Society (ERS).i 
 
2 SCOPE OF POLICY 
 
 The policy provides the national commissioning position for disease-
targeted medicines in the treatment of pulmonary hypertension in 
adults.   
 
 This commissioning policy should be read in conjunction with the 
national service specification for the pulmonary hypertension service. 
 
3 PULMONARY HYPERTENSION 
 
 3
.
1 
Definition 
 
  Pulmonary hypertension (PH) is a rare disorder of the blood vessels in 
the lung, characterised by raised pressure in the pulmonary artery, 
which results in a range of symptoms and may be life threatening.   
 
PH is defined as an increase in mean pulmonary artery pressure (PAP) 
of 25mmHg or greater at rest as assessed by right heart catheterisation.  
A definition of PH on exercise (as a mean PAP >30mm Hg) is not 
supported by published data.   
 
PH can be found in a diverse range of clinical conditions, including 
connective tissue disease, congenital heart diseases, chronic pulmonary 
thromboembolism, sickle cell disease, HIV infection, use of an appetite 
suppressant, and liver disease (Table 1).   
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Pulmonary arterial hypertension (PAH) is a clinical condition 
characterised by the presence of pre-capillary PH in the absence of 
other causes of pre-capillary PH such as lung disease, chronic 
thromboembolism, or other rare causes.  If the cause is unknown then it 
is referred to as idiopathic pulmonary arterial hypertension (IPAH).  
IPAH can occur sporadically or may be familial.   
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Table 1: Updated clinical classification of pulmonary hypertension (Dana 
Point, 2008)1 
 
1  Pulmonary arterial hypertension (PAH) 
  1.1 Idiopathic 
  1.2 Heritable 
   1.2.1 BMPR2 
   1.2.2 ALK1, endoglin (with or without hereditary  
   haemorrhagic telangiectasia) 
   1.2.3 Unknown 
  1.3 Drugs and toxins induced 
  1.4 Associated with (APAH) 
   1.4.1 Connective tissue diseases 
   1.4.2 HIV infection 
   1.4.3 Portal hypertension 
   1.4.4 Congenital heart disease 
   1.4.5 Schistosomiasis 
   1.4.6 Chronic haemolytic anaemia 
  1.5 Persistent pulmonary hypertension of the newborn 
 
1* Pulmonary veno-occlusive disease and/or pulmonary capillary 
 haemangiomatosis 
 
2  Pulmonary hypertension due to left heart disease 
  2.1 Systolic dysfunction 
  2.2 Diastolic dysfunction 
  2.3 Valvular disease 
 
3  Pulmonary hypertension due to lung diseases and/or hypoxia 
  3.1 Chronic obstructive pulmonary disease 
  3.2 Interstitial lung disease 
  3.3 Other pulmonary diseases with mixed restrictive and  
  obstructive pattern 
  3.4 Sleep-disordered breathing  
  3.5 Alveolar hypoventilation disorders  
  3.6 Chronic exposure to high altitude 
  3.7 Developmental abnormalities 
 
4  Chronic thromboembolic pulmonary hypertension 
 
5  PH with unclear and/or multifactorial mechanisms 
  5.1 Haematological disorders: myeloproliferative disorders, 
  splenectomy. 
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell 
histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, 
vasculitis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders 
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic 
renal failure on dialysis 
 
 
 
ALK-1 = activin receptor-like kinase 1 gene; APAH = associated pulmonary 
arterial hypertension; BMPR2 = bone morphogenetic protein receptor, type 2; 
HIV = human immunodeficiency virus; PAH = pulmonary arterial hypertension. 
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 3
.
2 
Signs and Symptoms 
 
  The symptoms of PH are non-specific and include breathlessness, 
fatigue, weakness, angina, syncope, and abdominal distension.  
Symptoms at rest are reported only in patients with very advanced 
disease.  Many of these symptoms are shared with other common 
diseases and the signs of pulmonary hypertension are difficult to elicit.  
The delay between onset of symptoms and diagnosis can be as long as 
two years.   
 
 3
.
3 
Incidence and Prevalence 
 
  Registries in Scotland and France have described the epidemiology of 
PAH.2, 3 The lowest estimates of the prevalence of PAH and IPAH are 
15 cases and 5.9 cases/million adult population, respectively.  The 
lowest estimate of PAH incidence is 2.4 cases/million adult 
population/year.   
Recent data from Scotland and other countries have confirmed that 
PAH prevalence is in the range 15–50 subjects per million population in 
Europe.3 In the French registry, 39.2% of patients had IPAH and 3.9% 
had family history of PAH.  In the sub-group of 
APAH, 15.3% had connective tissue diseases (CTDs; mainly systemic 
sclerosis), 11.3% had CHD, 10.4% had portal hypertension, 9.5% had 
anorexigen-associated PAH and 6.2% had human immunodeficiency 
virus (HIV) infection.2 
All designated treatment centres are required to register patients and 
submit data to the National Audit of Pulmonary Hypertension (NAPH) as 
a condition of funding.  This database will provide more accurate and 
detailed information on the prevalence and incidence of PH in England 
from 2011/12.   
 
 3
.
4 
Diagnosis 
 
  IPAH is a diagnosis of exclusion.  Admission is usually necessary in 
order to carry out a series of investigations regarding cause, baseline 
evaluation of pulmonary haemodynamics and function and 
responsiveness to potential therapy.  Assessments of disease severity 
and prognosis are also undertaken. 
 
  The diagnostic evaluation of PAH includes the following: 12-lead 
electrocardiogram, chest radiograph, echocardiogram, cardiopulmonary 
exercise testing (6 minutes walk or shuttle test), ventilation perfusion 
lung scan, high resolution CT scan, CT pulmonary angiogram and 
pulmonary function tests and in selected cases MRI and pulmonary 
angiography.  Liver function and thyroid function studies, collagen 
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vascular screen, and HIV antibody are useful in determining whether 
PAH is associated with systemic disorders. 
 
  Diagnosis is made at the time of right heart catheterisation (although in 
very sick unstable patients this may be dangerous and treatment may 
be commenced in the absence of catheter data if other indicators are 
consistent with severe disease).  It is performed primarily to confirm the 
diagnosis of PAH and as an indicator of disease severity.  
Cardiopulmonary haemodynamic measurement and vasoreactivity 
testing is performed to help guide therapy in selected patients, and 
decide on the appropriateness of calcium antagonist therapy. 
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4 TREATMENT CENTRES 
 
 3
.
5 
Functional class 
 
Assessment of WHO Functional Class (FC) is an 
important predictor of survival, despite large inter-
observer variation in its measurement.1  Table 2 
describes the characteristics of the four classes.   
 
In untreated patients with IPAH or heritable PAH, 
historical data suggests a median survival of 6 months 
in patients in WHO-FC IV, 2.5 years for those in WHO-
FC III, and 6 years for WHO-FC I and II.1 
 
It is expected that defining a patient’s functional class 
will be a multidisciplinary team decision. 
 
Table 2: Functional classification of PH1 
Class I  
 
Patients with pulmonary hypertension but 
without resulting limitation of physical 
activity.  Ordinary physical activity does 
not cause undue dyspnoea or fatigue, 
chest pain, or near syncope. 
Class II Patients with pulmonary hypertension 
resulting in slight limitation of physical 
activity.  They are comfortable at rest.  
Ordinary physical activity causes undue 
dyspnoea or fatigue, chest pain, or near 
syncope. 
Class III Patients with pulmonary hypertension 
resulting in marked limitation of physical 
activity.  They are comfortable at rest.  
Less than ordinary activity causes undue 
dyspnoea, fatigue, and chest pain or 
near syncope. 
Class IV Patients with pulmonary hypertension 
with inability to carry out any physical 
activity without symptoms.  These 
patients manifest signs of right heart 
failure.  Dyspnoea and/or fatigue may be 
present even at rest.  Discomfort is 
increased by any physical activity. 
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 Six centres are designated by the National Commissioning Group to provide 
pulmonary hypertension services for adults.  The centres offer investigation 
and treatment of patients with idiopathic pulmonary hypertension, 
pulmonary hypertension complicating other diseases and assessment of 
response to treatment.  The centres and staff also provide support for 
patients and their families. 
 
Importantly, only the designated centres are able to initiate treatment 
with a disease-targeted medicine under this policy.  In some 
circumstances, explicit and formalised shared-care agreements may be 
made by the designated centres with other specialist centres to prescribe 
disease-targeted therapies.  However, non-specialist clinicians and General 
Practitioners should not be asked to routinely prescribe these medicines 
since they are not able to submit information to the national database.   
 
Where a patient is started on a disease-targeted therapy, their GP should 
be informed and alerted to any potential for unwanted effects, including 
interactions with other medicines. 
 
 
 
A service specification including standards for the delivery of care was 
agreed by the National Commissioning Group (NCG) and each centre is 
measured against these standards.   
 
The designated centres are: 
London -   
 Imperial College Healthcare NHS Trust(Hammersmith Hospital) 
 
 Royal Brompton & Harefield NHS Foundation Trust 
 
 Royal Free Hampstead NHS Trust 
 
Cambridge –  
 Papworth Hospital NHS Foundation Trust 
 
Sheffield –  
 Sheffield Teaching Hospitals NHS Foundation Trust  
(Royal Hallamshire Hospital) 
 
Newcastle –  
 The Newcastle upon Tyne Hospitals NHS Foundation Trust  
 (Freeman Hospital) 
 
 NB:  Great Ormond Street Hospital is designated to provide pulmonary 
hypertension services for children.  This service is funded centrally by the 
National Commissioning Group. 
 
 Each centre has an agreed action plan to enable them to move towards 
  
 
 
 
264 
meeting all the standards.   
 
 There are discussions in progress to support the development of shared 
care arrangements with appropriate local clinical services.  There are also 
discussions taking place about links with the designated services for grown 
up congenital heart disease. 
 
5 COMMISSIONING OF TREATMENT 
 
 5.1 Included patient populations  
 
Treatment with disease-targeted medicines, as described in Section 5.3, will 
be routinely commissioned for adults, assessed as in WHO-FC III or IV, in 
one of the following clinical classifications (Table 1):  
 
 Group 1 Pulmonary arterial hypertension (PAH) 
 Group 1*  Pulmonary veno-occlusive disease (PVOD) and/or 
pulmonary            capillary haemangiomatosis (PCH) 
 Group 4  Inoperable chronic thromboembolic pulmonary 
hypertension (CTEPH) [NB This includes patients with potentially 
operable disease who refuse surgery or who are waiting for 
acceptance for surgery] 
 
Treatment will also be routinely commissioned for patients with chronic renal 
failure on dialysis or sarcoidosis associated with pulmonary hypertension, 
and for women who are pregnant (see 5.4.5 below), who fall within one of 
the allowed classes described above.   
 
 5.2 Excluded patient populations 
 
Treatment with disease-targeted medicines will not be routinely 
commissioned for patients in the following groups unless described 
otherwise above: 
 
 WHO-FC I or II: clinicians support the use of disease-targeted 
therapies in patients in WHO Functional Class II.  However, 
commissioners believe that further work is needed to assess the 
clinical and financial impact of their inclusion.  Estimating the number 
of such patients is difficult since many will be managed within other 
clinical services and not known to PH centres.   
 
 A further review of the evidence-base for targeted therapies in 
the  management of patients in functional class II will be 
submitted to the  National Commissioners Forum  by 
November 2011 for consideration for  2012/13 contracts.   
  
 
 Patients in clinical classifications 2 and 3: the use of targeted 
therapies for patients in these classifications is not recommended 
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until robust data are available.   
 
 PH with unclear or multifactorial mechanisms (clinical classification 
group 5): there is no robust evidence to support treatment with 
targeted therapies in these patient groups.  NB: treatment for patients 
with chronic renal impairment on dialysis and those with sarcoidosis 
is routinely commissioned as discussed in 5.1.   
 
 5
.
3 
Approved medicines 
 
 Three types of medicine may be used under this policy.  However, due to 
differences between some products within each class, particularly in price, 
they are commissioned by individual product rather than by type, unless 
stated otherwise.   
 
Doses above those specified (e.g. bosentan 250mg twice daily) will not 
be routinely funded. 
 
Commissioners with work with provider organisations to develop service 
specifications for the managed supply of targeted therapies and a standard 
approach to pricing.   
 
1) Phosphodiesterase type 5 inhibitors (PDE5i) 
a) Sildenafil (oral)  
i) As Viagra tablets (unlicensed indication): for dose escalation 25-
100mg three times daily 
ii) As Revatio tablets: for use only at licensed dose of 20mg three 
times daily 
b) Tadalafil (oral) tablets: for use only at licensed dose of 40mg once 
daily 
 
2) Endothelin receptor antagonists (ERA) (NB commissioned by type) 
a) Bosentan (oral) tablets: 62.5mg-125mg twice daily 
b) Ambrisentan (oral) tablets: 5-10mg once daily 
 
3) Prostanoids  
a) Epoprostenol (intravenous): dose titrated to response 
b) Iloprost (nebulised): 5 micrograms up to 9 times daily 
c) Iloprost (intravenous, unlicensed product): dose titrated to response   
 
NB Treprostinil will not be routinely commissioned for new patients but 
funding will continue for patients already established under the terms of 
the national policy.  Treprostinil is a prostanoid that may be administered 
by sub-cutaneous or intravenous routes (unlicensed product).  While it 
may have a role in the sub-cutaneous treatment of very small numbers of 
seriously ill patients with PH who are not suitable for nebulised or 
intravenous administration of a prostanoid, commissioners believe that, 
at around 3-4 times the price of equivalent alternatives, its new pricing 
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structure cannot be justified.   
  
 
 
 
 
Table 3: Approximate treatment costs at recommended doses 
 
 Cost 
without 
homecare 
Cost 
with 
home
care 
Sildenafil (as 
Viagra) 
£5,440 - 
£6,700 
£5,000 
- 
£6,700 
Tadalafil (as 
Adcirca) 
£6,400*  
Bosentan  £23,500 £21,00
0 
Ambrisentan ~£23,500 £21,00
0 
IV Iloprost (incl 
pump) 
£39,000 £37,00
0 
Nebulised 
Iloprost 
(Ventafee) 
£32,200 £31,50
0 
Epoprostenol 
(incl pump) 
c £35,000 £33,00
0 
Treprostinil 
(incl pump) 
~ 
£120,000 
 
 
 
* Basic NHS price.  Discounted price available through ‘home care’ provider 
that ensures supply at price similar price to lowest dose of sildenafil.   
  
 
 5.4 Approved regimens 
  5.4.1 First line  
 Monotherapy with an oral PDE5i will be routinely 
commissioned as first line therapy (see 5.3). 
 Where a PDE5i is not clinically appropriate, an ERA may be 
substituted.   
 The choice of medicine is subject to clinical discretion 
bearing in mind relative safety, evidence of efficacy, and 
Treatment should be initiated and, where appropriate, escalated with 
the least expensive suitable product.  Doses higher than those specified 
in 5.3 will not be routinely funded.   
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cost of treatment.   
 Monotherapy with a prostanoid will be routinely 
commissioned for patients at WHO FC-IV with clinical 
classification 1 or 1* (see Table 1). 
 
  5.4.2 Second-line therapy 
 Patients who have failed to respond to a trial of therapy of 
adequate dose and duration (typically 8-12 weeks 
treatment), or failed to tolerate one of the oral therapies 
should be switched to an alternative oral product as 
monotherapy. 
 Patients who have initially responded to first-line therapy 
but then deteriorated despite dose escalation (if 
appropriate) may be considered for dual therapy (see 
5.4.3).  
 Patients who have had a suboptimal response to first-line 
therapy (with dose escalation where appropriate) may be 
considered for dual therapy (see 5.4.3).  
 A prostanoid will be routinely commissioned for patients 
with clinical classification 1 and 1* (see Table 1) with WHO 
FC-III who have failed to respond adequately or tolerate 
dual therapy with an oral PDE5i and an oral ERA.  [NB In 
exceptional cases, where an acutely unwell patient requires 
in-patient treatment, monotherapy with a prostanoid may be 
initiated as an alternative to dual therapy]. 
 A prostanoid will not be routinely commissioned for use in 
patients with other clinical classification 
 
 
  5.4.3 Dual therapy  
 
Dual therapy will only be funded in combinations involving a PDE5i 
unless there are exceptional circumstances. 
 
Dual therapy will be commissioned for patients  
 with progressive disease who have failed to respond to 1st 
and 2nd-line monotherapy 
 who have initially responded to monotherapy but 
subsequently deteriorated despite dose escalation (if 
appropriate) 
 who have had a suboptimal response to monotherapy (with 
dose escalation, where appropriate). 
 
In exceptional cases, where a patient is acutely unwell and 
hospitalised, the progression to dual therapy may be accelerated.   
 
  5.4.4  Triple therapy 
Triple therapy will be routinely commissioned only for patients who 
have been accepted as suitable for transplant.   
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  5.4.5 Pregnancy 
PH in pregnancy is associated with high mortality.  Disease-
targeted therapies may used alone, or in combination, according 
to clinical signs and symptoms at the discretion of the treating 
clinician, irrespective of functional class. 
 
 6 EXCEPTIONALITY 
 
Responsibility for demonstrating exceptionality rests with the 
requesting clinician. 
 
  Only evidence of clinical need will be taken into consideration.  
Factors such as gender, ethnicity, age, lifestyle or other social 
factors such as employment or parenthood will not be considered 
on grounds of equality. 
 
  In order to demonstrate exceptionality the patient:  
  
 Must be significantly different to the population of interest (i.e. 
patients with pulmonary hypertension and/or the 
subpopulation). 
 
  AND 
 
   Be more likely to benefit from this intervention than might be 
expected than other patients with the condition. 
 
  The fact that the treatment might be efficacious for the patient is 
not, in itself, evidence of exceptionality.  Both criteria should be 
met (efficacy and clinical exceptionality). 
 
  If a patient’s clinical condition matches certain indications which 
might be seen as “accepted” (e.g. the trial inclusion criteria, the 
licensed indication, anecdotal or routine but un-researched clinical 
practice etc.) but these particular indications fall outside the 
commissioning policy, the patient is, by definition, not exceptional. 
 
  Pre-agreed exceptions for dual therapy in combination, not 
involving a PDE5i, are:  
 
  6
.
1 
Dual therapy: as a bridge for a patient switching from one 
mono-therapy to an alternative mono-therapy (up to a 
maximum of 12 weeks) 
 
  6
.
2 
Dual therapy: for patients who have been listed for the 
following surgery: 
 Heart-lung transplantation 
 Double lung transplantation 
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 Thrombo-endarterectomy (in patients with chronic 
thrombo-embolic disease) 
 
  6
.
3 
Continuation of existing treatments (including a prostanoid) 
for patients making the transition from children’s services to 
adult services where it would be inappropriate to change 
treatments only to comply with the commissioning policy. 
 
  6
.
4 
Continuation of existing treatments (including a prostanoid) 
for adult patients (i.e. started prior to the policy being agreed) 
which are not in accordance with the commissioning policy is 
permitted until the patient and their clinician consider it 
appropriate to stop. 
 
  In those situations where the principle of exceptionality cannot be 
applied (i.e. in situations where there is no reference group such 
as funding requests for very rare clinical conditions or 
complications) then the following will be considered: the nature of 
the condition, the nature of the treatment, consideration of the 
biological plausibility that this treatment might work in this clinical 
situation, clinical guidelines, audit data, advice from specialist 
reference group, an assessment of value for money and 
prioritisation against other competing demands. 
 
 6
.
5 
Clinical Trials 
 
The commissioners will not pick up the funding of patients exiting 
clinical trials funded by the pharmaceutical industry, extended 
access programmes or compassionate funding programmes 
unless prior arrangements have been made with the lead 
commissioner (NB until national commissioning arrangements are 
in place, the lead commissioner will vary between regions). 
 
  It is seen as the responsibility of those initiating therapy, and 
manufacturers sponsoring trials, to ensure that there is either an 
exit strategy or that ongoing treatment is provided.  Patients 
should be fully informed of these arrangements. 
 
  The commissioners will fund patients once the service 
development has been agreed. 
 
 6
.
6 
Patient Stopping Criteria 
 
The continued use of target therapies will be reviewed on a regular 
basis.  The key factors influencing the cessation of treatment will 
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be: 
 
    Successful surgery 
    Clinically relevant side-effects e.g. liver function 
  .  Poor/no response to treatment 
 No other active treatment option available 
 
  Drug therapies may also be withdrawn “at the end of life”. 
 
7 FUNDING APPROVAL 
 
 There will be no requirements to seek commissioner approval prior to the 
commencement of treatment BUT the release of commissioner funding is 
dependent on registration of the patient with the National Audit of 
Pulmonary Hypertension AND provision of the commissioner dataset. 
 
 The commissioner dataset is as follows:  
 
  Patient’s NHS number 
  Patient’s DoB and partial postcode 
  GP Practice Code 
  Name of drug 
 
 Expected maintenance dose:  
 
  Cost of drug 
  Starting date for treatment 
  Projected cost to year end (not yet achieved) 
  Primary diagnosis (i.e. underlying condition) 
  WHO/NYHA Functional Classification at baseline (i.e. treatment-
naïve) 
 
8 MONITORING INFORMATION 
 
 Each centre will need to provide each SCG with a monthly monitoring 
statement covering the following fields: - 
  ID number 
  Patient’s Initials 
  NHS number 
  PCT/SCG codes 
  Drug and dose 
  Notification of changes to drugs and dosage 
  Takeoff date 
  Reason for takeoff 
  Monthly cost 
  Annual cost 
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9 REVIEW 
 
 This policy will be reviewed on an annual basis and/or in the light of any 
new clinical or cost effectiveness evidence. 
 
 New treatment regimens will not be considered in the year unless there is 
evidence of a sustainable benefit. 
 
 New drugs coming onto the market may be added to the list in year via 
the commissioners under the following circumstances:  
 
 
  If they have the same or greater efficacy than current drugs 
 
 AND 
 
  If they have an equivalent or lower cost to current treatment 
 
1
0 
POLICY CHANGE PROTOCOL 
 
 The key steps in the policy change protocol are as follows: 
 
(
a
) 
All requests for changes to the national policy should be made to the lead 
SCG Director in writing. 
 
(
b
) 
The change request should clearly set out the evidence supporting the 
change, the anticipated benefits, and any financial implications. 
 
(
c
) 
Requests from the clinicians should come via the national clinicians 
group with the chair of the group writing formally to the lead SCG 
Directors. 
 
(
d
) 
The lead SCG Director will obtain a public health/specialist pharmacist 
review of the clinical and cost effectiveness and the cost implications. 
 
(
e
) 
The original request and the public health/specialist pharmacy opinion 
will be considered by the national PH Commissioners Forum. 
 
(
f
) 
The national PH Commissioners Forum will make a recommendation to 
SCGDN. 
 
  
 
 
 
272 
 
Reference 
                                            
1. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of 
the European Society of Cardiology (ESC) and the European Respiratory 
Society (ERS), endorsed by the International Society of Heart and Lung 
Transplantation (ISHLT).  Guidelines for the diagnosis and treatment of 
pulmonary hypertension.  European Heart Journal (2009) 30, 2493–2537.  
Available: http://www.escardio.org/guidelines-surveys/esc-
guidelines/GuidelinesDocuments/guidelines-PH-FT.pdf) 
2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, 
Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert 
M, Haloun A, Laurent M, Hachulla E, Simonneau G.  Pulmonary arterial 
hypertension in France: results from a national registry.  Am J Respir Crit Care 
Med 2006;173:1023–1030. 
3. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S.  An 
epidemiological study of pulmonary arterial hypertension.  Eur Respir J 
2007;30:104–109. 
